DNA, METHODS ETC

Abstract
The invention relates to the production of phage and transduction particles using DNAs (eg, plasmids and helper phage, mobile genetic elements (MGEs) or plasmids with chromosomally integrated helper phage genes), as well as the phage, helper phage, kits, compositions and methods involving these.
Description
CROSS REFERENCE TO RELATED APPLICATION

This application claims priority benefit to United Kingdom Patent Application Nos. GB1719896.1 filed on Nov. 29, 2017 and GB1808063.0 filed on May 17, 2018, the contents of which are incorporated herein by reference in their entireties.


SUBMISSION OF SEQUENCE LISTING ON ASCII TEXT FILE

The content of the following submission on ASCII text file is incorporated herein by reference in its entirety: a computer readable form (CRF) of the Sequence Listing (file name: 786212000400SEQLIST.txt, date recorded: May 21, 2018, size: 71 KB).


TECHNICAL FIELD

The invention relates to the production of phage using DNAs (eg, plasmids and helper phage, or plasmids with chromosomally integrated helper phage genes), as well as the phage, helper phage, kits, compositions and methods involving these.


BACKGROUND

The use of helper phage to package phagemid DNA into phage virus particles is known. An example is the M13KO7 helper phage, a derivative of M13, used in E coli host cells. Other examples are R408 and CM13.


SUMMARY OF THE INVENTION

The invention relates to the production of phage and provides:


In a First Configuration

  • A kit comprising
  • a) A first DNA; and
  • b) One or more second DNAs;
  • Wherein
  • (i) the DNAs together comprise all phage structural protein genes required to produce a packaged phage particle comprising a copy of the first DNA;
  • (ii) the first DNA comprises none or at least one, but not all, of the genes; and wherein the one or more second DNAs comprise the remainder of the genes;
  • (iii) the first DNA comprises a phage packaging signal for producing the packaged phage particle; and
  • (iv) the second DNA is devoid of a nucleotide sequence (eg, a packaging signal) required for packaging the second DNA into phage particles;
  • wherein the DNAs are operable when co-existing in a host bacterium for producing packaged phage that comprise the first DNA, wherein the phage require the second DNA for replicaton thereof to produce further phage particles.
  • There is also provided
  • A method of producing phage, the method comprising expressing in a cell comprising the DNAs the phage protein genes, wherein packaged phage are produced that comprise the first DNA, wherein the phage require the second DNA for replicaton thereof to produce further phage particles.


In a Seond Configuration


A population of helper phage, wherein the helper phage are capable of packaging first phage, wherein the first phage are different from the helper phage and the helper phage are incapable of self-replication.


In a third Configuration


A composition comprising a population of first phage, wherein the first phage require helper phage according to the First Configuration for replication; and wherein less than [20%] of total phage comprised by the composition are such helper phage.


In a Fourth Configuration


A method of producing first phage, wherein the first phage require helper phage to replicate, the method comprising

  • (a) Providing DNA comprising a packaging signal;
  • (b) Introducing the DNA into a host bacterial cell;
  • (c) Wherein the host bacterial cell comprises helper phage or wherein helper phage are introduced into the bacterial cell simultaneously or sequentially with step (b);
  • (d) Wherein the helper phage are according to the invention;
  • (e) Causing or allowing the helper phage to produce phage proteins, wherein the packaging signal is recognised in the host cell, whereby first phage are produced using the proteins, the first phage packaging the DNA;
  • (f) Wherein helper phage replication in the host cell is inhibited or reduced, thereby limiting the availability of helper phage;
  • (g) Optionally lysing the host cell and obtaining the first phage;
  • (h) Thereby producing a composition comprising first phage which require the helper phage for replication, wherein propagation of first phage is prevented or reduced by the limitation of helper phage availability.


In a Fifth Configuration


A phage production system, for producing phage (eg, the first phage of any preceding claim) comprising a nucleotide sequence of interest (NSI-phage), the system comprising components (i) to (iii):

  • (i) A first DNA;
  • (ii) A second DNA; and
  • (iii) a NSI-phage production factor (NPF) or an expressible nucleotide sequence that encodes a NPF;
  • Wherein
  • a) The first DNA encodes a helper phage (eg, said first helper phage recited in any preceding claim);
  • b) The second DNA comprises the nucleotide sequence of interest (NSI);
  • c) When the system is comprised by a bacterial host cell, helper phage proteins are expressed from the first DNA to form phage that package the second DNA in the presence of the NPF, thereby producing NSI-phage;
  • d) The system is devoid of a helper phage production factor (HPF) that is required for forming phage that package the first DNA, or is devoid of an expressible nucleotide sequence that encodes a functional HPF; or the system comprises a nucleotide sequence that comprises or encodes a functional HPF, the system further comprising means for targeted inactivation in the host cell of the HPF sequence to eliminate or minimise production of helper phage comprising the first DNA; and Whereby the system is capable of producing a product comprising a population of NSI-phage, wherein each NSI-phage requires a said helper phage for propagation, wherein the NSI-phage in the product are not mixed with helper phage or less than [20%] of total phage comprised by the product are said helper phage.


    The invention also provides:


A composition for use in antibacterial treatment of bacteria, the composition comprising an engineered mobile genetic element (MGE) that is capable of being mobilised in a first bacterial host cell of a first species or strain, the cell comprising a first phage genome, wherein in the cell the MGE is mobilised using proteins encoded by the phage and replication of first is inhibited, wherein the MGE encodes an antibacterial agent or encodes a component of such an agent.


A nucleic acid vector comprising the MGE integrated therein, wherein the vector is capable of transferring the MGE or a copy thereof into a host bacterial cell.


A non-self replicative transduction particle comprising said MGE or vector of the invention.


A composition comprising a plurality of transduction particles, wherein each particle comprises a MGE or vector according to the invention, wherein the transduction particles are capable of transferring the MGEs, or nucleic acid encoding the agent or component, or copies thereof into target bacterial cells, wherein

  • (i) target cells are killed by the antibacterial agent;
  • (ii) growth or proliferation of target cells is reduced; or
  • (iii) target cells are sensitised to an antibiotic, whereby the antibiotic is toxic to the cells.


A composition comprising a plurality of non-self replicative transduction particles, wherein each particle comprises a MGE or plasmid according to the invention, wherein the transduction particles are capable of transferring the MGEs, or nucleic acid encoding the agent or component, or copies thereof into target bacterial cells, wherein the agent is a CRISPR/Cas system and the component comprises a nucleic acid encoding a crRNA or a guide RNA that is operable with a Cas in a target bacterial cell to guide the Cas to a target nucleic acid sequence of the cell to modify the sequence, whereby

  • (i) target cells are killed by the antibacterial agent;
  • (ii) growth or proliferation of target cells is reduced; or
  • (iii) target cells are sensitised to an antibiotic, whereby the antibiotic is toxic to the cells.


A method of producing a plurality of transduction particles, the method comprising combining the composition of the invention with host bacterial cells of said first species, wherein the cells comprise the first phage, allowing a plurality of said MGEs to be introduced into host cells and culturing the host cells under conditions in which first phage-encoded proteins are expressed and MGE copies are packaged by first phage proteins to produce a plurality of transduction particles, and optionally separating the transduction particles from cells and obtaining a plurality of transduction particles separated from cells.


A bacterial host cell comprising a first phage and a MGE, vector or particle of the invention, wherein the agent is toxic to cells of the same species as the host cell, and wherein the host cell has been engineered so that the agent is not toxic to the host cell.


A bacterial host cell comprising a first phage, wherein the cell is comprised by a kit, the kit further comprising a composition of the invention, wherein the agent is toxic to cells of the same species as the host cell, and wherein the host cell has been engineered so that the agent is not toxic to the host cell.


A bacterial host cell comprising a first phage and a MGE, vector or particle of the invention, wherein the agent is not toxic to the host cell, but the agent is toxic to second cells of a species or strain that is different from the species or strain of the host cell, wherein the MGE is mobilizable in transduction particles producible by the host cell that are capable of transferring the MGE or a copy thereof into a said second cell, whereby the second cell is exposed to the antibacterial agent.


A bacterial host cell comprising a first phage, wherein the cell is comprised by a kit, the kit further comprising a composition of the invention, wherein the agent is not toxic to the host cell, but the agent is toxic to second cells of a species or strain that is different from the species or strain of the host cell, wherein the MGE is mobilizable in transduction particles producible by the host cell that are capable of transferring the MGE or a copy thereof into a said second cell, whereby the second cell is exposed to the antibacterial agent.


A bacterial host cell comprising a MGE, vector or particle of the invention and nucleic acid under the control of one or more inducible promoters, wherein the nucleic acid encodes all structural proteins necessary to produce a transduction particle that packages a copy of the MGE or plasmid, wherein the agent is not toxic to the host cell, but the agent is toxic to second cells of a species or strain that is different from the species or strain of the host cell, wherein the MGE is mobilizable in transduction particles producible by the host cell that are capable of transferring the MGE or a copy thereof into a said second cell, whereby the second cell is exposed to the antibacterial agent.


A plasmid comprising

    • (a) A nucleotide sequence encoding an antibacterial agent or component thereof for expression in target bacterial cells;
    • (b) A constitutive promoter for controlling the expression of the agent or component;
    • (c) An optional terS nucleotide sequence;
    • (d) An origin of replication (ori); and
    • (e) A phage packaging sequence (optionally pac, cos or a homologue thereof); and


      the plasmid being devoid of
    • (f) All nucleotide sequences encoding phage structural proteins necessary for the production of a transduction particle (optionally a phage), or the plasmid being devoid of at least one of such sequences; and
    • (g) Optionally terL.


A bacterial host cell comprising the genome of a helper phage that is incapable of self-replication, optionally wherein the genome is present as a prophage, and a plasmid according to the invention, wherein the helper phage is operable to package copies of the plasmid in transduction particles, wherein the particles are capable of infecting bacterial target cells to which the antibacterial agent is toxic.


A method of making a plurality of transduction particles, the method comprising culturing a plurality of host cells according to the invention, optionally inducing a lytic cycle of the helper phage, and incubating the cells under conditions wherein transducing particles comprising packaged copies of the plasmid are created, and optionally separating the particles from the cells to obtain a plurality of transduction particles.


A plurality of transduction particles obtainable by the method of the invention for use in medicine, eg, for treating or preventing an infection of a human or animal subject by target bacterial cells, wherein transducing particles are administered to the subject for infecting target cells and killing the cells using the antibacterial agent.


A method of making a plurality of transduction particles, the method comprising

    • (a) Producing host cells whose genomes comprise nucleic acid encoding structural proteins necessary to produce transduction particles that can package first DNA, wherein the genomes are devoid of a phage packaging signal, wherein the expression of the proteins is under the control of inducible promoter(s);
    • (b) Producing first DNA encoding an antibacterial agent or a component thereof, wherein the DNA comprises a phage packaging signal;
    • (c) Introducing the DNA into the host cells;
    • (d) Inducing production of the structural proteins in host cells, whereby transduction particles are produced that package the DNA;
    • (e) Optionally isolating a plurality of the transduction particles; and
    • (f) Optionally formulating the particles into a pharmaceutical composition for administration to a human or animal for medical use.


A plurality of transduction particles obtainable by the method.





BRIEF DESCRIPTION OF THE FIGURES


FIG. 1 shows a genetic map of P2 genome.



FIG. 2 shows an exemplary saPI system (SaPIbov1).



FIG. 3 shows exemplary SaPIs.





DETAILED DESCRIPTION

The invention relates to the production of phage using DNAs (eg, plasmids with helper phage), as well as the phage, helper phage, compositions and methods involving these. The invention finds utility, for example, for containing phage in environments ex vivo and in vivo, reducing the risk of acquisition of antibiotic resistance or other genes by phage, as well as controlling dosing of phage in an environment. The contamination of useful phage populations by helper phage may in examples also be restricted or eliminated, thereby controlling phage propagation and enhancing the proportion of desired phage in phage compositions, such as medicaments, herbicides and other agents where phage may usefully be used. Thus, the invention provides the following embodiments.


A kit comprising

  • a) A first DNA; and
  • b) One or more second DNAs;
  • Wherein
  • (i) the DNAs together comprise all phage structural protein genes required to produce a packaged phage particle comprising a copy of the first DNA;
  • (ii) the first DNA comprises none or at least one, but not all, of the genes; and wherein the one or more second DNAs comprise the remainder of the genes;
  • (iii) the first DNA comprises a phage packaging signal for producing the packaged phage particle; and
  • (iv) the second DNA is devoid of a nucleotide sequence required for packaging the second DNA into phage particles;
  • wherein the DNAs are operable when co-existing in a host bacterium for producing packaged phage that comprise the first DNA, wherein the phage require the second DNA for replicaton thereof to produce further phage particles.


For example the second DNA is devoid of a packaging signal for packaging second DNA. Additionally or alternatively, the second DNA is devoid of a nucleotide sequence required for replication of helper phage. Optionally, the nucleotide sequence enodes a sigma factor or comprises a sigma factor recognition site, a DNA polymerisation recognition site, or a promoter of a gene required for helper phage DNA replication when the second DNA is comprised by a helper prophage.


In an example, the second DNA is comprised by an M13 or M13-based helper phage. M13 encodes the following proteins required for phage packaging:

  • a. pIII: host recognition
  • b. pV: coat protein
  • c. pVII, pVIII, pIX: membrane proteins
  • d. pI, pIV, pXI: Channel for translocating the phage to the extracellular space.


In this example, the second DNA is devoid of one or more of the genes coding for these proteins, eg, is devoid of a gene endoding pIII, a gene encoding pV, a gene endoding pVII, a gene endoding pVIII, a gene endoding pIX, a gene endoding pI, a gene endoding pIV and/or a gene endoding XI.


In an embodiment, the phage particle of (i) is capable of infecting a target bacterium, the phage comprising a nucleotide sequence of interest (NSI) that is capable of expressing a protein or RNA in the target bacterium, or wherein the NSI comprises a regulatory element that is operable in the target bacterium. In an example, the NSI is capable of recombination with the target cell chromosome or an episome comprised by the target cell to modify the chromosome or episome. Optionally, this is carried out in a method wherein the chromosome or episome is cut (eg, at a predetermined site using a guided nuclease, such as a Cas, TALEN, zinc finger or meganuclease; or a restriction endonuclease) and simultaneously or sequentially the cell is infected by a phage particle that comprises the first DNA, wherein the DNA is introduced into the cell and the NSI or a sequence thereof is introduced into the chromosome or episome at or adjacent the cut site. In an example the first DNA comprises one or more components of a CRISPR/Cas system operable to perform the cutting (eg, comprising at least a nucleotide sequence encoding a guide RNA or crRNA for targeting the site to be cut) and further comprising the NSI.


In an embodiment, the presence in the target bacterium of the NSI or its encoded protein or RNA mediates target cell killing, or downregulation of growth or propagation of target cells, or mediates switching off of expression of one or more RNA or proteins encoded by the target cell genome, or downregulation thereof.


In an embodiment, the presence in the target bacterium of the NSI or its encoded protein or RNA mediates upregulation of growth or propagation of the target cell, or mediates switching on of expression of one or more RNA or proteins encoded by the target cell genome, or upregulation thereof.


In an embodiment, the NSI encodes a component of a CRISPR/Cas system that is toxic to the target bacterium.


In an embodiment, the DNA is a first DNA as defined in any preceding paragraph.


In an embodiment, the first DNA is comprised by a vector (eg, a plasmid or shuttle vector).


In an embodiment, the second DNA is comprised by a vector (eg, a plasmid or shuttle vector), helper phage (eg, a helper phagemid) or is integrated in the genome of a host bacterial cell.


An embodiment provides a bacterial cell comprising the first and second DNAs. Optionally, the cell is devoid of a functional CRISPR/Cas system before transfer therein of a first DNA, eg, a first DNA comprising a component of a CRISPR/Cas system that is toxic to the target bacterium. An embodiment provides an antibacterial composition comprising a plurality of cells, wherein each cell is optionally according to this paragraph, for administration to a human or animal subject for medical use.


A method of producing phage is provided, the method comprising expressing in a host bacterial cell the phage protein genes, wherein packaged phage are produced that comprise the first DNA, wherein the phage require the second DNA for replicaton thereof to produce further phage particles. Optionally, the method comprises isolating the phage particles.


A composition comprising a population of phage particles obtainable by the method is provided for administration to a human or animal subject for treating an infection of target bacterial cells, wherein the phage are capable of infecting and killing the target cells.


A method of treating an environment ex vivo, the method comprising exposing the environment to a population of phage particles obtainable by the method is provided, wherein the environment comprises target bacteria and the phage infect and kill the target bacteria. In an example thje subject is further administered an agent simultaneously or sequentially with the phage administration. In an example, the agent is a herbicide, pesticide, insecticide, plant fertilizer or cleaning agent.


Optionally, the method is for containing the treatment in the environment.


Optionally, the method is for controlling the dosing of the phage treatment in the environment.


Optionally, the method is for reducing the risk of acquisition of foreign gene sequence(s) by the phage in the environment.


A method of treating an infection of target bacteria in a human or animal subject is provided, the method comprising exposing the bacteria to a population of phage particles obtainable by the production method, wherein the phage infect and kill the target bacteria.


Optionally, the method for treating is for containing the treatment in the subject.


Optionally, the method for treating is for containing the treatment in the environment in which the subject exists.


Optionally, the method for treating is for controlling the dosing of the phage treatment in the subject.


Optionally, the method for treating is for reducing the risk of acquisition of foreign gene sequence(s) by the phage in the subject.


Optionally, the method for treating is for reducing the risk of acquisition of foreign gene sequence(s) by the phage in the environment in which the subject exists.


Optionally, target bacteria herein are comprised by a microbiome of the subject, eg, a gut microbiome. Altertnatively, the microbiome is a skin, scalp, hair, eye, ear, oral, throat, lung, blood, rectal, anal, vaginal, scrotal, penile, nasal or tongue microbiome.


In an example thje subject is further administered a medicament simultaneously or sequentially with the phage administration. In an example, the medicament is an antibiotic, antibody, immune checkpoint inhibitor (eg, an anti-PD-1, anti-PD-L1 or anti-CTLA4 antibody), adoptive cell therapy (eg, CAR-T therapy) or a vaccine.


In an example, the invention employs helper phage for packaging the phage nucleic acid of interest. Thus, the invention provides the following illustrative Aspects:

  • 1. A population of helper phage, wherein the helper phage are capable of packaging first phage nucleic acid to produce first phage particles, wherein the first phage are different from the helper phage and the helper phage are incapable themselves of producing helper phage particles.
  • 2. A composition comprising a population of first phage, wherein the first phage require helper phage according to Aspect 1 for replication of first phage particles; and optionally wherein less than 20, 15, 10, 5, 4, 3, 2, 1, 0.5, 0.4, 0.2 or 0.1% of total phage particles comprised by the composition are particles of such helper phage.


In an example, the population comprises at least 103,104,105 or 106 phage particles, as indicated a transduction assay, for example. To have a measure of the first phage concentration, for example, one can perform a standard transduction assay when the first phage genome contains an antibiotic marker. Thus, in this case the first phage are capable of infecting target bacteria and in a sample of 1 ml the population comprises at least 103,104,105 or 106 transducing particles, which can be determined by infecting susceptible bacteria at a multiplicity of infection <0.1 and determining the number of infected cells by plating on a selective agar plate corresponding to the antibiotic marker in vitro at 20 to 37 degrees centigrade, eg, at 20 or 37 degrees centigrade.


Optionally at least 99.9, 99.8, 99.7, 99.6, 99.5, 99.4, 99.3, 99.2, 99.1, 90, 85, 80, 70, 60, 50 or 40% of total phage particles comprised by the composition are particles of first phage.


In an example, the first phage genome comprises an f1 origin of replication.


In an example, the helper phage are E coli phage. In an example, the first phage are E coli, C Streptococcus, Klebsiella, Pseudomonas, Acitenobacter, Enterobacteracea, Firmicutes or Bacteroidetes phage. In an example, the helper phage are engineered M13 phage.


In an example, the first phage genome comprises a phagemid, wherein the phagemid comprises a packaging signal for packaging first phage particles in the presence of the helper phage.


The first phage particles may contain a nucleotide sequence of interest (NSI), eg, as defined herein, such as a NSI that encodes a component of a CRISPR/Cas system operable in target bacteria that can be infected by the first phage particles. Once inside the target bacteria, the first phage DNA is incapable of being packaged to form first phage particles in the absence of the helper phage. This usefully contains the activity of the first phage genome and its encoded products (protieins and/or nucleic acid), as well as limits or controls dosing of the NSI and its encoded products in an environment comprising the target bacteria that have been exposed to the first phage. This is useful, for example to control the medical treatment of an environment comprised by a human or animal subject, plant or other environment (eg, soil or a foodstiff or food ingredient).

  • 3. The helper phage or composition of any preceding Aspect, wherein the genome of each first phage is devoid of genes encoding first phage structural proteins.
  • 4. The composition of Aspect 2 or 3, wherein the composition comprises helper phage DNA.
  • 5. The composition of Aspect 4, wherein the DNA comprises helper DNA fragments.
  • 6. The helper phage or composition of any one preceding Aspect, wherein the helper phage are in the form of prophage.


Thus, the prophage is integrated in the chromosome of a host cell.


Examples of phage structural proteins are phage coat proteins, collar proteins and phage tail fibre proteins.

  • 7. The composition of any one of Aspects 2 or 3, wherein the composition comprises no helper phage DNA comprising a sequence of 20 contiguous nucleotides or more, eg, no helper phage DNA.


This can be determined, for example, using DNA probes (designed on the basis of the known heper phge genome sequence) with PCR, as is conventional. In an example, the composition may comprise residual helper prophage DNA, but essentially otherwise is devoid of helper DNA.

  • 8. The composition of any one of Aspects 2 to 5 and 7, wherein the helper phage are capable of infecting host bacteria and the composition does not comprise host bacteria.
  • 9. The composition of any one of Aspects 2 to 8, wherein the composition is a lysate of host bacterial cells, wherein the lysate comprises helper prophage DNA, eg, such DNA comprises 20 contiguous nucleotides or more of helper phage DNA.
  • 10. The composition of any one of Aspects 2 to 8, wherein the composition is a lysate of host bacterial cells, wherein the lysate has been processed (eg, filtered) to remove all or some helper phage DNA; or the composition is a lysate of host bacterial cells that is devoid of cellular material.
  • 11. The composition of any one of Aspects 2 to 10, wherein the composition does not comprise helper phage particles.
  • 12. The composition of any one of Aspects 2 to 11, wherein at least 95% (eg, 100%) of phage particles comprised by the composition are first phage particles.


In another embodiment, the composition comprises second phage particles, wherein the second phage are different from the first phage and are not helper phage.

  • 13. The composition of any one of Aspects 2 to 12, wherein the population comprises at least 103, 104, 105 or 106 phage particles, as indicated in a transduction assay.
  • 14. The helper phage or composition of any preceding Aspect, wherein the first phage are capable of replicating in host bacteria in the presence of the helper phage (eg, helper prophage), wherein the first phage comprise antibacterial means for killing target bacteria of a first strain or species, wherein the target bacteria are of a different strain or species and the antibacterial means is not operable to kill the target bacteria.
  • 15. A composition comprising a population of phage, the population comprising
    • (a) A first sub-population of first phage that require a helper phage for packaging the first phage;
    • (b) A second sub-population of phage comprising the helper phage, wherein the helper phage are as recited in any preceding Aspect.
  • 16. The helper phage or composition of any preceding Aspect, wherein the helper phage are phagemids.
  • 17. A composition comprising
    • (a) A population of helper phage as recited in any preceding Aspect; and
    • (b) A population of nucleic acid vectors comprising vector DNA that comprises a first phage packaging signal;
    • (c) wherein the helper phage are capable of packaging the vector DNA to produce first phage.
  • 18. The composition of Aspect 17, wherein the vectors are phage.
  • 19. The composition of Aspect 17, wherein the vectors are plasmids or phagemids.
  • 20. The composition of Aspect 19, the vectors are shuttle vectors (eg, pUC vectors) that can be replicated in first bacteria, wherein the vectors can further be replicated and packaged into first phage in second bacteria (host bacteria) in the presence of the helper phage, wherein the first bacteria are of a strain or species that is different to the strain or species of the host bacteria.
  • 21. The composition of Aspect 21, wherein the first phage are capable of infecting third bacteria of a strain or species that is different to the second (and optionally also the first) bacteria.
  • 22. The composition of any one of Aspects 17 to 21, wherein the first phage are capable of replicating in host bacteria in the presence of the helper phage (eg, helper prophage), wherein the first phage comprise antibacterial means for killing target bacteria of a first strain or species, wherein the host bacteria are of a different strain or species and the antibacterial means is not operable to kill the host bacteria.
  • 23. The helper phage or composition of any preceding Aspect, wherein the genome is devoid of a packaging signal (eg, SEQ ID NO:1 below), wherein the helper phage are incapable of self-replication.
  • 24. The helper phage or composition of Aspect 24, wherein the signal is a pac or cos sequence.
  • 25. The helper phage or composition of any preceding Aspect, wherein the helper phage genome is capable of replication in a host cell.


Thus, the genome is capable of nucleic acid replication but not packaging of helper phage.

  • 26. The helper phage or composition of any one of Aspects 1 to 24, wherein the genome is devoid of a nucleotide sequence required for production of helper phage particles.
  • 27. The helper phage or composition of Aspect 26, wherein the nucleotide sequence enodes a sigma factor (eg, sigma-70) or comprises a sigma factor recognition site, a DNA polymerisation recognition site, or a promoter of a gene required for helper phage DNA replication.
  • 28. The helper phage or composition of any preceding Aspect, wherein the helper phage are temperate phage.
  • 29. The helper phage or composition of any one of Aspects 1 to 27, wherein the helper phage are lytic phage.
  • 30. The helper phage or composition of any preceding Aspect, wherein the first phage are capable of infecting target bacteria, the first phage comprising a nucleotide sequence of interest (NSI) that is capable of expressing a protein or RNA (eg, gRNA or crRNA) in target bacteria, or wherein the NSI comprises a regulatory element that is operable in target bacteria.
  • 31. The helper phage or composition of Aspect 30, wherein the presence in target bacteria of the NSI or its encoded protein or RNA mediates target cell killing, or downregulation of growth or propagation of target cells, or mediates switching off of expression of one or more RNA or proteins encoded by the target cell genomes, or downregulation thereof.
  • 32. The helper phage or composition of Aspect 30, wherein the presence in target bacteria of the NSI or its encoded protein or RNA mediates upregulation of growth or propagation of target cells, or mediates switching on of expression of one or more RNA or proteins encoded by the target cell genomes, or upregulation thereof.
  • 33. An antibacterial composition according to any one of Aspects 2 to 32, wherein the first phage are capable of infecting target bacteria and each first phage comprises engineered antibacterial means for killing target bacteria.


By use of the term “engineered” it will be readily apparent to the skilled addressee that the relevant means has been introduced and is not naturally-occurring in the phage. For example, the means is recombinant, artificial or synthetic.

  • 34. The composition of Aspect 14, 22 or 33, wherein the antibacterial means comprises one or more components of a CRISPR/Cas system.
  • 35. The composition of caim 34, wherein the component(s) comprise (i) a DNA sequence encoding a guide RNA (eg, a single guide RNA) or comprising a CRISPR array for producing guide RNA, wherein the guide RNA is capable of targeting the genome of target bacteria; (ii) a Cas nuclease-encoding DNA sequence; and/or (iii) a DNA sequence encoding one or more components of Cascade.


In an example, a Cas herein is a Cas9. In an example, a Cas herein is a Cas3. The Cas may be identical to a Cas encoded by the target bacteria.

  • 36. The composition of any one of Aspects 14, 22 or 33 to 35, wherein the antibacterial means comprises a nucleic acid encoding a guided nuclease, such as a Cas nuclease, TALEN, zinc finger nuclease or meganuclease.
  • 37. The helper phage or composition of any preceding Aspect, wherein the helper phage is for use in medicine practised on a human or animal subject, or the composition is a pharmaceutical composition for use in medicine practised on a human or animal subject.


In an example, the animak is a livestock or companion pet animal (eg, a cow, pig, goat, sheep, horse, dog, cat or rabbit). In an example, the animal is an insect (an insect at any stage of its lifecycle, eg, egg, larva or pupa). In an example, the animal is a protozoan. In an example, the animal is a cephalopod.

  • 38. The composition of any one of Aspects 2 to 36, wherein the composition is a herbicide, pesticide, food or beverage processing agent, food or beverage additive, petrochemical or fuel processing agent, water purifying agent, cosmetic additive, detergent additive or environmental (eg, soil) additive or cleaning agent.
  • 39. The helper phage or composition of any one of Aspects 1 to 37 for use in a contained method of treating a disease or condition of a human or animal subject, wherein the disease or condition is mediated by the target bacteria and the target bacteria are comprised by the subject, the method comprising administering the composition to the subject, whereby the target bacteria are exposed to the antibacterial means and killed and propagation of the first phage is contained.


The inability of the first phage to self-replicate and to require helper phage or second DNA to do this usefully provides containment in the location (eg, gut) of action of the composition and/or in the environment of the subject, eg, when exposed to secretions such as urine and faeces of the subject that otherwise may contain replicated first phage. Inability of the helper phage or second DNA to self-package limits availability of factors required by the first phage to form packaged particles, hence providing containment by limiting first phage propagation. This may be useful, for example, to contain an antibacterial acitivity provided by the first phage, such as a CRISPR/Cas killing principle.

  • 40. A bacterial cell or a plurality of bacterial cells comprising the helper phage or composition of any preceding Aspect, wherein the first phage are capable of replication in the presence of the helper phage in the cell.


The cell may, for example, act as a carrier for the genome of the first phage, wherein the first phage DNA is capable of horizontal transfer from the carrier to the target bacteria once the carrier bacteria have been administered to an environment to be treated, eg, a soil or a human gut or other environment described herein. In an example, the environment is comprised by a human or animal subject and the carrier are commensal or probiotic in the subject. For example the carrier bacteria are Lactobacillus (eg, L reuteri or L lactis), E coli or Streptococcus (eg, S thermophilus) bacteria. The horizontal transfer can be transfer of a plasmid (such as a conjugative plasmid) to the target bacteria or first phage infection of the target bacteria, wherein the first phage have been prior packaged in the carrier. The use of a carrier is useful too for oral administration or other routes where the carrier can provide protection for the phage, helper or composition from the acid stomach or other harsh environments in the subject. Furthermore, the carrier can be formulated into a beverage, for example, a probiotic drink, eg, an adapted Yakult (trademark), Actimel (trademark), Kevita (trademark), Activia (trademark), Jarrow (trademark) or similar drink for human consumption.

  • 41. The cell(s) of Aspect 40 for administration to a human or animal subject for medical use, comprising killing target bacteria using first phage, wherein the target bacteria mediate as disease or condition in the subject.


In an example, when the subject is a human, the subject is not an embryo.

  • 42. The cell(s) of Aspect 41, wherein the cell(s) comprises helper phage and is symbiotic or probiotic in the subject.
  • 43. A method of killing target bacteria in an environment, optionally wherein the method is not practised on a human or animal body, wherein the method comprises exposing the environment to the cell(s) according to Aspect 42, or a composition obtained or obtainable by the method of any one of Aspects 57 to 65, wherein the environment is or has been exposed to first phage or said vectors to produce first phage in the presence of the helper phage, wherein the first phage are capable of replication in the environment and kill target bacteria.
  • 44. The cell(s) or method of any one of Aspects 40 to 43, wherein the cell is an E coli, Lactobacillus (eg, L lactis or retueri) or Streptococcus (eg, thermophilus) cell.
  • 45. The cell(s) or method of Aspects 40 to 44 wherein the subject is administered or has been administered a cell comprising first phage.
  • 46. The composition of any one of Aspects 2 to 45 in combination with a target bacterial cell wherein the first phage are capable of infecting the target bacterial cell.
  • 47. Use of the helper phage, composition or cell(s) of any one of Aspects 1 to 42 and 44 to 46, or a composition obtained or obtainable by the method of any one of Aspects 57 to 65, in the manufacture of an antibacterial agent that kills target bacteria, for containment of the antibacterial in an environment, eg, containment ex vivo; or containment in a human or animal subject comprising the environment.
  • 48. Use of the helper phage, composition or cell(s) of any one of Aspects 1 to 42 and 44 to 46, or a composition obtained or obtainable by the method of any one of Aspects 57 to 65, in the manufacture of an antibacterial agent that kills the target bacteria, for reducing the risk of acquisition by the first phage of foreign genes.


For example, this is useful for reducing the risk of antibiotic resistance genes by the phage, such as when the phage are in the presence of other phage or plasmids in the environment.

  • 49. Use of the helper phage, composition or cell(s) of any one of Aspects 1 to 42 and 44 to 46, or a composition obtained or obtainable by the method of any one of Aspects 57 to 65, in the manufacture of an antibacterial agent that kills the target bacteria, for reducing the risk of acquisition by the first phage of one or more antibiotic resistance genes. 50. A method of reducing the risk of acquisition by first phage of foreign genes, the method comprising
    • (a) Providing the composition of any one of Aspects 2 to 42 and 44 to 46, or a composition obtained or obtainable by the method of any one of Aspects 57 to 65; and
    • (b) Exposing target bacteria to the composition, wherein the first phage infect the target bacteria;
    • (c) wherein the helper phage are incapable of self-replication and propagation of first phage is thereby limited, wherein propagation of first phage is prevented or reduced, thereby reducing the risk of acquisition of first phage of foreign genes (eg, antibiotic resistance genes).
  • 51. A method of containing an antibacterial activity in an environment (e.g., ex vivo), the method comprising
    • (a) Providing an antibacterial composition according to any one of Aspects 2 to 42 and 44 to 46, or a composition obtained or obtainable by the method of any one of Aspects 57 to 65; and
    • (b) Exposing target bacteria in the environment to the composition, wherein the bacteria are exposed to the first phage and antibacterial means and are killed;
    • (c) wherein the helper phage are incapable of self-replication and propagation of first phage is thereby limited, wherein propagation of first phage is prevented or reduced, thereby containing the antibacterial activity.


52. A method of controlling the dosing of first phage in an environment (e.g., ex vivo), the method comprising

    • (a) Providing an antibacterial composition according to any one of Aspects 2 to 42 and 44 to 46, or a composition obtained or obtainable by the method of any one of Aspects 57 to 65; and
    • (b) Exposing target bacteria in the environment to the composition, wherein the bacteria are infected by first phage;
    • (c) wherein the helper phage are incapable of self-replication and propagation of first phage is thereby limited, wherein propagation of first phage is prevented or reduced, thereby controlling dosing of first phage in the environment.
  • 53. The method of any one of Aspects 43 to 45, 51 and 52, or the use of Aspect 47, wherein the environment is a human or animal microbiome, e.g., a gut microbiome.
  • 54. The method of any one of Aspects 43 to 45, 51 and 52, or the use of Aspect 47, wherein the environment is a microbiome of soil; a plant, part of a part (e.g., a leaf, fruit, vegetable or flower) or plant product (e.g., pulp); water; a waterway; a fluid; a foodstuff or ingredient thereof; a beverage or ingredient thereof; a medical device; a cosmetic; a detergent; blood; a bodily fluid; a medical apparatus; an industrial apparatus; an oil rig; a petrochemical processing, storage or transport apparatus; a vehicle or a container.
  • 55. The method of any one of Aspects 43 to 45, 51 and 52, or the use of Aspect 47, wherein the environment is an ex vivo bodily fluid (e.g., urine, blood, blood product, sweat, tears, sputum or spit), bodily solid (e.g., faeces) or tissue of a human or animal subject that has been administered the composition.
  • 56. The method of any one of Aspects 43 to 45, 51 and 52, or the use of Aspect 47, wherein the environment is an in vivo bodily fluid (e.g., urine, blood, blood product, sweat, tears, sputum or spit), bodily solid (e.g., faeces) or tissue of a human or animal subject that has been administered the composition.
  • 57. A method of producing first phage, wherein the first phage require helper phage to replicate, the method comprising
    • (a) Providing DNA comprising a packaging signal;
    • (b) Introducing the DNA into a host bacterial cell;
    • (c) Wherein the host bacterial cell comprises helper phage or wherein helper phage are introduced into the bacterial cell simultaneously or sequentially with step (b);
    • (d) Wherein the helper phage are according to any preceding Aspect;
    • (e) Causing or allowing the helper phage to produce phage coat proteins, wherein the packaging signal is recognised in the host cell, whereby first phage are produced using the proteins, the first phage packaging the DNA;
    • (f) Wherein helper phage particle production in the host cell is inhibited or reduced, thereby limiting the availability of helper phage particles;
    • (g) Optionally lysing the host cell and obtaining the first phage;
    • (h) Thereby producing a composition comprising first phage which require the helper phage for replication, wherein further production of first phage particles is prevented or reduced by the limitation of helper phage availability in the composition.


In an embodiment, the DNA is comprised by a phagemid or cloning vector (eg, a shuttle vector, eg, a pUC vector).


There may be a modest amount of helper phage DNA replication to enable first phage protein production efficiently, or should replication of helper phage DNA may be eliminated totally eliminated.

  • 58. The method of Aspect 57, wherein in (c) the helper phage are prophage integrated in the bacterial cell chromosome.
  • 59. The method of Aspect 59, wherein (e) comprises inducing replication of helper phage DNA and/or expression of the proteins, eg, using UV, mitomycin.
  • 60. The method of any one of Aspects 57 to 59, wherein (g) comprises further separating the first phage from cellular material or helper phage DNA.
  • 61. The method of any one of Aspects 57 to 60, wherein the composition comprises a population of first phage particles, wherein the composition does not comprise helper phage DNA and/or particles.
  • 62. The method of any one of Aspects 57 to 61, wherein the DNA of (a) comprises engineered antibacterial means for killing target bacteria.
  • 63. The method of Aspect 62, wherein the antibacterial means comprises one or more components of a CRISPR/Cas system.
  • 64. The method of Aspect 63, wherein the component(s) comprise (i) a DNA sequence encoding a guide RNA (eg, a single guide RNA) or comprising a CRISPR array for producing guide RNA, wherein the guide RNA is capable of targeting the genome of target bacteria; (ii) a Cas (eg, Cas9, Cas3, Cpfl, CasX or CasY) nuclease-encoding DNA sequence; and/or (iii) a DNA sequence encoding one or more components of Cascade (eg, CasA).
  • 65. The method of any one of Aspects 62 to 64, wherein the antibacterial means comprises a nucleic acid encoding a guided nuclease, such as a Cas nuclease, TALEN, zinc finger nuclease or meganuclease.
  • 66. The helper phage, composition or cell(s) of any one of Aspects 1 to 42 and 44 to 46, or a composition obtained or obtainable by the method of any one of Aspects 57 to 65, for antibacterial treatment of target bacteria in a human or animal subject whereby the antibacterial treatment is contained in the subject.
  • 67. The helper phage, composition or cell(s) of any one of Aspects 1 to 42 and 44 to 46, or a composition obtained or obtainable by the method of any one of Aspects 57 to 65, for antibacterial treatment of target bacteria in a gut of a human or animal subject whereby the antibacterial activity in one or more bodily excretions of the subject is reduced.


This is useful as a safety measure to reduce or eliminate first phage activity outside the subject.

  • 68. The helper phage, composition or cell(s) of Aspect 67, wherein the antibacterial activity in one or more bodily excretions of the subject is eliminated.
  • 69. The helper phage, composition or cell(s) of any one of Aspects 1 to 42 and 44 to 46, or a composition obtained or obtainable by the method of any one of Aspects 57 to 65, for controlling the dosing of antibacterial treatment of target bacteria in a human or animal subject, eg, in the gut of the subject.


Usefully, propagation of the first phage is restricted or eliminated, so dosing in the subject can be controlled, or even pre-determined within a narrow expected range. This is useful, for example, for medicaments comprising the first phage or composition, and may be aid approval of such medicines before FDA and simiar authorities.


Alternatively, the dosing is dosing of an environment, such as soil etc disclosed herein, wherein limitation of the first phage or composition activity is also desirable to limit spread of activities in natural and other terrains.

  • 70. The helper phage, composition or cell(s) of any one of Aspects 1 to 42 and 44 to 46, or a composition obtained or obtainable by the method of any one of Aspects 57 to 65, for fixing the dosing of antibacterial treatment of target bacteria in a human or animal subject, eg, in the gut of the subject.
  • 71. A phage production system, for producing phage (eg, the first phage of any preceding Aspect) comprising a nucleotide sequence of interest (NSI-phage), the system comprising components (i) to (iii):
    • (a) A first DNA;
    • (b) A second DNA; and
    • (c) a NSI-phage production factor (NPF) or an expressible nucleotide sequence that encodes a NPF;
    • Wherein
    • (d) The first DNA encodes a helper phage (eg, said first helper phage recited in any preceding Aspect);
    • (e) The second DNA comprises the nucleotide sequence of interest (NSI);
    • (f) When the system is comprised by a bacterial host cell, helper phage proteins are expressed from the first DNA to form phage that package the second DNA in the presence of the NPF, thereby producing NSI-phage; and
    • (g) The system is devoid of a helper phage production factor (HPF) that is required for forming helper phage particles that package the first DNA, or is devoid of an expressible nucleotide sequence that encodes a functional HPF; or the system comprises a nucleotide sequence that comprises or encodes a functional HPF, the system further comprising means for targeted inactivation in the host cell of the HPF sequence to eliminate or minimise production of helper phage comprising the first DNA;


Whereby the system is capable of producing a product comprising a population of NSI-phage, wherein each NSI-phage requires a said helper phage for propagation, optionally wherein the NSI-phage in the product are not mixed with helper phage or less than 20% of total phage comprised by the product are said helper phage.


The invention includes within its concept relatively low level of helper phage particle production if there is a residual capability of helper phage to replicate to produce particles, such as for example in the case that a helper phage packaging signal or other HPF nucleotide sequence in the helper phage genome is mutated (eg, by deletion, substitution or addition of nucleotides therein) to knock down the ability to form phage particles. Preferably, there is no production of helper phage particles, such as by deleting all or part of the sequence from the helper phage genome or inactivating the sequence.

  • 72. A method of producing first phage, wherein the first phage require helper phage to replicate, the method comprising
    • (a) Providing in host cells the system of Aspect 71;
    • (b) Causing or allowing the helper phage proteins to be produced, whereby the second DNA is packaged to produce first phage; and
    • (c) Optionally lysing the host cells and obtaining a composition comprising first phage.
  • 73. The method of Aspect 72, wherein step (c) comprises separating the first phage from cellular material.
  • 74. The method of Aspect 72 or 73, wherein the composition comprises a population of first phage, wherein less than 20, 10, 5, 4, 3, 2, 1, 0.5 or 0.1% of total phage comprised by the composition are helper phage.
  • 75. The method of any one of Aspects 72 to 74, wherein the second DNA comprises engineered antibacterial means for killing target bacteria.
  • 76. The method of Aspect 75, wherein the antibacterial means comprises one or more components of a CRISPR/Cas system.
  • 77. The method of Aspect 76 wherein the component(s) comprise (i) a DNA sequence encoding a guide RNA (eg, a single guide RNA) or comprising a CRISPR array for producing guide RNA, wherein the guide RNA is capable of targeting the genome of target bacteria; (ii) a Cas nuclease-encoding DNA sequence; and/or (iii) a DNA sequence encoding one or more components of Cascade.
  • 78. The method of any one of Aspects 75 to 77, wherein the antibacterial means comprises a nucleic acid encoding a guided nuclease, such as a Cas nuclease, TALEN, zinc finger nuclease or meganuclease
  • 79. The system of method of any one of Aspects 71 to 78, wherein the first phage are capable of infecting target bacteria, the NSI being capable of expressing a protein or RNA in target bacteria, or wherein the NSI comprises a regulatory element that is operable in target bacteria.
  • 80. The system or method of Aspect 79, wherein the presence in target bacteria of the NSI or its encoded protein or RNA mediates target cell killing, or downregulation of growth or propagation of target cells, or mediates switching off of expression of one or more RNA or proteins encoded by the target cell genomes, or downregulation thereof.
  • 81. The system or method of Aspect 79, wherein the presence in target bacteria of the NSI or its encoded protein or RNA mediates upregulation of growth or propagation of target cells, or mediates switching on of expression of one or more RNA or proteins encoded by the target cell genomes, or upregulation thereof.
  • 82. The system of method of any one of Aspects 71 to 81, wherein each of the NPF and HPF is a packaging signal, eg, SEQ ID NO:1 or a sequence that is at least 70, 80, 90, 95, 96, 97, 98 or 99% identical thereto, or is a homologue from a different species.
  • 83. The system of method of Aspect 82, wherein each signal is a pac or cos sequence, or is a homologue.
  • 84. The system of method of any one of Aspects 71 to 81, wherein the HPF is a nucleotide sequence required for replication of helper phage.
  • 85. The system of method of any one of Aspects 71 to 81, wherein the HPF enodes a sigma factor (eg, sigma-70) or comprises a sigma factor recognition site, a DNA polymerisation recognition site, or a promoter of a gene required for helper phage DNA replication, a helper phage integrase, a helper phage excissionase or a helper phage origin of replication,
  • 86. A composition comprising a population of first phage obtainable by the method of any one of Aspects 72 to 85, wherein the genome of each first phage is devoid of genes encoding phage proteins.
  • 87. The composition of Aspect 86, wherein the first phage comprise antibacterial means as recited in any one of Aspects 75 to 78.
  • 88. The composition of Aspect 87, comprising DNA identical to the first DNA or fragments thereof.
  • 89. The composition of Aspect 88, wherein the DNA of the composition is identical to the first DNA and is devoid of a helper phage packaging signal.
  • 90. The composition of any one of Aspects 86 to 89 for antibacterial treatment of target bacteria in a human or animal subject whereby the antibacterial treatment is contained in the subject.
  • 91. The composition of any one of Aspects 86 to 89 for antibacterial treatment of target bacteria in a gut of a human or animal subject whereby the antibacterial activity in one or more bodily excretions of the subject is reduced.
  • 92. The composition of Aspect 91, wherein the antibacterial activity in one or more bodily excretions of the subject is eliminated.
  • 93. The composition of any one of Aspects 86 to 89 for controlling the dosing of antibacterial treatment of target bacteria in a human or animal subject, eg, in the gut of the subject.
  • 94. The composition of any one of Aspects 86 to 89 for fixing the dosing of antibacterial treatment of target bacteria in a human or animal subject, eg, in the gut of the subject.
  • 95. An isolated DNA comprising all structural protein genes of a helper phage genome that are required for producing phage particles, wherein the DNA is devoid of a helper phage production factor (HPF) that is required for producing packaged helper phage, optionally wherein the DNA comprises one or more promoters for expression of the genes when the DNA is integrated in the genone of a host bacterial cell.
  • 96. The DNA of Aspect 95, wherein the DNA is devoid of any phage packaging signals.
  • 97. The DNA of Aspect 95 or 96, wherein the HPF is a sigma factor-encoding nucleotide sequence or comprises a sigma factor recognition site, a DNA polymerisation recognition site, a promoter of a gene required for helper phage DNA replication, a helper phage integrase-encoding nucleotide sequence, a helper phage excissionase-encoding nucleotide sequence or a helper phage origin of replication.
  • 98. The DNA of any one of Aspects 95 to 97, wherein the DNA comprises a nucleotide sequence encoding a CRISPR/Cas system repressor.
  • 99. The DNA of any one of Aspects 95 to 98, wherein the DNA is integrated in the chromosome of a host bacterial cell, wherein the genes are expressible in the host cell.
  • 100. The DNA of Aspect 99, wherein the cell is devoid of an active CRISPR/Cas system.
  • 101. The DNA of any one of Aspects 95 to 100 in combination with a second DNA, wherein the second DNA comprises the HPF.
  • 102. The DNA of any one of Aspects 95 to 100 in combination with a second DNA, wherein the second DNA comprises a phage packaging signal and optionally the first DNA is devoid of a phage packaging signal.
  • 103. The DNA of Aspect 101 or 102, wherein the second DNA is comprised by a phagemid or a plasmid (eg, a shuttle vector).


In an example, the kit, DNA(s), first phage, helper phage or composition is comprised by a medical container, eg, a syringe, vial, IV bag, inhaler, eye dropper or nebulizer. In an example, the kit, DNA(s), first phage, helper phage or composition is comprised by a sterile container. In an example, the kit, DNA(s), first phage, helper phage or composition is comprised by a medically-compatible container. In an example, the kit, DNA(s), first phage, helper phage or composition is comprised by a fermentation vessel, eg, a metal, glass or plastic vessel.


In an example, the kit, DNA(s), first phage, helper phage or composition is comprised by a medicament, e,g in combination with instructions or a packaging label with directions to administer the medicament by oral, IV, subcutaneous, intranasal, intraocular, vaginal, topical, rectal or inhaled administration to a human or animal subject. In an example, the kit, DNA(s), first phage, helper phage or composition is comprised by an oral medicament formulation. In an example, the kit, DNA(s), first phage, helper phage or composition is comprised by an intranasal or ocular medicament formulation. In an example, the kit, DNA(s), first phage, helper phage or composition is comprised by a personal hygiene composition (eg, shampoo, soap or deodorant) or cosmetic formulation. In an example, the kit, DNA(s), first phage, helper phage or composition is comprised by a detergent formulation. In an example, the kit, DNA(s), first phage, helper phage or composition is comprised by a cleaning formulation, eg, for cleaning a medical or industrial device or apparatatus. In an example, the kit, DNA(s), first phage, helper phage or composition is comprised by foodstuff, foodstuff ingredient or foodstuff processing agent. In an example, the kit, DNA(s), first phage, helper phage or composition is comprised by beverage, beverage ingredient or beverage processing agent. In an example, the kit, DNA(s), first phage, helper phage or composition is comprised by a medical bandage, fabric, plaster or swab. In an example, the kit, DNA(s), first phage, helper phage or composition is comprised by a herbicide or pesticide. In an example, the kit, DNA(s), first phage, helper phage or composition is comprised by an insecticide.


In an example, the first phage is a is a Corticoviridae, Cystoviridae, Inoviridae, Leviviridae, Microviridae, Myoviridae, Podoviridae, Siphoviridae, or Tectiviridae virus. In an example, the helper phage is a is a Corticoviridae, Cystoviridae, Inoviridae, Leviviridae, Microviridae, Myoviridae, Podoviridae, Siphoviridae, or Tectiviridae virus. In an example, the helper phage is a filamentous M13, a Noviridae, a tailed phage (eg, a Myoviridae, Siphoviridae or Podoviridae), or a non-tailed phage (eg, a Tectiviridae).


In an example, both the first and helper phage are Corticoviridae. In an example, both the first and helper phage are Cystoviridae. In an example, both the first and helper phage are Inoviridae. In an example, both the first and helper phage are Leviviridae. In an example, both the first and helper phage are Microviridae. In an example, both the first and helper phage are Podoviridae. In an example, both the first and helper phage are Siphoviridae. In an example, both the first and helper phage are Tectiviridae.


In an example, the CRISPR/Cas component(s) are component(s) of a Type I CRISPR/Cas system. In an example, the CRISPR/Cas component(s) are component(s) of a Type II CRISPR/Cas system. In an example, the CRISPR/Cas component(s) are component(s) of a Type III CRISPR/Cas system. In an example, the CRISPR/Cas component(s) are component(s) of a Type IV CRISPR/Cas system. In an example, the CRISPR/Cas component(s) are component(s) of a Type V CRISPR/Cas system. In an example, the CRISPR/Cas component(s) comprise a Cas9-encoding nucleotide sequence (eg, S pyogenes Cas9, S aureus Cas9 or S thermophilus Cas9). In an example, the CRISPR/Cas component(s) comprise a Cas3-encoding nucleotide sequence (eg, E coli Cas3, C dificile Cas3 or Salmonella Cas3). In an example, the CRISPR/Cas component(s) comprise a Cpf-encoding nucleotide sequence. In an example, the CRISPR/Cas component(s) comprise a CasX-encoding nucleotide sequence. In an example, the CRISPR/Cas component(s) comprise a CasY-encoding nucleotide sequence.


In an example, the first DNA, first phage or vector encode a CRISPR/Cas component or protein of interest from a nucleotide sequence comprising a promoter that is operable in the target bacteria.


In an example, the host bacteria and/or target bacteria are E coli. In an example, the host bacteria and/or target bacteria are C dificile (eg, the vector is a shuttle vector operable in E coli and the host bacteria are C dificile). In an example, the host bacteria and/or target bacteria are Streptococcus, such as S thermophilus (eg, the vector is a shuttle vector operable in E coli and the host bacteria are Streptococcus). In an example, the host bacteria and/or target bacteria are Pseudomonas, such as P aeruginosa (eg, the vector is a shuttle vector operable in E coli and the host bacteria are P aeruginosa). In an example, the host bacteria and/or target bacteria are Klebsiella (eg, the vector is a shuttle vector operable in E coli and the host bacteria are Klebsiella). In an example, the host bacteria and/or target bacteria are Salmonella, eg, S typhimurium (eg, the vector is a shuttle vector operable in E coli and the host bacteria are Salmonella).


Optionally, host and/or target bacteria is a gram negative bacterium (eg, a spirilla or vibrio). Optionally, host and/or target bacteria is a gram positive bacterium. Optionally, host and/or target bacteria is a mycoplasma, chlamydiae, spirochete or mycobacterium. Optionally, host and/or target bacteria is a Streptococcus (eg, pyogenes or thermophilus). Optionally, host and/or target bacteria is a Staphylococcus (eg, aureus, eg, MRSA). Optionally, host and/or target bacteria is an E. coli (eg, O157: H7) host, eg, wherein the Cas is encoded by the vecor or an endogenous host Cas nuclease activity is de-repressed. Optionally, host and/or target bacteria is a Pseudomonas (eg, aeruginosa). Optionally, host and/or target bacteria is a Vibro (eg, cholerae (eg, O139) or vulnificus). Optionally, host and/or target bacteria is a Neisseria (eg, gonnorrhoeae or meningitidis). Optionally, host and/or target bacteria is a Bordetella (eg, pertussis). Optionally, host and/or target bacteria is a Haemophilus (eg, influenzae). Optionally, host and/or target bacteria is a Shigella (eg, dysenteriae). Optionally, host and/or target bacteria is a Brucella (eg, abortus). Optionally, host and/or target bacteria is a Francisella host. Optionally, host and/or target bacteria is a Xanthomonas host. Optionally, host and/or target bacteria is a Agrobacterium host. Optionally, host and/or target bacteria is a Erwinia host. Optionally, host and/or target bacteria is a Legionella (eg, pneumophila). Optionally, host and/or target bacteria is a Listeria (eg, monocytogenes). Optionally, host and/or target bacteria is a Campylobacter (eg, jejuni). Optionally, host and/or target bacteria is a Yersinia (eg, pestis). Optionally, host and/or target bacteria is a Borelia (eg, burgdorferi). Optionally, host and/or target bacteria is a Helicobacter (eg, pylori). Optionally, host and/or target bacteria is a Clostridium (eg, dificile or botulinum). Optionally, host and/or target bacteria is a Erlichia (eg, chaffeensis). Optionally, host and/or target bacteria is a Salmonella (eg, typhi or enterica, eg, serotype typhimurium, eg, DT 104). Optionally, host and/or target bacteria is a Chlamydia (eg, pneumoniae). Optionally, host and/or target bacteria is a Parachlamydia host. Optionally, host and/or target bacteria is a Corynebacterium (eg, amycolatum). Optionally, host and/or target bacteria is a Klebsiella (eg, pneumoniae). Optionally, host and/or target bacteria is an Enterococcus (eg, faecalis or faecim, eg, linezolid-resistant). Optionally, host and/or target bacteria is an Acinetobacter (eg, baumannii, eg, multiple drug resistant).


Further examples of target cells and targeting of antibiotic resistance in such cells using the present invention are as follows:

  • 1. Optionally the target bacteria are Staphylococcus aureus cells, eg, resistant to an antibiotic selected from methicillin, vancomycin, linezolid, daptomycin, quinupristin, dalfopristin and teicoplanin.
  • 2. Optionally the target bacteria are Pseudomonas aeuroginosa cells, eg, resistant to an antibiotic selected from cephalosporins (eg, ceftazidime), carbapenems (eg, imipenem or meropenem), fluoroquinolones, aminoglycosides (eg, gentamicin or tobramycin) and colistin.
  • 3. Optionally the target bacteria are Klebsiella (eg, pneumoniae) cells, eg, resistant to carbapenem.
  • 4. Optionally the target bacteria are Streptoccocus (eg, thermophilus, pneumoniae or pyogenes) cells, eg, resistant to an antibiotic selected from erythromycin, clindamycin, beta-lactam, macrolide, amoxicillin, azithromycin and penicillin.
  • 5. Optionally the target bacteria are Salmonella (eg, serotype Typhi) cells, eg, resistant to an antibiotic selected from ceftriaxone, azithromycin and ciprofloxacin.
  • 6. Optionally the target bacteria are Shigella cells, eg, resistant to an antibiotic selected from ciprofloxacin and azithromycin.
  • 7. Optionally the target bacteria are mycobacterium tuberculosis cells, eg, resistant to an antibiotic selected from Resistance to isoniazid (INH), rifampicin (RMP), fluoroquinolone, amikacin, kanamycin and capreomycin and azithromycin.
  • 8. Optionally the target bacteria are Enterococcus cells, eg, resistant to vancomycin. 9. Optionally the target bacteria are Enterobacteriaceae cells, eg, resistant to an antibiotic selected from a cephalosporin and carbapenem.
  • 10. Optionally the target bacteria are E. coli cells, eg, resistant to an antibiotic selected from trimethoprim, itrofurantoin, cefalexin and amoxicillin.
  • 11. Optionally the target bacteria are Clostridium (eg, dificile) cells, eg, resistant to an antibiotic selected from fluoroquinolone antibiotic and carbapenem.
  • 12. Optionally the target bacteria are Neisseria gonnorrhoea cells, eg, resistant to an antibiotic selected from cefixime (eg, an oral cephalosporin), ceftriaxone (an injectable cephalosporin), azithromycin and tetracycline.
  • 13. Optionally the target bacteria are Acinetoebacter baumannii cells, eg, resistant to an antibiotic selected from beta-lactam, meropenem and a carbapenem.
  • 14. Optionally the target bacteria are Campylobacter cells, eg, resistant to an antibiotic selected from ciprofloxacin and azithromycin.
  • 15. Optionally, the target cell(s) produce Beta (β)-lactamase.
  • 16. Optionally, the target cell(s) are bacterial cells that are resistant to an antibiotic recited in any one of examples 1 to 14.


Mobile Genetic Elements, Genomic Islands, Pathogenicity Islands etc.

Genetic variation of bacteria and archaea can be achieved through mutations, rearrangements and horizontal gene transfers and recombinations. Increasing genome sequence data have demonstrated that, besides the core genes encoding house-keeping functions such as essential metabolic activities, information processing, and bacterial structural and regulatory components, a vast number of accessory genes encoding antimicrobial resistance, toxins, and enzymes that contribute to adaptation and survival under certain environmental conditions are acquired by horizontal gene transfer of mobile genetic elements (MGEs). Mobile genetic elements are a heterogeneous group of molecules that include plasmids, bacteriophages, genomic islands, chromosomal cassettes, pathogenicity islands, and integrative and conjugative elements. Genomic islands are relatively large segments of DNA ranging from 10 to 200 kb often integrated into tRNA gene clusters flanked by 16-20 bp direct repeats. They are recognized as discrete DNA segments acquired by horizontal gene transfer since they can differ from the rest of the chromosome in terms of GC content (%G+C) and codon usage.


Pathogenicity islands (PTIs) are a subset of horizontally transferred genetic elements known as genomic islands. There exists a particular family of highly mobile PTIs in Staphylococcus aureus that are induced to excise and replicate by certain resident prophages. These PTIs are packaged into small headed phage-like particles and are transferred at frequencies commensurate with the plaque-forming titer of the phage. This process is referred to as the SaPI excision replication-packaging (ERP) cycle, and the high-frequency SaPI transfer is referred to as SaPI-specific transfer (SPST) to distinguish it from classical generalized transduction (CGT). The SaPIs have a highly conserved genetic organization that parallels that of bacteriophages and clearly distinguishes them from all other horizontally acquired genomic islands. The SaPI1-encoded and SaPIbov2-encoded integrates are used for both excision and integration of the corresponding elements, and it is assumed that the same is true for the other SaPIs. Phage 80a can induce several different SaPIs, including SaPI1, SaPI2, and SaPIbov1, whereas φ11 can induce SaPIbov1 but neither of the other two SaPIs.


Reference is made to “Staphylococcal pathogenicity island DNA packaging system involving cos-site packaging and phage-encoded HNH endonucleases”, Quiles-Puchalt et al, PNAS Apr. 22, 2014. 111 (16) 6016-6021. Staphylococcal pathogenicity islands (SaPIs) are highly mobile and carry and disseminate superantigen and other virulence genes. It was reported that SaPIs hijack the packaging machinery of the phages they victimise, using two unrelated and complementary mechanisms. Phage packaging starts with the recognition in the phage DNA of a specific sequence, termed “pac” or “cos” depending on the phage type. The SaPI strategies involve carriage of the helper phage pac- or cos-like sequences in the SaPI genome, which ensures SaPI packaging in full-sized phage particles, depending on the helper phage machinery. These strategies interfere with phage reproduction, which ultimately is a critical advantage for the bacterial population by reducing the number of phage particles.


Staphylococcal pathogenicity islands (SaPIs) are the prototypical members of a widespread family of chromosomally located mobile genetic elements that contribute substantially to intra- and interspecies gene transfer, host adaptation, and virulence. The key feature of their mobility is the induction of SaPI excision and replication by certain helper phages and their efficient encapsidation into phage-like infectious particles. Most SaPIs use the headful packaging mechanism and encode small terminase subunit (TerS) homologs that recognize the SaPI-specific pac site and determine SaPI packaging specificity. Several of the known SaPIs do not encode a recognizable TerS homolog but are nevertheless packaged efficiently by helper phages and transferred at high frequencies. Quiles-Puchalt et al report that one of the non-terS-coding SaPIs, SaPIbov5, and found that it uses two different, undescribed packaging strategies. SaPIbov5 is packaged in full-sized phage-like particles either by typical pac-type helper phages, or by cos-type phages—i.e., it has both pac and cossites and uses the two different phage-coded TerSs. This is an example of SaPI packaging by a cos phage, and in this, it resembles the P4 plasmid of Escherichia coli. Cos-site packaging in Staphylococcus aureus is additionally unique in that it requires the HNH nuclease, carried only by cos phages, in addition to the large terminase subunit, for cos-site cleavage and melting.


Characterization of several of the phage-inducible SaPIs and their helper phages has established that the pac (or headful) mechanism is used for encapsidation. In keeping with this concept, some SaPIs encode a homolog of TerS, which complexes with the phage-coded large terminase subunit TerL to enable packaging of the SaPI DNA in infectious particles composed of phage proteins. These also contain a morphogenesis (cpm) module that causes the formation of small capsids commensurate with the small SaPI genomes. Among the SaPI sequences first characterized, there were several that did not include either a TerS homolog or a cpm homolog, and the same is true of several subsequently identified SaPIs from bovine sources and for many phage-inducible chromosomal islands from other species. It was assumed, for these several islands, either that they were defective derivatives of elements that originally possessed these genes, or that terS and cpm genes were present but not recognized by homology.


Quiles-Puchalt et al observed that an important feature of φSLT/SaPIbov5 packaging is the requirement for an HNH nuclease, which is encoded next to the φSLT terminase module. Proteins carrying HNH domains are widespread in nature, being present in organisms of all kingdoms. The HNH motif is a degenerate small nucleic acid-binding and cleavage module of about 30-40 aa residues and is bound by a single divalent metal ion. The HNH motif has been found in a variety of enzymes playing important roles in many different cellular processes, including bacterial killing; DNA repair, replication, and recombination; and processes related to RNA. HNH endonucleases are present in a number of cos-site bacteriophages of Gram-positive and -negative bacteria, always adjacent to the genes encoding the terminases and other morphogenetic proteins. Quiles-Puchalt et al have demonstrated that the HNH nucleases encoded by φ12 and the closely related φSLT have nonspecific nuclease activity and are required for the packaging of these phages and of SaPIbov5. Quiles-Puchalt et al have shown that HNH and TerL are jointly required for cos-site cleavage. Quiles-Puchalt et al have also observed that only cos phages of Gram-negative as well as of Gram-positive bacteria encode HNH nucleases, consistent with a special requirement for cos-site cleavage as opposed to pac-site cleavage, which generates flush-ended products. The demonstration that HNH nuclease activity is required for some but not other cos phages suggests that there is a difference between the TerL proteins of the two types of phages—one able to cut both strands and the other needing a second protein to enable the generation of a double-stranded cut.


The invention, also involves, in certain configurations the use of mobile genetic elements (MGEs). Thus, there are provided the following Clauses. Any of the other configurations, Aspects, Examples or description of the invention above or elsewhere herein are combinable mutatis mutandis with any of these Clauses:

  • 1. A composition for use in antibacterial treatment of bacteria, the composition comprising an engineered mobile genetic element (MGE) that is capable of being mobilised in a first bacterial host cell of a first species or strain, the cell comprising a first phage genome, wherein in the cell the MGE is mobilised using proteins encoded by the phage and replication of first is inhibited, wherein the MGE encodes an antibacterial agent or encodes a component of such an agent.


In the alternative, instead of a bacteria, the host cell is a archaeal cell and instead of a phage there is a virus that is capable of infecting the archaeal cell.


In an example, the MGE is capable of integration into the genome of the host cell comprising the genome of a first phage, for example integration in the chromosome of the host cell and/or an episome thereof. Optionally, the MGE inhibits first phage replication.


In an example, first phage replication is totally inhibited. In an example, it is reduced by at least 50, 60, 70, 80 or 90% compared to replication in the absence of the MGE in host cells. This can be assessed by a standard in vitro plaque assay to determine the relative amount of first phage plaque formation.


Optionally, in the presence of the agent,

    • (i) host cells are killed by the antibacterial agent;
    • (ii) growth or proliferation of host cells is reduced; and/or
    • (iii) host cells are sensitised to an antibiotic, whereby the antibiotic is toxic to the cells.
    • 2. The composition of Clause 1, wherein the agent is toxic to cells of the same species or strain as the host cell.
    • 3. The composition of Clause 1 or 2, wherein the agent is toxic to cells of a species or strain that is different from the strain or species of the host cell.
    • 4. The composition of Clause 1, wherein the agent is toxic to cells of the same species as the host cell, and wherein the host cell has been engineered so that the agent is not toxic to the host cell.
    • 5. The composition of Clause 4, wherein the agent is a guided nuclease system (optionally a CRISPR/Cas system) and cells of the same species as the host cell comprise a target sequence that is cut by the nuclease, wherein the target sequence has been removed or altered in the host cell whereby the nuclease is not capable of cutting the target sequence.


Viruses undergo lysogenic and lytic cycles in a host cell. If the lysogenic cycle is adopted, the phage chromosome can be integrated into the bacterial chromosome, or it can establish itself as a stable plasmid in the host, where it can remain dormant for long periods of time. If the lysogen is induced, the phage genome is excised from the bacterial chromosome and initiates the lytic cycle, which culminates in lysis of the cell and the release of phage particles. The lytic cycle leads to the production of new phage particles which are released by lysis of the host.

  • 6. The composition of any preceding Clause, wherein the first phage is a temperate phage.
  • 7. The composition of any preceding Clause, wherein the first cell comprises the first phage as a prophage.
  • 8. The composition of any one of Clauses 1 to 5, wherein the first phage is a lytic phage.
  • 9. The composition of any preceding Clause, wherein in the presence of a first phage the mobilisation of the MGE causes host cell lysis.
  • 10. The composition of any preceding Clause, wherein the MGE is capable of being packaged in transduction particles that comprise some, but not all, structural proteins of the first phage.


“Transduction particles” may be phage or smaller than phage and are particles that are capable of transducing nucleic acid encoding the antibiotic or component thereof into target bacterial cells.


Examples of structural proteins are phage proteins selected from one, more or all of the major head and tail proteins, the portal protein, tail fibre proteins, and minor tail proteins.


The MGE comprises a packaging signal sequence operable with proteins encoded by the first phage to package the MGE (or at least nucleic acid thereof encoding the agent or one or more components thereof) into transduction particles that are capable of infecting host cells of the same species or strain as the first host cell.

  • 11. The composition of any preceding Clause, wherein mobilisation of the MGE comprises packaging of copies of the MGE or nucleic acid encoding the agent or component into transduction particles that are capable of transferring the copies into target bacterial cells for antibacterial treatment of the target cells.
  • 12. The composition of Clause 10 or 11, wherein the transduction particles are particles of second phage that are capable of infecting cells of said first species or strain.
  • 13. The composition of any one of Clauses 10 to 12, wherein the transduction particles are non-self replicative particles.


A “non-self replicative transduction particle” refers to a particle, (eg, a phage or phage-like particle; or a particle produced from a genomic island (eg, a SaPI) or a modified version thereof) capable of delivering a nucleic acid molecule encoding an antibacterial agent or component into a bacterial cell, but does not package its own replicated genome into the transduction particle. In an alternative herein, instead of a phage, there is used or packaged a virus that infects an animal, human, plant or yeast cell. For example, an adenovirus when the cell is a human cell.

  • 14. The composition of any preceding Clause, wherein the MGE is devoid of genes encoding phage structural proteins.


Optionally, the MGE is devoid of one or more phage genes rinA, terS and terL. In an example, in a host cell a protein complex comprising the small terminase (encoded by terS) and large terminase (encoded by terL) proteins is able to recognise and cleave a double-stranded DNA molecule of the MGE at or near the pac site (cos site or other packaging signal sequence comprised by the MGE), and this allows the MGE or plasmid DNA molecule to be packaged into a phage capsid. When first phage as prophage in the host cell is induced, the lytic cycle of the phage produces the phage's structural proteins and the phage's large terminase protein. The MGE or plasmid is replicated, and the small terminase protein encoded by the MGE or plasmid is expressed. The replicated MGE or plasmid DNA containing the terS (and the nucleotide sequence encoding the antibacterial agent or component) are packaged into phage capsids, resulting in non-self replicative transduction particles carrying only MGE or plasmid DNA.

  • 15. The composition of any one of Clauses 1 to 13, wherein the MGE comprises phage structural genes and a packaging signal sequence and the first phage is devoid of a packaging signal sequence.
  • 16. The composition of any preceding Clause, wherein the MGE is a modified version of a MGE that is naturally found in bacterial cells of the first species or strain.
  • 17. The composition of any preceding Clause, wherein the MGE comprises a modified genomic island.


Optionally, the genomic island is an island that is naturally found in bacterial cells of the first species or strain. In an example, the genomic island is selected from the group consisting of a SaPI, a SaPI1, a SaPI2, a SaPIbov1 and a SaPibov2 genomic island.

  • 18. The composition of any preceding Clause, wherein the MGE comprises a modified pathogenicity island.


Optionally, the pathogenicity island is an island that is naturally found in bacterial cells of the first species or strain, eg, a Staphylococcus SaPI or a Vibro PLE or a P. aeruginosa pathogenicity island (eg, a PAPI or a PAGI, eg, PAPI-1, PAGI-5, PAGI-6, PAGI-7, PAGI-8, PAGI-9, PAGI-10, or PAGI-text missing or illegible when filed

  • 19. The composition of Clause 18, wherein the pathogenicity island is a SaPI (S aureus pathogenicity island).
  • 20. The composition of Clause 19, wherein the first phage is φ11, 80 α, φ12 or φSLT. Staphylococcus phage 80α appears to mobilise all known SaPIs. Thus, in an example, the MGE comprises a modified SaPI and the first phage is a 80α.
  • 21. The composition of Clause 18, wherein the pathogenicity island is a V. cholerae PLE (phage-inducible chromosomal island-like element) and optionally the first phage is ICP1.
  • 22. The composition of Clause 18, wherein the pathogenicity island is a E coli PLE.
  • 23. The composition of any one of Clauses 1 to 16, wherein the MGE comprises P4 DNA, eg, a P4 packaging signal sequence.
  • 24. The composition of Clause 23, wherein the first phage are P2 phage or a modified P2 phage that is self-replicative defective; optionally present as a prophage.
  • 25. The composition of any preceding Clause, wherein the MGE comprises a pacA gene of the Enterobacteriaceae bacteriophage P1.
  • 26. The composition of any preceding Clause, wherein the MGE comprises a packaging initiation site sequence, optionally a packaging initiation site sequence of P1.
  • 27. The composition of any preceding Clause, wherein the MGE comprises a nucleotide sequence that is beneficial to cells of the first species or strain, optionally encoding a protein that is beneficial to cells of the first species or strain.


This is useful where, not only does the presence of the MGE reduce first phage replication in the host cell, but also the MGE is taken up and may provide a survival, growth or other benefit to the host cell, promoting uptake and/or retention of MGEs by host cells. In an example, expression of the antibacterial agent in the host cell is under the control of an inducible promoter or weak promoter to allow for a period where uptake of MGEs into host cells may be favoured owing to the presence of the nucleotide sequence that is beneficial to cells of the first species or strain.

  • 28. The composition of any preceding Clause, wherein the MGE is devoid of rinA.
  • 29. The composition of any preceding Clause, wherein the MGE is is devoid of terL.
  • 30. The composition of any preceding Clause, wherein the MGE comprises a terS or a homologue thereof, and optionally is devoid of any other terminase gene.


The terS homologues are sequences which, like terS, recognise the SaPI-specific pac site (or other packaging sequence) comprised by the MGE or plasmid and determine packaging specificity for packaging the MGE.


Examples of terminase genes are pacA, pacB, terA, terB and terL.

  • 31. The composition of any preceding Clause, wherein the first phage is a pac-type phage (eg, φ11 or 80α) operable with a pac comprised by the MGE.
  • 32. The composition of any one of Clauses 1 to 30, wherein the first phage is a cos-type phage (eg, φ12 or φSLT) operable with a cos comprised by the MGE.


Optionally, the phage is P2. Optionally, the first phage is a T7 or T7-like phage that recognises direct repeat sequences comprised by the MGE for packaging.

  • 33. The composition of any preceding Clause, wherein the plasmid or MGE comprises a pac and/or cos sequence or a homologue thereof.
  • 34. The composition of any preceding Clause, wherein the plasmid or MGE comprises a terS or a homologue thereof and optionally devoid of terL.


The terS homologues are sequences which, like terS, recognise the SaPI-specific pac site (or other packaging sequence) comprised by the MGE or plasmid and determine packaging specificity for packaging the MGE.


In an example, the terS comprises the sequence of SEQ ID NO: 2:









SEQ ID NO: 2


AATTGGCAGTAAAGTGGCAGTTTTTGATACCTAAAATGAGATATTATGAT





AGTGTAGGATAT





TGACTATCTTACTGCGTTTCCCTTATCGCAATTAGGAATAAAGGATCTAT





GTGGGTTGGCTG





ATTATAGCCAATCCTTTTTTAATTTTAAAAAGCGTATAGCGCGAGAGTTG





GTGGTAAATGAA





ATGAACGAAAAACAAAAGAGATTCGCAGATGAATATATAATGAATGGATG





TAATGGTAAAAA





AGCAGCAATTTCAGCAGGTTATAGTAAGAAAACAGCAGAGTCTTTAGCAA





GTCGATTGTTAA





GAAATGTTAATGTTTCGGAATATATTAAAGAACGATTAGAACAGATACAA





GAAGAGCGTTTA





ATGAGCATTACAGAAGCTTTAGCGTTATCTGCTTCTATTGCTAGAGGAGA





ACCTCAAGAGGC





TTACAGTAAGAAATATGACCATTTAAACGATGAAGTGGAAAAAGAGGTTA





CTTACACAATCA





CACCAACTTTTGAAGAGCGTCAGAGATCTATTGACCACATACTAAAAGTT





CATGGTGCGTAT





ATCGACAAAAAAGAAATTACTCAGAAGAATATTGAGATTAATATTGGTGA





GTACGATGACGA





AAGTTAAATTAAACTTTAACAAACCATCTAATGTTTTCAACAG






  • 35. The composition of Clause 34, wherein the terS is a S aureus bacteriophage φ80α terS or a bacteriophage φ11 terS.

  • 36. The composition of any preceding Clause, wherein the MGE is a modified SaPIbov1 or SaPIbov5 and is devoid of a terS.

  • 37. The composition of any preceding Clause, wherein the first phage is devoid of a functional packaging signal sequence and the MGE comprises a packaging signal sequence operable with proteins encoded by the first phage for producing transduction particles that package copies of the MGE or copies of a nucleic acid encoding the agent or component.

  • 38. The composition of any preceding Clause, wherein the MGE or plasmid comprises a Ppi or homologue, which is capable of complexing with first phage TerS, thereby blocking function of the TerS.

  • 39. The composition of any preceding Clause, wherein the MGE comprises a morphogenesis (cpm) module.

  • 40. The composition of any preceding Clause, wherein the MGE comprises cpmA and/or cpmB.



Optionally the cpmA and B are from any SaPI disclosed herein. In an example any SaPI is a SaPI disclosed in FIG. 3 and optionally the host cell or target cell is any corresponding Staphylococcus disclosed in the table.

  • 41. The composition of any preceding Clause, wherein the MGE or first phage comprises one, more or all genes cp1, cp2, and cp3.


In an example, the MGE comprises a modified SaPI and comprises one, more or all genes cp1, cp2, and cp3.

  • 42. The composition of any preceding Clause, wherein the MGE or first phage encodes a HNH nuclease.
  • 43. The composition of any preceding Clause, wherein the MGE or first phage comprises an integrase gene that encodes an integrase for excising the MGE and integrating the MGE into a bacterial cell genome.
  • 44. The composition of any preceding Clause, wherein the MGE is devoid of a functional integrase gene, and the first phage or host cell genome (eg, bacterial chromosome or a bacterial episome) comprises a functional integrase gene.
  • 45. The composition of any preceding Clause, wherein the transcription of MGE nucleic acid is under the control of a constitutive promoter, for transcription of copies of the agent or component in a host cell.


Optionally, Constitutive transcription and production of the agent in target cells may be used where the target cells should be killed, eg, in medical settings.


Optionally, the transcription of MGE nucleic acid is under the control of an inducible promoter, for transcription of copies of the agent or component in a host cell. This may be useful, for example, to control switching on of the antibacterial activity against target bacterial cells, such as in an environment (eg, soil or water) or in an industrial culture or fermentation container containing the target cells. For example, the target cells may be useful in an industrial process (eg, for fermentation, eg, in the brewing or dairy industry) and the induction enables the process to be controlled (eg, stopped or reduced) by using the antibacterial agent against the target bacteria.

  • 46. The composition of Clause 45, wherein the promoter is foreign to the host cell.
  • 47. The composition of Clause 45 or 46, wherein the promoter comprises a nucleotide sequence that is at least 80% identical to an endogenous promoter sequence of the host cell.
  • 48. The composition of any preceding Clause comprising a nucleic acid that is separate from the MGE, wherein the nucleic acid comprises all genes necessary for producing first phage particles.
  • 49. The composition of any one of Clauses 1 to 47 comprising a nucleic acid that is separate from the MGE, wherein the nucleic acid comprises less than, all genes necessary for producing first phage particles, but comprises genes encoding structural proteins for production of transduction particles that package MGE nucleic acid encoding the antibacterial agent or one or more components thereof.


When the agent comprises a plurality of components, eg, wherein the agent is a CRISPR/Cas system, or is a CRISPR array encoding crRNA or a nucleic acid encoding a guide RNA (eg, single guide RNA) operable with a Cas in host cells, wherein the crRNA or gRNA guides the Cas to a target sequence in the host cell to modify the target (eg, cut it or repress transcription from it).

  • 50. The composition of Clause 48 or 49, wherein the genes are comprised by the host cell chromosome and/or one or more host cell episome(s).
  • 51. The composition of Clause 50, wherein the genes are comprised by a chromosomally-integrated prophage of the first phage.
  • 52. The composition of any preceding Clause, wherein the agent is a guided nuclease system or a component thereof, wherein the agent is capable of recognising and cutting host cell DNA (eg, chromosomal DNA).


In examples, such cutting causes one or more of the following:

    • (i) The host cel is killed by the antibacterial agent;
    • (ii) growth or proliferation of the host cell is reduced; and/or
    • (iii) The host cell is sensitised to an antibiotic, whereby the antibiotic is toxic to the cell.
  • 53. The composition of Clause 52, wherein the guided nuclease system is selected from a CRISPR/Cas system, TALEN system, meganuclease system or zinc finger system.
  • 54. The composition of Clause 52, wherein the system is a CRISPR/Cas system and each MGE encodes a (a) CRISPR array encoding crRNA or (b) a nucleic acid encoding a guide RNA (gRNA, eg, single guide RNA), wherein the crRNA or gRNA is operable with a Cas in target bacterial cells, wherein the crRNA or gRNA guides the Cas to a target nucleic acid sequence in the host cell to modify the target sequence (eg, cut it or repress transcription from it).


Optionally, the Cas is a Cas encoded by a functional endogenous nucleic acid of a host cell. For example, the target is comprised by a DNA or RNA of the host cell.

  • 55. The composition of Clause 52, wherein the system is a CRISPR/Cas system and each MGE encodes a Cas (eg, a Cas nuclease) that is operable in a target bacterial cells to modify a target nucleic acid sequence comprised by the target cell.
  • 56. The composition of Clause 53, 54 or 55, wherein the Cas is a Cas3, Cas9, Cas13, CasX, CasY or Cpf1.
  • 57. The composition of any one of Clauses 52 to 56, wherein the system is a CRISPR/Cas system and each MGE encodes one or more Cascade Cas (eg, Cas, A, B, C, D and E).
  • 58. The composition of any one of Clauses 52 to 57, wherein each MGE further encodes a Cas3 that is operable in a target bacterial cell with the Cascade Cas.
  • 59. The composition of any preceding Clause, wherein the first species or strain is a gram positive species or strain.
  • 60. The composition of any one of Clauses 1 to 58, wherein the first species or strain is a gram negative species or strain.
  • 61. The composition of any preceding Clause, wherein the first species or strain is selected from Table 1.


In an example, the first species of strain is a Staphylococcus (eg, S aureus) species or strain and optionally the MGE is a modified SaPI; and optionally the first phage is a φ80α or φ11. In an example, the first species of strain is a Vibrio (eg, V cholerae) species or strain and optionally the MGE is Vibrio (eg, V cholerae) PLE.

  • 62. The composition of any preceding Clause, wherein the first species or strain is selected from Shigella, E coli, Salmonella, Serratia, Klebsiella, Yersinia, Pseudomonas and Enterobacter.


These are species that P2 phage can infect. Thus, in an embodiment, the MGE comprises one or more P4 sequences (eg, a P4 packaging sequence) and the first phage is P2. Thus, the MGE is packaged by P2 structural proteins and the resultant transduction particles can infect a broad spectrum of species, ie, two or more of Shigella, E coli, Salmonella, Serratia, Klebsiella, Yersinia, Pseudomonas and Enterobacter.

  • 63. A nucleic acid vector comprising a MGE integrated therein, wherein the MGE is according to any preceding Clause and the vector is capable of transferring the MGE or a copy thereof into a host bacterial cell.


Suitable vectors are plasmids (eg, conjugative plasmids) or viruses (eg, phage or packaged phagemids).

  • 64. The vector of Clause 63, wherein the vector is a shuttle vector.


A shuttle vector is a vector (usually a plasmid) constructed so that it can propagate in two different host species. Therefore, DNA inserted into a shuttle vector can be tested or manipulated in two different cell types.

  • 65. The vector of Clause 63, wherein the vector is a plasmid, wherein the plasmid is capable of being transformed into a host bacterial cell comprising a first phage.
  • 66. A non-self replicative transduction particle comprising said MGE or vector of any preceding Clause.


By “non-replicative” it is meant that the MGE is not capable by itself of self-replicating. For example, the MGE is devoid of one or more nucleotide sequences encoding a protein (eg, a structural protein) that is necessary to produce a transduction particle comprising a copy of the MGE.

  • 67. A composition comprising a plurality of transduction particles, wherein each particle comprises a MGE or vector according to any one of Clauses 1 to 65, wherein the transduction particles are capable of transferring the MGEs, or nucleic acid encoding the agent or component, or copies thereof into target bacterial cells, wherein
    • a. target cells are killed by the antibacterial agent;
    • b. growth or proliferation of target cells is reduced; or
    • c. target cells are sensitised to an antibiotic, whereby the antibiotic is toxic to the cells.


In an example, the reduction in growth or proliferation of host cells is at least 50, 60, 70, 80, 90 or 95%. The antibiotic can be any antibiotic disclosed herein.

  • 68. The composition of Clause 67, wherein the agent is a guided nuclease system or a component thereof, wherein the agent is capable of recognising and cutting host cell DNA (eg, chromosomal DNA) whereby
    • a. target cells are killed by the antibacterial agent;
    • b. growth or proliferation of target cells is reduced; or
    • c. target cells are sensitised to an antibiotic, whereby the antibiotic is toxic to the cells.
  • 69. A composition comprising a plurality of non-self replicative transduction particles, wherein each particle comprises a MGE or plasmid according to any one of Clauses 1 to 65, wherein the transduction particles are capable of transferring the MGEs, or nucleic acid encoding the agent or component, or copies thereof into target bacterial cells, wherein the agent is a CRISPR/Cas system and the component comprises a nucleic acid encoding a crRNA or a guide RNA that is operable with a Cas in a target bacterial cell to guide the Cas to a target nucleic acid sequence of the cell to modify the sequence, whereby
    • a. target cells are killed by the antibacterial agent;
    • b. growth or proliferation of target cells is reduced; or
    • c. target cells are sensitised to an antibiotic, whereby the antibiotic is toxic to the cells.


In an example, the reduction in growth or proliferation of host cells is at least 50, 60, 70, 80, 90 or 95%. The antibiotic can be any antibiotic disclosed herein.

  • 70. A kit comprising the composition of Clause 69 and said antibiotic.
  • 71. The composition of Clause 69, wherein the composition comprises said antibiotic.
  • 72. The composition of any one of Clauses 67 to 69, wherein less than 10% of transduction particles comprise by the composition are first phage particles.
  • 73. The composition of any one of Clauses 67 to 69, wherein no first phage particles are present in the composition.
  • 74. The MGE, vector, particle, composition or kit of any preceding Clause for medical use in a human or animal patient.
  • 75. The MGE, vector, particle, composition or kit of any preceding Clause for treating or preventing an infection by target bacterial cells in a human or animal patient, wherein the antibacterial agent is toxic to the target cells.
  • 76. The MGE, vector, particle, composition or kit of any preceding Clause for treating or preventing an infection by target bacterial cells in a human or animal patient, wherein in the presence of the antibacterial agent
    • a. target cells are killed by the antibacterial agent;
    • b. growth or proliferation of target cells is reduced; and/or
    • c. target cells are sensitised to an antibiotic, whereby the antibiotic is toxic to the cells.
  • 77. A method of producing a plurality of transduction particles, the method comprising combining the composition of any one of Clauses 1 to 62, 67 to 69 and 71 to 76 with host bacterial cells of said first species, wherein the cells comprise the first phage, allowing a plurality of said MGEs to be introduced into host cells and culturing the host cells under conditions in which first phage-encoded proteins are expressed and MGE copies are packaged by first phage proteins to produce a plurality of transduction particles, and optionally separating the transduction particles from cells and obtaining a plurality of transduction particles separated from cells.
  • 78. The method of Clause 77, comprising separating the transduction particles from any first phage, optionally by filtering or centrifugation, thereby obtaining a plurality of transduction particles in the absence of first phage.
  • 79. The method of Clause 77 or 78, wherein the particles encode a guided nuclease system (optionally a CRISPR/Cas system) or component thereof for cutting a target nucleic acid sequence comprised by target bacterial cells.
  • 80. The method of Clause 79, wherein the sequence is comprised by an antibiotic resistance gene and the method comprises combining the plurality of particles with said antibiotic in a kit or a mixture.
  • 81. The method of any one of Clauses 77 to 80, wherein said conditions comprise induction of a lytic cycle of the first phage.
  • 82. A bacterial host cell comprising a first phage and a MGE, vector or particle as recited in any one of Clauses 1 to 66, wherein the agent is toxic to cells of the same species as the host cell, and wherein the host cell has been engineered so that the agent is not toxic to the host cell.
  • 83. A bacterial host cell comprising a first phage, wherein the cell is comprised by a kit, the kit further comprising a composition as recited in any one of Clauses 1 to 62, 67 to 69 and 71 to 76, wherein the agent is toxic to cells of the same species as the host cell, and wherein the host cell has been engineered so that the agent is not toxic to the host cell.
  • 84. The cell of Clause 83, wherein the agent is a guided nuclease system (optionally a CRISPR/Cas system) and cells of the same species as the host cell comprise a target sequence that is cut by the nuclease, wherein the target sequence has been removed or altered in the host cell whereby the nuclease is not capable of cutting the target sequence.
  • 85. A bacterial host cell comprising a first phage and a MGE, vector or particle as recited in any one of Clauses 1 to 66, wherein the agent is not toxic to the host cell, but the agent is toxic to second cells of a species or strain that is different from the species or strain of the host cell, wherein the MGE is mobilizable in transduction particles producible by the host cell that are capable of transferring the MGE or a copy thereof into a said second cell, whereby the second cell is exposed to the antibacterial agent.
  • 86. A bacterial host cell comprising a first phage, wherein the cell is comprised by a kit, the kit further comprising a composition as recited in any one of Clauses 1 to 62, 67 to 69 and 71 to 76, wherein the agent is not toxic to the host cell, but the agent is toxic to second cells of a species or strain that is different from the species or strain of the host cell, wherein the MGE is mobilizable in transduction particles producible by the host cell that are capable of transferring the MGE or a copy thereof into a said second cell, whereby the second cell is exposed to the antibacterial agent.
  • 87. The cell of Clause 86, wherein the first phage is a prophage.
  • 88. A bacterial host cell comprising a MGE, vector or particle as recited in any one of Clauses 1 to 66 and nucleic acid under the control of one or more inducible promoters, wherein the nucleic acid encodes all structural proteins necessary to produce a transduction particle that packages a copy of the MGE or plasmid, wherein the agent is not toxic to the host cell, but the agent is toxic to second cells of a species or strain that is different from the species or strain of the host cell, wherein the MGE is mobilizable in transduction particles producible by the host cell that are capable of transferring the MGE or a copy thereof into a said second cell, whereby the second cell is exposed to the antibacterial agent.
  • 89. The cell of Clause 88, wherein the structural proteins are structural proteins of a lytic phage. 90. The cell of Clause 88 or 89, wherein the nucleic acid comprises terS and/or terL.
  • 91. The cell of any one of Clauses 88 to 90, wherein the host and second cells are of the same species and the host cell has been engineered so that the antibiotic is not toxic to the host cell.
  • 92. The cell of any one of Clauses 88 to 91, wherein the nucleic acid is comprised by a plasmid.
  • 93. The cell of any one of Clauses 88 to 92, wherein the agent is a guided nuclease system (optionally a CRISPR/Cas system) and the second cells comprise a target sequence that is cut by the nuclease, wherein the target sequence is absent in the genome of the host cell whereby the nuclease is not capable of cutting the host cell genome.
  • 94. The composition, vector, particle, kit or method of any preceding Clause, wherein the cell, host cell or target cell is selected from a Staphylococcal, Vibrio, Pseudomonas, Clostridium, E coli, Helicobacter, Klebsiella and Salmonella cell. 95. A plasmid comprising
    • a. A nucleotide sequence encoding an antibacterial agent or component thereof for expression in target bacterial cells;
    • b. A constitutive promoter for controlling the expression of the agent or component;
    • c. An optional terS nucleotide sequence;
    • d. An origin of replication (ori); and
    • e. A phage packaging sequence (optionally pac, cos or a homologue thereof); and
    • f. the plasmid being devoid of
    • g. All nucleotide sequences encoding phage structural proteins necessary for the production of a transduction particle (optionally a phage), or the plasmid being devoid of at least one of such sequences; and
    • h. Optionally terL.
  • 96. The plasmid of Clause 95, wherein the antibacterial agent is a CRISPR/Cas system and the plasmid encodes a crRNa or guide RNA (eg, single gRNA) that is operable with a Cas in the target cells to guide the Cas to a target nucleotide sequence to modify (eg, cut) the sequence, whereby
    • a. target cells are killed by the antibacterial agent;
    • b. growth or proliferation of target cells is reduced; or
    • c. target cells are sensitised to an antibiotic, whereby the antibiotic is toxic to the cells.
  • 97. The plasmid of Clause 95 or 96, wherein the antibacterial agent is a CRISPR/Cas system and the plasmid encodes a Cas that is operable with a crRNa or guide RNA (eg, single gRNA) in the target cells to guide the Cas to a target nucleotide sequence to modify (eg, cut) the sequence, whereby
    • a. target cells are killed by the antibacterial agent;
    • b. growth or proliferation of target cells is reduced; or
    • c. target cells are sensitised to an antibiotic, whereby the antibiotic is toxic to the cells.
  • 98. The plasmid of Clause 97, wherein the plasmid further encodes said crRNA or gRNA.
  • 99. A host cell comprising the plasmid of any one of Clauses 95 to 98, wherein the host cell does not comprise the target nucleotide sequence.
  • 100. The host cell of Clause 99, wherein the cell is capable of replicating the plasmid and packaging the replicated plasmid in transduction particles that are capable of infecting target bacterial cells.
  • 101. The host cell of Clause 99 or 100, wherein the host cell comprises, integrated in the cell chromosome and/or one or more episomes of the cell,
    • a. A terL;
    • b. An optional terS; and
    • c. Expressible nucleotide sequences encoding all structural proteins necessary for the production of transduction particles that package copies of the plasmid;
    • d. wherein the chromosome and episomes of the cell (other than said plasmid) are devoid of a phage packaging sequence, wherein the phage packaging sequence comprised by the plasmid is operable together with the product of said terS and terL in the production of packaged plasmid.
  • 102. The cell of Clause 101, wherein the terL, optional terS and nucleotide sequences encoding the structural proteins are comprised by a phage (optionally a prophage) genome in the host cell.
  • 103. A bacterial host cell comprising the genome of a helper phage that is incapable of self-replication, optionally wherein the genome is present as a prophage, and a plasmid according to any one of Clauses 95 to 98, wherein the helper phage is operable to package copies of the plasmid in transduction particles, wherein the particles are capable of infecting bacterial target cells to which the antibacterial agent is toxic.
  • 104. The cell of Clause 103, wherein the host cell is a cell of first species or strain and the target cells are of the same species or strain, and optionally wherein the hosts cell is an engineered cell that to which the antibacterial agent is not toxic.
  • 105. The cell of Clause 103, wherein the host cell is a cell of first species or strain and the target cells are of a different species or strain, wherein the antibacterial agent is not toxic to the host cell.
  • 106. A method of making a plurality of transduction particles, the method comprising culturing a plurality of host cells according to any one of Clauses 103 to 105, optionally inducing a lytic cycle of the helper phage, and incubating the cells under conditions wherein transducing particles comprising packaged copies of the plasmid are created, and optionally separating the particles from the cells to obtain a plurality of transduction particles.
  • 107. A plurality of transduction particles obtainable by the method of Clause 106 for use in medicine, eg, for treating or preventing an infection of a human or animal subject by target bacterial cells, wherein transducing particles are administered to the subject for infecting target cells and killing the cells using the antibacterial agent.
  • 108. A method of making a plurality of transduction particles, the method comprising
    • i. Producing host cells whose genomes comprise nucleic acid encoding structural proteins necessary to produce transduction particles that can package first DNA, wherein the genomes are devoid of a phage packaging signal, wherein the expression of the proteins is under the control of inducible promoter(s);
    • ii. Producing first DNA encoding an antibacterial agent or a component thereof (eg, as defined in any preceding Clause), wherein the DNA comprises a phage packaging signal;
    • iii. Introducing the DNA into the host cells;
    • iv. Inducing production of the structural proteins in host cells, whereby transduction particles are produced that package the DNA;
    • v. Optionally isolating a plurality of the transduction particles; and
    • vi. Optionally formulating the particles into a pharmaceutical composition for administration to a human or animal for medical use.
  • 109. The method of Clause 108, wherein the DNA comprises a MGE as defined in any preceding Clause.
  • 110. The method of Clause 108 or 109, wherein the structural proteins are P2 phage proteins and optionally the packaging signal is a P4 phage packaging signal.
  • 111. The method of Clause 108 or 109, wherein the DNA comprises a modified SaPI or a genomic island DNA.
  • 112. The method of any one of Clauses 108 to 111, wherein the cells in step (iv) comprise a gene encoding a helper phage activator, optionally wherein the activator is a P4 phage delta or ogr protein when the structural proteins are P2 proteins; or the activator is a SaPI rinA, ptiA, ptiB or ptiM when the MGE comprises a modified SaPI; and optionally the expression of the activator(s) is controlled by an inducible promoter, eg, a T7 promoter.
  • 113. The method of any one of Clauses 108 to 112, wherein the packaging signal is P4 phage Sid and/or psu; or the signal is SaPI cpmA and/or cpmB.


This is useful for packaging DNAs into smaller capsids.

  • 114. The method of any one of Clauses 108 to 113, wherein the cell genomes comprise prophages, wherein each prophage comprises said nucleic acid encoding structural proteins.
  • 115. The method of Clause 114, wherein the prophages are P2 prophages devoid of cos and optionally one, more or all genes selected from int, cox orf78, B, orf80, orf81, orf82, orf83, A, orf91, tin, old, orf30 and fun(Z); and optionally the packaging signal of (ii) is a cos or P4 packaging signal.
  • 116. The method of Clause 114 or 115, wherein the prophages are P2 prophages devoid of cos and comprising genes from Q to S, V to G and FI to ogr.
  • 117. The method of Clause 114, wherein the prophages are phi11 prophages devoid of a packaging signal and comprising gene 29 (terS) to gene 53 (lysin); and optionally the packaging signal of (ii) is a phi11 packaging signal.
  • 118. A plurality of transduction particles obtainable by the method of any one of Clauses 108 to 117.
  • 119. The particles of Clause 118 for administration to a human or animal for medical use.


Further Concepts of the invention are as follows:


The present invention is optionally for an industrial or domestic use, or is used in a method for such use. For example, it is for or used in agriculture, oil or petroleum industry, food or drink industry, clothing industry, packaging industry, electronics industry, computer industry, environmental industry, chemical industry, aeorspace industry, automotive industry, biotechnology industry, medical industry, healthcare industry, dentistry industry, energy industry, consumer products industry, pharmaceutical industry, mining industry, cleaning industry, forestry industry, fishing industry, leisure industry, recycling industry, cosmetics industry, plastics industry, pulp or paper industry, textile industry, clothing industry, leather or suede or animal hide industry, tobacco industry or steel industry.


The present invention is optionally for use in an industry or the environment is an industrial environment, wherein the industry is an industry of a field selected from the group consisting of the medical and healthcare; pharmaceutical; human food; animal food; plant fertilizers; beverage; dairy; meat processing; agriculture; livestock farming; poultry farming; fish and shellfish farming; veterinary; oil; gas; petrochemical; water treatment; sewage treatment; packaging; electronics and computer; personal healthcare and toiletries; cosmetics; dental; non-medical dental; ophthalmic; non-medical ophthalmic; mineral mining and processing; metals mining and processing; quarrying; aviation; automotive; rail; shipping; space; environmental; soil treatment; pulp and paper; clothing manufacture; dyes; printing; adhesives; air treatment; solvents; biodefence; vitamin supplements; cold storage; fibre retting and production; biotechnology; chemical; industrial cleaning products; domestic cleaning products; soaps and detergents; consumer products; forestry; fishing; leisure; recycling; plastics; hide, leather and suede; waste management; funeral and undertaking; fuel; building; energy; steel; and tobacco industry fields.


In an example, the ifirst DNA, first phage or vector comprises a CRISPR array that targets target bacteria, wherein the array comprises one, or two or more spacers (eg, 2, 3, 4, 5, 6, 7, 8, 9, 10, 20, 30, 40, 50 or more spacers) for targeting the genome of target bacteria.


In an example, the target bacteria are comprised by an environment as follows. In an example, the environment is a microbiome of a human, eg, the oral cavity microbiome or gut microbiome or the bloodstream. In an example, the environment is not an environment in or on a human In an example, the environment is not an environment in or on a non-human animal In an embodiment, the environment is an air environment. In an embodiment, the environment is an agricultural environment. In an embodiment, the environment is an oil or petroleum recovery environment, eg, an oil or petroleum field or well. In an example, the environment is an environment in or on a foodstuff or beverage for human or non-human animal consumption.


In an example, the environment is a a human or animal microbiome (eg, gut, vaginal, scalp, armpit, skin or oral cavity microbiome). In an example, the target bacteria are comprised by a human or animal microbiome (eg, gut, vaginal, scalp, armpit, skin or oral cavity microbiome).


In an example, the DNAs, phage or composition of the invention are administered intranasally, topically or orally to a human or non-human animal, or is for such administration. The skilled person aiming to treat a microbiome of the human or animal will be able to determine the best route of administration, depending upon the microbiome of interest. For example, when the microbiome is a gut microbiome, administration can be intranasally or orally. When the microbiome is a scalp or armpit microbiome, administration can be topically. When the microbiome is in the mouth or throat, the administration can be orally.


In an example, the environment is harboured by a beverage or water (eg, a waterway or drinking water for human consumption) or soil. The water is optionally in a heating, cooling or industrial system, or in a drinking water storage container.


In an example, the host and/or target bacteraia are Firmicutes selected from Anaerotruncus, Acetanaerobacterium, Acetitomaculum, Acetivibrio, Anaerococcus, Anaerofilum, Anaerosinus, Anaerostipes, Anaerovorax, Butyrivibrio, Clostridium, Capracoccus, Dehalobacter, Dialister, Dorea, Enterococcus, Ethanoligenens, Faecalibacterium, Fusobacterium, Gracilibacter, Guggenheimella, Hespellia, Lachnobacterium, Lachnospira, Lactobacillus, Leuconostoc, Megamonas, Moryella, Mitsuokella, Oribacterium, Oxobacter, Papillibacter, Proprionispira,Pseudobutyrivibrio, Pseudoramibacter, Roseburia, Ruminococcus, Sarcina, Seinonella, Shuttleworthia, Sporobacter, Sporobacterium, Streptococcus, Subdoligranulum, Syntrophococcus, Thermobacillus, Turibacter and Weisella.


In an example, the kit, DNA(s), first phage, helper phage, composition, use or method is for reducing pathogenic infections or for re-balancing gut or oral microbiota eg, for treating or preventing obesity or disease in a human or animal For example, the first phage, helper phage, composition, use or method is for knocking-down Clostridium dificile or E coli bacteria in a gut microbiota of a human or animal.


In an example, the packaging signal, NPF and/or HPF consists or comprises SEQ ID NO: 1 or a structural or functional homologue thereof.


In an example, the packaging signal, NPF and/or HPF consists or comprises SEQ ID NO: 1 or a nucleotide sequence that is at least 70, 75, 80, 85, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99% identical thereto.


In an example, the disease or condition is a cancer, inflammatory or autoimmune disease or condition, eg, obesity, diabetes IBD, a GI tract condition or an oral cavity condition.


Optionally, the environment is comprised by, or the target bacteria are comprised by, a gut microbiota, skin microbiota, oral cavity microbiota, throat microbiota, hair microbiota, armpit microbiota, vaginal microbiota, rectal microbiota, anal microbiota, ocular microbiota, nasal microbiota, tongue microbiota, lung microbiota, liver microbiota, kidney microbiota, genital microbiota, penile microbiota, scrotal microbiota, mammary gland microbiota, ear microbiota, urethra microbiota, labial microbiota, organ microbiota or dental microbiota. Optionally, the environment is comprised by, or the target bacteria are comprised by, a plant (eg, a tobacco, crop plant, fruit plant, vegetable plant or tobacco, eg on the surface of a plant or contained in a plant) or by an environment (eg, soil or water or a waterway or acqueous liquid).


Optionally, the disease or condition of a human or animal subject is selected from

    • (a) A neurodegenerative disease or condition;
    • (b) A brain disease or condition;
    • (c) A CNS disease or condition;
    • (d) Memory loss or impairment;
    • (e) A heart or cardiovascular disease or condition, eg, heart attack, stroke or atrial fibrillation;
    • (f) A liver disease or condition;
    • (g) A kidney disease or condition, eg, chronic kidney disease (CKD);
    • (h) A pancreas disease or condition;
    • (i) A lung disease or condition, eg, cystic fibrosis or COPD;
    • (j) A gastrointestinal disease or condition;
    • (k) A throat or oral cavity disease or condition;
    • (l) An ocular disease or condition;
    • (m) A genital disease or condition, eg, a vaginal, labial, penile or scrotal disease or condition;
    • (n) A sexually-transmissible disease or condition, eg, gonorrhea, HIV infection, syphilis or Chlamydia infection;
    • (o) An ear disease or condition;
    • (p) A skin disease or condition;
    • (q) A heart disease or condition;
    • (r) A nasal disease or condition
    • (s) A haematological disease or condition, eg, anaemia, eg, anaemia of chronic disease or cancer;
    • (t) A viral infection;
    • (u) A pathogenic bacterial infection;
    • (v) A cancer;
    • (w) An autoimmune disease or condition, eg, SLE;
    • (x) An inflammatory disease or condition, eg, rheumatoid arthritis, psoriasis, eczema, asthma, ulcerative colitis, colitis, Crohn's disease or IBD;
    • (y) Autism;
    • (z) ADHD;
    • (aa) Bipolar disorder;
    • (bb) ALS [Amyotrophic Lateral Sclerosis];
    • (cc) Osteoarthritis;
    • (dd) A congenital or development defect or condition;
    • (ee) Miscarriage;
    • (ff) A blood clotting condition;
    • (gg) Bronchitis;
    • (hh) Dry or wet AMD;
    • (ii) Neovascularisation (eg, of a tumour or in the eye);
    • (jj) Common cold;
    • (kk) Epilepsy;
    • (ll) Fibrosis, eg, liver or lung fibrosis;
    • (mm) A fungal disease or condition, eg, thrush;
    • (nn) A metabolic disease or condition, eg, obesity, anorexia, diabetes, Type I or Type II diabetes.
    • (oo) Ulcer(s), eg, gastric ulceration or skin ulceration;
    • (pp) Dry skin;
    • (qq) Sjogren's syndrome;
    • (rr) Cytokine storm;
    • (ss) Deafness, hearing loss or impairment;
    • (tt) Slow or fast metabolism (ie, slower or faster than average for the weight, sex and age of the subject);
    • (uu) Conception disorder, eg, infertility or low fertility;
    • (vv) Jaundice;
    • (ww) Skin rash;
    • (xx) Kawasaki Disease;
    • (yy) Lyme Disease;
    • (zz) An allergy, eg, a nut, grass, pollen, dust mite, cat or dog fur or dander allergy;
    • (aaa) Malaria, typhoid fever, tuberculosis or cholera;
    • (bbb) Depression;
    • (ccc) Mental retardation;
    • (ddd) Microcephaly;
    • (eee) Malnutrition;
    • (fff) Conjunctivitis;
    • (ggg) Pneumonia;
    • (hhh) Pulmonary embolism;
    • (iii) Pulmonary hypertension;
    • (jjj) A bone disorder;
    • (kkk) Sepsis or septic shock;
    • (lll) Sinusitus;
    • (mmm) Stress (eg, occupational stress);
    • (nnn) Thalassaemia, anaemia, von Willebrand Disease, or haemophilia;
    • (ooo) Shingles or cold sore;
    • (ppp) Menstruation;
    • (qqq) Low sperm count.


Neurodegenerative or Cns Diseases or Conditions for Treatment or Prevention by the Invention


In an example, the neurodegenerative or CNS disease or condition is selected from the group consisting of Alzheimer disease, geriopsychosis, Down syndrome, Parkinson's disease, Creutzfeldt-jakob disease, diabetic neuropathy, Parkinson syndrome, Huntington's disease, Machado-Joseph disease, amyotrophic lateral sclerosis, diabetic neuropathy, and Creutzfeldt Creutzfeldt-Jakob disease. For example, the disease is Alzheimer disease. For example, the disease is Parkinson syndrome.


In an example, wherein the method of the invention is practised on a human or animal subject for treating a CNS or neurodegenerative disease or condition, the method causes downregulation of Treg cells in the subject, thereby promoting entry of systemic monocyte-derived macrophages and/or Treg cells across the choroid plexus into the brain of the subject, whereby the disease or condition (eg, Alzheimer's disease) is treated, prevented or progression thereof is reduced. In an embodiment the method causes an increase of IFN-gamma in the CNS system (eg, in the brain and/or CSF) of the subject. In an example, the method restores nerve fibre and//or reduces the progression of nerve fibre damage. In an example, the method restores nerve myelin and//or reduces the progression of nerve myelin damage. In an example, the method of the invention treats or prevents a disease or condition disclosed in WO2015136541 and/or the method can be used with any method disclosed in WO2015136541 (the disclosure of this document is incorporated by reference herein in its entirety, eg, for providing disclosure of such methods, diseases, conditions and potential therapeutic agents that can be administered to the subject for effecting treatement and/or prevention of CNS and neurodegenerative diseases and conditions, eg, agents such as immune checkpoint inhibitors, eg, anti-PD-1, anti-PD-L1, anti-TIM3 or other antibodies disclosed therein).


Cancers for Treatment or Prevention by the Method


Cancers that may be treated include tumours that are not vascularized, or not substantially vascularized, as well as vascularized tumours. The cancers may comprise non-solid tumours (such as haematological tumours, for example, leukaemias and lymphomas) or may comprise solid tumours. Types of cancers to be treated with the invention include, but are not limited to, carcinoma, blastoma, and sarcoma, and certain leukaemia or lymphoid malignancies, benign and malignant tumours, and malignancies e.g., sarcomas, carcinomas, and melanomas. Adult tumours/cancers and paediatric tumours/cancers are also included.


Haematologic cancers are cancers of the blood or bone marrow. Examples of haematological (or haematogenous) cancers include leukaemias, including acute leukaemias (such as acute lymphocytic leukaemia, acute myelocytic leukaemia, acute myelogenous leukaemia and myeloblasts, promyeiocytic, myelomonocytic, monocytic and erythroleukaemia), chronic leukaemias (such as chronic myelocytic (granulocytic) leukaemia, chronic myelogenous leukaemia, and chronic lymphocytic leukaemia), polycythemia vera, lymphoma, Hodgkin's disease, non-Hodgkin's lymphoma (indolent and high grade forms), multiple myeloma, Waldenstrom's macroglobulinemia, heavy chain disease, myeiodysplastic syndrome, hairy cell leukaemia and myelodysplasia.


Solid tumours are abnormal masses of tissue that usually do not contain cysts or liquid areas. Solid tumours can be benign or malignant. Different types of solid tumours are named for the type of cells that form them (such as sarcomas, carcinomas, and lymphomas). Examples of solid tumours, such as sarcomas and carcinomas, include fibrosarcoma, myxosarcoma, liposarcoma, chondrosarcoma, osteosarcoma, and other sarcomas, synovioma, mesothelioma, Ewing's tumour, leiomyosarcoma, rhabdomyosarcoma, colon carcinoma, lymphoid malignancy, pancreatic cancer, breast cancer, lung cancers, ovarian cancer, prostate cancer, hepatocellular carcinoma, squamous eel! carcinoma, basal cell carcinoma, adenocarcinoma, sweat gland carcinoma, medullary thyroid carcinoma, papillary thyroid carcinoma, pheochromocytomas sebaceous gland carcinoma, papillary carcinoma, papillary adenocarcinomas, medullary carcinoma, bronchogenic carcinoma, renal cell carcinoma, hepatoma, bile duct carcinoma, choriocarcinoma, Wilms' tumour, cervical cancer, testicular tumour, seminoma, bladder carcinoma, melanoma, and CNS tumours (such as a glioma (such as brainstem glioma and mixed gliomas), glioblastoma (also known as glioblastoma multiforme) astrocytoma, CNS lymphoma, germinoma, medu!loblastoma, Schwannoma craniopharyogioma, ependymoma, pineaioma, hemangioblastoma, acoustic neuroma, oligodendroglioma, menangioma, neuroblastoma, retinoblastoma and brain metastases).


Autoimmune Diseases for Treatment or Prevention by the Method

    • 1. Acute Disseminated Encephalomyelitis (ADEM)
    • 2. Acute necrotizing hemorrhagic leukoencephalitis
    • 3. Addison's disease
    • 4. Agammaglobulinemia
    • 5. Alopecia areata
    • 6. Amyloidosis
    • 7. Ankylosing spondylitis
    • 8. Anti-GBM/Anti-TBM nephritis
    • 9. Antiphospholipid syndrome (APS)
    • 10. Autoimmune angioedema
    • 11. Autoimmune aplastic anemia
    • 12. Autoimmune dysautonomia
    • 13. Autoimmune hepatitis
    • 14. Autoimmune hyperlipidemia
    • 15. Autoimmune immunodeficiency
    • 16. Autoimmune inner ear disease (AIED)
    • 17. Autoimmune myocarditis
    • 18. Autoimmune oophoritis
    • 19. Autoimmune pancreatitis
    • 20. Autoimmune retinopathy
    • 21. Autoimmune thrombocytopenic purpura (ATP)
    • 22. Autoimmune thyroid disease
    • 23. Autoimmune urticaria
    • 24. Axonal & neuronal neuropathies
    • 25. Balo disease
    • 26. Behcet's disease
    • 27. Bullous pemphigoid
    • 28. Cardiomyopathy
    • 29. Castleman disease
    • 30. Celiac disease
    • 31. Chagas disease
    • 32. Chronic fatigue syndrome
    • 33. Chronic inflammatory demyelinating polyneuropathy (CIDP)
    • 34. Chronic recurrent multifocal ostomyelitis (CRMO)
    • 35. Churg-Strauss syndrome
    • 36. Cicatricial pemphigoid/benign mucosal pemphigoid
    • 37. Crohn's disease
    • 38. Cogans syndrome
    • 39. Cold agglutinin disease
    • 40. Congenital heart block
    • 41. Coxsackie myocarditis
    • 42. CREST disease
    • 43. Essential mixed cryoglobulinemia
    • 44. Demyelinating neuropathies
    • 45. Dermatitis herpetiformis
    • 46. Dermatomyositis
    • 47. Devic's disease (neuromyelitis optica)
    • 48. Discoid lupus
    • 49. Dressler's syndrome
    • 50. Endometriosis
    • 51. Eosinophilic esophagitis
    • 52. Eosinophilic fasciitis
    • 53. Erythema nodosum
    • 54. Experimental allergic encephalomyelitis
    • 55. Evans syndrome
    • 56. Fibromyalgia
    • 57. Fibrosing alveolitis
    • 58. Giant cell arteritis (temporal arteritis)
    • 59. Giant cell myocarditis
    • 60. Glomerulonephritis
    • 61. Goodpasture's syndrome
    • 62. Granulomatosis with Polyangiitis (GPA) (formerly called Wegener's Granulomatosis)
    • 63. Graves' disease
    • 64. Guillain-Barre syndrome
    • 65. Hashimoto's encephalitis
    • 66. Hashimoto's thyroiditis
    • 67. Hemolytic anemia
    • 68. Henoch-Schonlein purpura
    • 69. Herpes gestationis
    • 70. Hypogammaglobulinemia
    • 71. Idiopathic thrombocytopenic purpura (ITP)
    • 72. IgA nephropathy
    • 73. IgG4-related sclerosing disease
    • 74 Immunoregulatory lipoproteins
    • 75. Inclusion body myositis
    • 76. Interstitial cystitis
    • 77. Juvenile arthritis
    • 78. Juvenile diabetes (Type 1 diabetes)
    • 79. Juvenile myositis
    • 80. Kawasaki syndrome
    • 81. Lambert-Eaton syndrome
    • 82. Leukocytoclastic vasculitis
    • 83. Lichen planus
    • 84. Lichen sclerosus
    • 85. Ligneous conjunctivitis
    • 86. Linear IgA disease (LAD)
    • 87. Lupus (SLE)
    • 88. Lyme disease, chronic
    • 89. Meniere's disease
    • 90. Microscopic polyangiitis
    • 91. Mixed connective tissue disease (MCTD)
    • 92. Mooren's ulcer
    • 93. Mucha-Habermann disease
    • 94. Multiple sclerosis
    • 95. Myasthenia gravis
    • 96. Myositis
    • 97. Narcolepsy
    • 98. Neuromyelitis optica (Devic's)
    • 99. Neutropenia
    • 100. Ocular cicatricial pemphigoid
    • 101. Optic neuritis
    • 102. Palindromic rheumatism
    • 103. PANDAS (Pediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcus)
    • 104. Paraneoplastic cerebellar degeneration
    • 105. Paroxysmal nocturnal hemoglobinuria (PNH)
    • 106. Parry Romberg syndrome
    • 107. Parsonnage-Turner syndrome
    • 108. Pars planitis (peripheral uveitis)
    • 109. Pemphigus
    • 110. Peripheral neuropathy
    • 111. Perivenous encephalomyelitis
    • 112. Pernicious anemia
    • 113. POEMS syndrome
    • 114. Polyarteritis nodosa
    • 115. Type I, II, & III autoimmune polyglandular syndromes
    • 116. Polymyalgia rheumatica
    • 117. Polymyositis
    • 118. Postmyocardial infarction syndrome
    • 119. Postpericardiotomy syndrome
    • 120. Progesterone dermatitis
    • 121. Primary biliary cirrhosis
    • 122. Primary sclerosing cholangitis
    • 123. Psoriasis
    • 124. Psoriatic arthritis
    • 125. Idiopathic pulmonary fibrosis
    • 126. Pyoderma gangrenosum
    • 127. Pure red cell aplasia
    • 128. Raynauds phenomenon
    • 129. Reactive Arthritis
    • 130. Reflex sympathetic dystrophy
    • 131. Reiter's syndrome
    • 132. Relapsing polychondritis
    • 133. Restless legs syndrome
    • 134. Retroperitoneal fibrosis
    • 135. Rheumatic fever
    • 136. Rheumatoid arthritis
    • 137. Sarcoidosis
    • 138. Schmidt syndrome
    • 139. Scleritis
    • 140. Scleroderma
    • 141. Sjogren's syndrome
    • 142. Sperm & testicular autoimmunity
    • 143. Stiff person syndrome
    • 144. Subacute bacterial endocarditis (SBE)
    • 145. Susac's syndrome
    • 146. Sympathetic ophthalmia
    • 147. Takayasu's arteritis
    • 148. Temporal arteritis/Giant cell arteritis
    • 149. Thrombocytopenic purpura (TTP)
    • 150. Tolosa-Hunt syndrome
    • 151. Transverse myelitis
    • 152. Type 1 diabetes
    • 153. Ulcerative colitis
    • 154. Undifferentiated connective tissue disease (UCTD)
    • 155. Uveitis
    • 156. Vasculitis
    • 157. Vesiculobullous dermatosis
    • 158. Vitiligo
    • 159. Wegener's granulomatosis (now termed Granulomatosis with Polyangiitis (GPA).


Inflammatory Diseases for Treatment or Prevention by the Method

    • 1. Alzheimer
    • 2. ankylosing spondylitis
    • 3. arthritis (osteoarthritis, rheumatoid arthritis (RA), psoriatic arthritis)
    • 4. asthma
    • 5. atherosclerosis
    • 6. Crohn's disease
    • 7. colitis
    • 8. dermatitis
    • 9. diverticulitis
    • 10. fibromyalgia
    • 11. hepatitis
    • 12. irritable bowel syndrome (IBS)
    • 13. systemic lupus erythematous (SLE)
    • 14. nephritis
    • 15. Parkinson's disease
    • 16. ulcerative colitis.


EXAMPLES
Example 1
Efficient Phage CRISPR Delivery Vehicle Production

Background


We designed a strategy for efficient production of phage particles comprising components of a CRISPR/Cas system for killing target E coli Nissle strain bacteria. So our phage composition will consist of a lysate primarily containing CRISPR/Cas system components packaged in phage particles which will be devoid of phage protein-encoding sequences and which will have no or a very low proportion of helper phage. Also the strategy will work alternatively in less well characterised phage/bacterial strain combinations.


Outline of strategy for CRISPR/Cas component packaging in hitherto unknown phages

  • (i) Identify a high copy number cloning/lshuttle vector (capable of cloning and propagation in a first E coli strain and then transfer to a second bacterial host strain of interest) containing an E coli on for replication in the E coli cloning strain;
  • (j) Isolate temperate phage against the host (second) bacterium;
  • (k) Identify or engineer a phage production strain of the host bacteria that has an inactive CRISPR/Cas system (eg, a repressed Cas3 or other nuclease) and which can be infected and lysogenized with the temperate phage; or repress or inactivate the system in the production strain;
  • (l) In that strain make a lysogen using the temperate phage (helper phage) and test that it can be induced;
  • (m) Identify the packaging sequence (pac or cos) using PhageTerm (https://)www.ncbi.nlm.nih.gov/pmc/articles/PMC5557969/) on whole genome sequenced phage;
  • (n) Delete the pac/cos packaging signal sequence in the helper phage in the host bacteria;
  • (o) Incorporate the packaging signal in the shuttle vector along with a CRISPR-array (and other components of the CRISPR/Cas system, such as a Cas9-encoding nucleotide sequence, orCas3 and/or Cascade-encoding sequence);
    • (p) Transform the vector into production host strain;
    • (q) UV or mitomycin C induce and harvest phage comprising the CRISPR/Cas component(s). Alternatively, use a system with inducible RecA in trans to simulate SOS (needs to be activated RecA).


Example of the above specifically for E coli Nissle using phage P2:


Nissle is useful due to its GRAS (Generally Regarded as Safe) status and P2 has a relatively broad host range (most E coli, Shigella, Klebsiella, Salmonella in addtition to DNA delivery into e.g. Pseudomonas; Kahn et al 1991).


We will use pUC19 or other high copy number cloning vector. Temperate phage P2 can lysogenize Nissle. Most E coli K strains have an inactive CRISPR/Cas system and can be infected by P2 and thus all regular cloning hosts can be used (here exemplified by E coli TOP10).


P2 is introduced into TOP10 to produce a lysogen. P2 cannot be induced with mitomycin C or UV but we will use the epsilon anti-repressor from the parasite phage P4 that derepresses P2 and makes it go into lytic phase. We will express this gene from an inducible promoter in the production host strain.


The 325 bp packaging signal sequence as follows will be used









(SEQ ID NO: 1)


GCATGCGTTTTCCTGCCTCATTTTCTGCAAACCGCGCCATTCCCGGCGCG





GTCTGAGCGTGTCAGTGCAACTGCATTAAAACCGCCCCGCAAAGCGGGCG





GGCGAGGCGGGGAAAGCACCGCGCGCAAACCCAGAAGTTAGTTAATTATT





TGTGTAGTCAAAGTGCCTTGACTACATACCTCGTTAATACATTGGAGCAT





AATGAAGAAAATCTATGGCCTATGGTCCAAAACTGTCTTTTTTGATGGCA





CTATCCTGAAAAATATGCAAAAAATAGATTGATGTAAGGTGGTTCTTGTC





AGTGTCGCAAGATCCTTAAGAATTC






The packaging sequence will be deleted in the P2 prophage of the lysogenic production TOP10 strain.


A pUC19 shuttle vector encoding a guide RNA that targets the genome of the target Nissle strain (or alternatively comprising a CRISPR array for producing such a guide RNA) will be constructed and the packaging signal will be added. If the target Nissle harbours it own endogenous CRISPR/Cas system, we will use an activation strategy to activate the endogenous Cas3 by including Cas activating genes in the vector. If not, we will include an exogenous Cas3-encoding nucleotide sequence (and optionally one or more nucleotide sequences encoding one or more required Cascade components) in the vector for expression in the target Nissle. We will transform the vector into the TOP10 production strain, induce the P4 anti-repressor and harvest phage comprising the CRISPR/Cas component(s).


Since the induced (helper) phage DNA does not contain a packaging signal we will be able to isolate particles with only the vector DNA packaged. Thus, we will obtain a composition comprising such phage which can be used to infect target Nissle bacteria and introduce the CRISPR/Cas component(s) therein for killing the target bacteria.


Example 2
MGEs, Genomics Islands etc

Overview of possible different MGE packaging strategies follow.


Applicable to different types of phages:


Identify packaging signal and structural genes in the helper phage (delivery vehicle)


Delete packaging signal in helper phage and place on plasmid comprising MGE


Place both helper and plasmid in production strain


Induce structural gene transcription of helper to get production of helper-phage-packaged MGEs


For using parasitic mobile elements (P4 phage or SaPI etc) activation of helper phage structural genes is done by induction of a helper phage activator obtained from the parasitic element Delta in P4 or one, more or al of ptiA/B/M in SaPI.


If one wants smaller size particle one can choose to package in a parasite-size capsid (typically 10-20 kb) by including in the MGE or vector P4 Sid and psu or cpmA/B from a SaPI.


One can use defective helper phages where at least the packaging signal has been removed and structural genes are either on a plasmid or integrated as a cryptic prophage in the production host. If for some reason one cannot use this approach and need to use functional helper phages, one will include in the MGE or vector the genes on the parasite that hijack the phage packaging machinery to preferentially package parasite DNA (in our case CGV) over phage DNA.


List of the minimal genes one could Include on a plasmid vector from P4. P4 sequence: see world wide web.ncbi.nlm.nih.gov/nuccore/x51522









Cos packaging site (SEQ ID NO: 3):


GCATGCGTTTTCCTGCCTCATTTTCTGCAAACCGCGCCATTCCCGGCGCG





GTCTGAGCGTGTCAGTGCAACTGCATTAAAACCGCCCCGCAAAGCGGGCG





GGCGAGGCGGGGAAAGCACCGCGCGCAAACCGACAAGTTAGTTAATTATT





TGTGTAGTCAAAGTGCCTTCAGTACATACCTCGTTAATACATTGGAGCAT





AATGAAGAAAATCTATGGCCTATGGTC






The homology between P2 and P4 pasted below; this may be used as a packaging signal in the MGE or vector:









(SEQ ID NO: 4)


TGCATTAAAACCGCCCCGCAAAGCGGGCGGGCGAGGCGGGGAAAGCACCG


CGCGC






For small capsid size (packages 11.4 kb instead of 33.5 kb) Sid and/or Psu can be included in the MGE or vector:









Sid (SEQ ID NO: 5):


ATGTCTGACCACACTATCCCTGAATATCTGCAACCCGCACTGGCACAACT





GGAAAAGGCCAGAGCCGCCCATCTTGAGAACGCCCGCCTGATGGATGAGA





CCGTCACGGCCATTGAACGGGCAGAGCAGGAAAAAAATGCGCTGGCGCAG





GCCGACGGAAACGACGCTGACGACTGGCGCACGGCCTTTCGTGCAGCCGG





TGGTGTCCTGAGCGACGAGCTGAAACAGCGCCACATTGAGCGCGTGGCAC





GCCGGGAGCTGGTACAGGAATATGACAATCTGGCCGTGGTGCTGAATTTC





GAACGTGAACGCCTGAAAGGGGCGTGTGACAGCACGGCCACCGCCTACCG





GAAGGCACATCATCACCTTCTGAGTCTGTATGCAGAGCATGAGCTGGAAC





ACGCCCTGAATGAAACCTGTGAGGCGCTTGTCCGGGCAATGCATCTGAGC





ATTCTGGTACAGGAAAATCCGCTCGCCAACACCACCGGCCATCAGGGCTA





CGTCGCACCGGAAAAGGCTGTCATGCAGCAGGTGAAATCATCGCTGGAAC





AGAAAATTAAACAGATGCAAATCAGCCTCACCGGCGAGCCGGTTCTCCGG





CTGACCGGACTGTCAGCGGCAACACTCCCGCACATGGATTATGAGGTGGC





AGGCACACCGGCACAGCGCAAGGTGTGGCAGGACAAAATAGACCAGCAGG





GAGCAGAGCTTAAGGCCAGAGGGCTGCTGTCATGA





Psu (SEQ ID NO: 6):


ATGGAAAGCACAGCCTTACAGCAGGCCTTTGACACCTGTCAGAATAACAA





AGCAGCATGGCTGCAACGCAAAAATGAGCTGGCAGCGGCCGAACAGGAAT





ATCTGCGGCTTCTGTCAGGAGAAGGCAGAAACGTCAGTCGCCTGGACGAA





TTACGCAATATTATCGAAGTCAGAAAATGGCAGGTGAATCAGGCCGCCGG





TCGTTATATTCGTTCGCATGAAGCCGTTCAGCACATCAGCATCCGCGACC





GGCTGAATGATTTTATGCAGCAGCACGGCACAGCACTGGCGGCCGCACTG





GCACCGGAGCTGATGGGCTACAGTGAGCTGACGGCCATTGCCCGAAACTG





TGCCATACAGCGTGCCACAGATGCCCTGCGTGAAGCCCTTCTGTCCTGGC





TTGCGAAGGGTGAAAAAATTAATTATTCCGCACAGGATAGCGACATTTTA





ACGACCATCGGATTCAGGCCTGACGTGGCTTCGGTGGATGACAGCCGTGA





AAAATTCACCCCTGCGCAGAACATGATTTTTTCGCGTAAAAGTGCGCAAC





TGGCATCACGTCAGTCAGTGTAA






To activate helper phage P2, Delta can be included in a host cell genome (provided separately in a host cell, not on the MGE or vector to be packaged)









Delta (SEQ ID NO: 7):


ATGATTTACTGTCCGTCGTGTGGACATGTTGCTCACACCCGTCGCGCACA





TTTCATGGACGATGGCACCAAGATAATGATTGCACAGTGCCGGAATATTT





ATTGCTCTGCGACATTTGAAGCGAGTGAAAGCTTTTTCTCTGACAGTAAA





GATTCAGGAATGGAATACATTTCAGGCAAACAGAGATACCGCGATTCACT





GACGTCAGCCTCCTGCGGTATGAAACGCCCGAAAAGAATGCTTGTTACCG





GATATTGTTGTCGGAGATGTAAAGGCCTTGCACTGTCAAGAACATCGCGG





CGTCTGTCTCAGGAAGTCACCGAGCGTTTTTATGTGTGCACGGATCCGGG





CTGTGGTCTGGTGTTTAAAACGCTTCAGACCATCAACCGCTTCATTGTCC





GCCCGGTCACGCCGGACGAACTGGCAGAACGCCTGCATGAAAAACAGGAA





CTGCCGCCAGTACGGTTAAAAACACAATCATATTCGCTGCGTCTGGAATG





A






Minimum genes to include in the host chromosome/episome from P2. P2 sequence (acc.number: NC_001895)



FIG. 1 shows a genetic map of P2 genome with non-essential genes boxed in red—one, more or all of these can be excluded. Cos is deleted and preferably the whole region from int through cos. This region may, for example, be swapped with a resistance marker while the orf30 and fun(Z) genes are left intact.










″Q″ through ″S″



(SEQ ID NO: 8)



TCAGTCGTTGTCAGTGTCCAGTGAGTAGTTTTTAAAGCGGATGACCTCCTGACCGAGCCA






GCCGTTTATCTCGCGGATCCTGTCCTGTAACGGGATAAGCTCATTGCGGACAAAGACCTT





TGCCACTTTCTCAATATCACCCAGCGACCCGACGTTCTCCGGCTTGCCACCCATCAACTG





AAAGGGGATGCGGTGCGCGTCCAGCAGGTCAGCGGCGCTGGCTTTTTTGATATTAAAAA





AATCGTCCTTCGTCGCCACTTCACTGAGGGGGATAATTTTAATGCCGTCGGCTTTCCCCTG





TGGGGCATAGAGAAACAGGTTTTTAAAGTTGTTGCGGCCTTTCGACTTGACCATGTTTTC





GCGAAGCATTTCGATATCGTTGCGATCCTGCACGGCATCGGTGACATACATGATGTATCC





GGCATGTGCGCCATTTTCGTAATACTTGCGGCGGAACAACGTGGCCGACTCATTCAGCCA





GGCAGAGTTAAGGGCGCTGAGATATTCCGGCAGGCCGTACAGCTCCTGATTAATATCCG





GCTCCAGCAGGTGAAACACGGAGCCGGGCGCGAAGGCTGTCGGCTCGTTGAAGGACGGC





ACCCACCAGTAAACATCCTCTTCCACGCCACGGCGGGTATATTTTGCCGGTGAGGTTTCC





AGTCTGATGACCTTACCGGTGGTGCTGTAACGCTTTTCCAGAAACGCATTACCGAACACC





AGAAAATCCAGCACAAAGCGGCTGAAATCCTGCTGGGAAAGCCATGGATGCGGGATAA





ATGTCGAGGCCAGAATATTGCGTTTGACGTAAATCGGCGAGCTGTGATGCACGGCAGCC





CGCAGGCTTTTTGCCAGACCGGTAAAGCTGACCGGTGGCTCATACCATCTGCCGTTACTG





ATGCACTCGACGTAATCCAGAATGTCACGGCGGTCGAGTACCGGCACCGGCTCACCAAA





GGTGAATGCCTCCATTTTCGGGCCGCTGGCGGTCATTGTTTTTGCCGCAGGTTGCGGTGTT





TTCCCTTTTTTCTTGCTCATCAGTAAAACTCCAGAATGGTGGATGTCAGCGGGGTGCTGAT





ACCGGCGGTGAGTGGCTCATTTAACAGGGCGTGCATGGTCGCCCAGGCGAGGTCGGCGT





GGCTGGCTTCCTCGCTGCGGCTGGCCTCATAGGTGGCGCTGCGTCCGCTGCTGGTCATGG





TCTTGCGGATAGCCATAAACGAGCTGGTGATGTCGGTGGCGCTGACGTCGTATTCCAGAC





AGCCACGGCGGATAACGTCTTTTGCCTTGAGCACCATTGCGGTTTTCATTTCCGGCGTGT





AGCGGATATCACGCGCGGCGGGATAGAACGAGCGCACGAGCTGGAACACGCCGACACC





GAGGCCGGTGGCATCAATACCGATGTATTCGACGTTGTATTTTTCGGTGAGTTTGCGGAT





GGATTCCGCCTGGGTGGCAAAGTCCATGCCTTTCCACTGGTGACGCTCAAGTATTCTGAA





TTTGCCACCGGCCACCACCGGCGGTGCCAGTACCACGCATCCGGCGCTGTCGCCACGGTG





TGACGGGTCGTAACCAATCCATACCGGGCGGGAGCCGAACGGATTGGCGGCAAACGGCG





CATAGTCTTCCCATTCTTCCAGCGTGTCGACCATGCAGCGTTGCAGCTCCTCGAACGGGA





ACACCGATGCCTTGTCGTCAACAAATTCACACATGAACAGGTTTTTAAAATCGTCGGCGC





TGTTTTCGCGTTTGAGCTGCTCAATGTCGAACAGCGTGCAGCCGCCTTTCAGGGCGTCCT





CAATGGTGACAATCTGTCGCCACTGGCCGTCCGCACAGAGAAGCCCACCGGCAAGGGCG





TTATGACTGACGTCGATTTCCACGCGTTCGGCGGCGCTGGCGCGTCCCCGGTTAAACAGT





TCACCCGACCAGAACGGGTAGGCGTCGTGCGCCAGCGTGGACGGGGTGGAGAAATAGGT





CGAGCGCAGGTGACTCTGTGAGGCCATACCTGATGCCACCTTACGCAGTACCTGAAAATT





CGGGATCCAGAAAATCTCATCGACGTACAGGTCGCCGTTATGACTCTGCGCGGTGTTGGA





GTTGGTGCCGAGAAAAATCAGTTTTGCGCCGTTATTGCCCAGGACAATCGGGTCACCGGT





CAGGTCAACGTCAACCAGACGGGCAAAGGCGATGATGTATTCGCGGAACACATACGCCT





GTGTTTTACTGGCCGACAGAAAAATCTGGTTATGACCGGTTTTCAGGGCACGCAGCAGCG





CCTCGCGGGAAAAATAAAACGTCGCGCCAATCTGGCGGGATTTCAGGATATCGCGGATG





CGGTGCTCAAGCCCGGCACGATACCAGTGCAGCTGATAGTCGAAAGACTGCTCAAAGAA





AATCTGCTCCAGCTTTTCGATGGCCTCGTCACTGAAAAAATTCTTTTTCGGTTTGCGCCGT





CCGCCTTTGTTACGGTTAGCGACGTTCGGATTAAGGTCTGCCTCGTTGCCGGTCTGGCTGT





AGCGGTTGACCCGTGCCAGTCGTTCAATCTGGCGTCCCAGCAGGTCAATTTCCTTGAAGT





CACCGCCGGTTTTCTGTGGTTTGATGATGAGCTGGGTCAGCCGCGCTTCCAGACTCATTTC





GACACGGCTGATGGGGGCAACGCTGTCCCAGCCGTCGCGCTGTTTCCAGCTCTGCACTGT





CGGGCGTTTCATCTGCAACATGGCGGCAATCTGCGGCACGGAAAACCCCTGCCAGTACA





GCAGCGCCGCCTGACGACGCGGGTCGTGTAAAAGAGTGGTGTCTGTGGTGATGGTCATG





AATACCTCGCCGTGATGAATACACGGCAAGGCTACTGAGTCGCGCCCCGCGATTCGCTA





AGGTGCTGTTGTGTCAGTGATAAGCCATCCGGGACTGATGGCGGAGGATGCGCATCGTC





GGGAAACTGATGCCGACATGTGACTCCTCTAATCACTATTCAGGACTCCTGACAATGGCA





AAAAAAGTCTCAAAATTCTTTCGTATCGGCGTTGAGGGTGACACCTGTGACGGGCGTGTC





ATCAGTGCGCAGGATATTCAGGAAATGGCCGAAACCTTTGACCCGCGTGTCTATGGTTGC





CGCATTAACCTGGAACATCTGCGCGGCATCCTGCCTGACGGTATTTTTAAGCGTTATGGC





GATGTGGCCGAACTGAAGGCCGAAAAGATTGACGATGATTCGGCGCTGAAAGGCAAATG





GGCGCTGTTTGCGAAAATCACCCCGACCGATGACCTTATCGCGATGAACAAGGCCGCGC





AGAAGGTCTACACCTCAATGGAAATTCAGCCGAACTTTGCCAACACCGGCAAATGTTATC





TGGTGGGTCTGGCCGTCACCGATGACCCGGCAAGCCTCGGCACGGAATACCTGGAATTCT





GCCGCACGGCAAAACACAACCCCCTGAACCGCTTCAAATTAAGCCCTGAAAACCTGATT





TCAGTGGCAACGCCTGTTGAGCTGGAATTTGAAGACCTGCCTGAAACCGTGTTCACCGCC





CTGACCGAAAAGGTGAAGTCCATTTTTGGCCGCAAACAGGCCAGCGATGATGCCCGTCT





GAATGACGTGCATGAAGCGGTGACCGCTGTTGCTGAACATGTGCAGGAAAAACTGAGCG





CCACTGAGCAGCGCCTCGCTGAGATGGAAACCGCCTTTTCTGCACTTAAGCAGGAGGTG





ACTGACAGGGCGGATGAAACCAGCCAGGCATTCACCCGCCTGAAAAACAGTCTCGACCA





CACCGAAAGTCTGACCCAGCAGCGCCGCAGCAAAGCCACCGGCGGTGGCGGTGACGCCC





TGATGACGAACTGCTGACCGGCGTCAGTCAGTCCGGGAAAACCTTCACGATTAACCCTTA





ATTTCAGGAAAAACTATGCGCCAGGAAACCCGCTTTAAATTTAATGCCTACCTGTCCCGT





GTTGCCGAACTGAACGGCATCGACGCCGGTGATGTGTCGAAAAAATTCACCGTTGAACC





GTCGGTCACCCAGACCCTGATGAACACCATGCAGGAGTCCTCTGACTTTCTGACCCGCAT





CAATATTGTGCCGGTCAGCGAAATGAAAGGGGAAAAAATTGGTATCGGTGTCACCGGCT





CCATCGCCAGCACTACCGACACTGCCGGTGGTACCGAGCGTCAGCCGAAGGACTTCTCG





AAGCTGGCGTCAAACAAGTACGAATGCGACCAGATTAACTTCGATTTTTATATCCGCTAC





AAAACGCTGGACCTGTGGGCGCGTTATCAGGATTTCCAGCTCCGTATCCGTAACGCCATT





ATCAAACGCCAGTCCCTTGATTTCATCATGGCCGGTTTTAACGGCGTGAAGCGTGCCGAA





ACCTCTGACCGCAGCAGCAATCCGATGTTGCAGGATGTGGCGGTCGGCTGGCTGCAGAA





ATACCGCAATGAAGCACCGGCGCGCGTGATGAGCAAGGTCACTGACGAGGAAGGCCGC





ACCACCTCTGAGGTTATCCGCGTGGGTAAGGGCGGTGATTATGCCAGCCTTGATGCACTG





GTGATGGATGCGACCAACAACCTGATTGAACCGTGGTATCAGGAAGACCCTGACCTTGT





GGTGATTGTGGGGCGTCAGCTACTGGCGGACAAGTATTTCCCCATCGTCAACAAGGAGC





AGGACAACAGCGAAATGCTGGCCGCTGACGTCATCATCAGCCAGAAACGCATCGGTAAC





CTACCAGCGGTACGCGTCCCGTACTTCCCGGCGGATGCGATGCTCATCACGAAGCTGGAA





AACCTGTCCATCTACTACATGGATGACAGCCATCGCCGCGTGATTGAGGAAAACCCGAA





ACTCGACCGCGTGGAGAACTACGAGTCAATGAACATTGATTACGTGGTGGAAGACTACG





CCGCCGGTTGTCTGGTGGAAAAAATCAAGGTCGGTGACTTCTCCACACCGGCTAAGGCG





ACCGCAGAGCCGGGAGCGTAACCGATGACGAGTCCCGCACAGCGCCACATGATGCGGGT





CTCGGCAGCGATGACCGCGCAGCGGGAAGCCGCCCCGCTGCGACATGCAACTGTCTATG





AGCAGATGCTGGTTAAGCTCGCCGCAGACCAGCGCACACTGAAAGCGATTTACTCAAAA





GAGCTGAAGGCCGCAAAAAAACGCGAACTGCTGCCGTTCTGGTTGCCGTGGGTGAACGG





CGTGCTGGAGCTGGGCAAAGGTGCACAGGATGACATTCTGATGACGGTCATGCTGTGGC





GTCTGGATACCGGCGATATTGCCGGTGCGCTGGAGATTGCCCGTTATGCCCTGAAGTACG





GTCTGACCATGCCGGGTAAACACCGCCGTACCCCGCCGTACATGTTCACCGAGGAGGTA





GCGCTTGCGGCCATGCGCGCTCACGCTGCCGGTGAGTCTGTGGATACCCGCCTGCTGACG





GAGACCCTTGAACTGACCGCCACGGCTGACATGCCTGATGAAGTGCGCGCAAAGCTGCA





CAAAATCACCGGTCTGTTTCTGCGTGACGGTGGTGATGCCGCCGGTGCGCTGGCGCACCT





GCAACGTGCGACACAGCTCGACTGTCAGGCAGGCGTCAAAAAAGAGATTGAACGACTGG





AGCGGGAGCTGAAACCGAAGCCGGAGCCGCAGCCCAAAGCGGCCACCCGCGCCCCGCG





TAAGACCCGGAGCGTGACACCGGCAAAACGTGGACGCCCGAAAAAGAAAGCCAGTTAA





CAACCGAATGCGCCCCGCGCCAGGGCGGCACGCCGGTCAGTGACGGTGAATCACCTGAC





ACTGCACCGGCGTCCACCGCCCGACTTTTCAGAGGTAGTCATGATGACGCTGATTATTCC





GCGAAAGGAGGCTCCCGTGTCCGGTGAGGGTACGGTGGTCATCCCGCAACCGGCAGGCG





ACGAGCCGGTGATTAAAAACACGTTCTTTTTTCCCGATATCGACCCGAAGCGCGTCCGGG





AACGTATGCGCCTTGAGCAGACCGTCGCCCCCGCCCGTCTGCGTGAGGCCATCAAGTCAG





GCATGGCTGAAACGAATGCGGAGCTGTACGAGTACCGCGAACAGAAAATTGCCGCCGGT





TTTACGCGTCTGGCTGACGTCCCGGCGGACGATATCGACGGTGAAAGCATCAAGGTTTTT





TACTACGAGCGCGCCGTGTGTGCGATGGCGACCGCGTCGCTTTATGAGCGTTATCGCGGT





GTGGATGCCAGTGCGAAAGGCGACAAGAAGGCTGACAGCATTGACAGCACCATTGATGA





GCTGTGGCGGGATATGCGCTGGGCGGTGGCGCGCATCCAGGGCAAGCCGCGCTGCATCG





TGAGTCAAATCTGATGAAGACCTTTGCGCTACAGGGCGACACGCTCGACGCCATTTGTGT





CCGCTATTACGGGCGCACTGAGGGCGTGGTTGAGACCGTGCTCGCCGCAAATCCGGGAC





TGGCTGAACTGGGGGCGGTGCTGCCACACGGCACCGCCGTCGAACTGCCCGACGTTCAG





ACCGCGCCCGTGGCTGAAACTGTCAATCTGTGGGAGTAACGCATGACAGCAGAAGAAAA





AAGCGTCCTGTCGCTTTTCATGATTGGGGTGCTGATTGTTGTCGGCAAGGTGCTTGCCGG





TGGTGAACCTATCACCCCGCGTCTGTTTATCGGGCGCATGTTGCTCGGTGGTTTTGTCTCG





ATGGTTGCCGGTGTTGTTCTGGTGCAGTTTCCTGACCTGTCACTGCCAGCGGTGTGCGGC





ATCGGCTCCATGCTGGGTATCGCCGGTTATCAGGTGATTGAGATTGCCATTCAGCGCCGC





TTTAAGGGCAGGGGGAAACAGTAATGCCGGTAATTAACACGCATCAGAATATCGCCGCC





TTTCTCGACATGCTGGCCGTGTCCGAAGGGACGGCGAATCATCCACTGACGAAAAACCG





GGGCTATGACGTGATAGTCACCGGACTGGACGGGAAGCCGGAAATTTTCACCGACTACA





GTGACCACCCGTTCGCACATGGCCGACCGGCGAAGGTGTTTAACCGTCGCGGTGAAAAA





TCCACGGCCTCCGGTCGCTATCAGCAGCTTTACCTGTTCTGGCCGCATTACCGCAAACAG





CTTGCCCTGCCGGATTTCAGTCCGTTGTCACAGGACAGACTCGCCATTCAGTTGATCCGC





GAACGCGGAGCACTGGATGACATCCGGGCGGGACGCATTGAGCGCGCCATTTCACGCTG





TCGCAATATCTGGGCGTCCCTGCCGGGTGCCGGTTACGGTCAGCGTGAGCATTCACTGGA





AAAACTGGTCACCGTCTGGCGTACCGCTGGCGGCGTACCGGCTTAAACGGAGTAAATAC





CATGAAGAAATTATCCCTTTCACTGATGCTGAACGTGTCGCTGGCGCTGATGCTGGCACT





GTCCCTGATTTACCCGCAGAGCGTGGCCGTCAATTTTGTCGCTGCCTGGGCGATTCTGGC





GACGGTTATCTGTGTGGTTGCCGGTGGTGTGGGCGTGTATGCCACTGAGTATGTGCTGGA





ACGCTACGGGCGGGAGCTGCCGCCGGAATCGCTGGCCGTGAAGATTGTCACGTCGCTGT





TTTTGCAGCCGGTGCCGTGGCGCAGACGGGCGGCGGCTCTGGTAGTGGTGGTGGCGACG





TTTATCTCGCTGGTCGCTGCCGGGTGGATTTTTACCGCGCTGATTTATCTTGTGGTGTCGC





TGTTTTTCCGGCTGATACGTAAAGCCTGTCGTCAGCGTCTTGAGGGGCGGGAACCATGTC





AAGGCTGATGATTGTGCTGGTCGTGTTGTTATCGCTGGCGGTGGCCGGTCTGTTTCTGGT





GAAACACAAAAATGCCAGCCTGCGCGCCTCGCTGGACAGGGCGAACAACGTCGCCAGCG





GTCAGCAGACGACCATCACCATGCTGAAAAATCAGCTTCATGTTGCGCTCACCAGGGCA





GATAAAAACGAGCTGGCGCAGGTGGCACTGCGTCAGGAACTGGAGAACGCCGCGAAAC





GTGAAGCACAGCGCGAGAAAACCATCACGAGGTTACTTAATGAGAACGAAGATTTTCGC





CGCTGGTACGGTGCTGACCTGCCTGATGCTGTGCGCCGGTTGCACCAGCGCCCCGCCTGC





ACCGACGCCAGTGATTGTCCCCAACGCATGCCCGAAAGTGAGCCTTTGCCCGATGCCGG





GCAGTGACCCGCAGACGAACGGCGATTTAAGTGCCGATATCCGGCAGCTTGAGAACGCG





CTGGCACGCTGTGCCAGCCAGGTAAAAATGATTAAACACTGTCAGGACGAAAACGATGC





TCAAACCCGACAGCCTGCGCAGGGCGCTGACTGATGCCGTCACGGTGCTGAAAACTAAC





CCCGATATGCTGCGGATATTCGTGGATAACGGGAGTATTGCCTCCACACTGGCGGCGTCG





CTGTCATTCGAAAAGCGTTACACGCTCAATGTGATTGTGACCGACTTTACCGGTGATTTT





GACCTGCTCATTGTGCCGGTGCTGGCGTGGCTGCGGGAAAATCAGCCCGACATCATGACC





ACCGACGAAGGCCAGAAAAAGGGCTTCACGTTTTATGCAGACATCAACAATGACAGCAG





CTTTGATATCAGTATCAGCCTGATGCTGACCGAGCGCACGCTGGTCAGTGAGGTGGACGG





CGCACTGCATGTGAAGAATATCTCGGAACCCCCGCCGCCGGAGCCGGTCACCCGCCCGA





TGGAGCTGTATATCAATGGCGAACTGGTGAGTAAGTGGGATGAATGAGTTTAAGCGTTTT





GAAGACCGGCTGACCGGACTGATTGAATCGCTGTCACCGTCAGGGCGTCGGCGACTGAG





TGCCGAACTGGCGAAACGTCTGCGGCAGAGTCAGCAGCGTCGGGTGATGGCACAGAAAG





CCCCGGACGGCACACCCTACGCGCCACGCCAGCAGCAGAGCGTCAGAAAAAAGACCGGT





CGCGTTAAGCGAAAAATGTTTGCGAAACTTATTACCAGTCGTTTTTTGCATATCCGTGCC





AGCCCGGAGCAGGCATCAATGGAATTTTACGGCGGGAAGTCGCCGAAAATCGCCAGTGT





GCATCAGTTTGGTCTGTCGGAAGAAAACCGGAAAGACGGTAAGAAAATTGATTATCCGG





CGCGTCCCCTGCTCGGCTTTACCGGTGAGGATGTGCAGATGATTGAAGAGATTATCCTGG





CTCACCTTGAGCGTTAG





″V″ through ″G″ (SEQ ID NO: 9):


ATGAACACTCTCGCAAATATTCAGGAACTCGCGCGCGCACTGCGCAACATGATTCGCACT





GGCATTATCGTCGAAACCGACCTTAACGCCGGTCGCTGCCGCGTGCAGACCGGCGGCAT





GTGCACCGACTGGCTTCAGTGGCTGACCCATCGCGCAGGACGTTCGCGCACATGGTGGG





CACCTTCCGTGGGGGAACAGGTGCTGATTCTGGCCGTGGGTGGTGAACTCGACACGGCG





TTCGTTCTGCCGGGGATTTATTCCGGCGATAACCCCTCGCCGTCTGTGTCGGCGGATGCC





CTGCATATCCGTTTCCCTGACGGGGCGGTGATTGAATATGAACCCGAAACCAGTGCACTC





ACGGTAAGCGGAATTAAAACGGCCAGCGTGACGGCTTCCGGTTCTGTTACTGCCACGGT





GCCGGTGGTCATGGTGAAAGCATCAACCCGCGTCACCCTGGACACCCCGGAGGTGGTCT





GCACCAACAGGCTGATTACCGGCACGCTGGAAGTGCAGAAAGGCGGGACGATGCGCGG





CAACATTGAACACACCGGCGGTGAACTCTCATCAAACGGTAAGGTACTGCATACCCATA





AACACCCCGGCGACAGCGGCGGCACAACCGGGAGTCCTTTATGACAGCGCGTTATCTCG





GAATGAATCGCAGTGATGGCCTGACTGTCACTGACCTTGAGCATATCAGCCAGAGTATCG





GCGATATCCTGCGCACACCGGTCGGCTCACGGGTGATGCGTCGTGATTACGGCTCGTTGC





TGGCGTCAATGATTGACCAGCCGCAGACCCCGGCGCTTGAGTTGCAGATTAAAGTCGCCT





GTTACATGGCAGTGCTGAAATGGGAACCCCGCGTCACCCTGTCATCCGTCACCACGGCGC





GCAGTTTTGACGGGCGAATGACGGTCACGTTAACCGGCCAGCACAACGACACCGGCCAG





CCACTTTCATTAACCATCCCTGTGAGTTGAAACCATGCCGATTATCGACCTGAACCAGCT





ACCCGCACCGGATGTGGTCGAGGAGCTGGACTTTGAAAGCATTCTCGCTGAACGCAAGG





CGACACTGATTTCCCTTTACCCGGAAGATCAGCAGGAGGCGGTCGCCCGTACCCTGACAC





TGGAATCTGAGCCTCTCGTCAAACTGCTGGAAGAAAATGCTTATCGTGAGCTTATCTGGC





GTCAGCGTGTGAATGAGGCCGCACGGGCGGTGATGCTGGCCTGTGCCGCCGGTAATGAC





CTTGATGTGATTGGTGCCAATTACAACACCACGCGCCTGACTATCACCCCGGCAGATGAT





TCGACCATCCCGCCGACACCGGCAGTGATGGAATCTGACACCGATTATCGTCTGCGTATT





CAGCAGGCTTTTGAGGGCTTAAGCGTCGCCGGGTCAGTGGGAGCCTATCAGTATCATGGT





CGCAGTGCTGACGGGCGTGTCGCGGATATTTCTGTCACCAGTCCGTCTCCGGCCTGTGTC





ACCATCTCTGTGCTGTCACGTGAAAATAACGGCGTCGCATCCGAAGACCTGCTGGCTGTG





GTGCGTAACGCCCTTAATGGCGAGGACGTCAGGCCGGTGGCCGACCGCGTGACCGTGCA





GTCTGCCGCCATCGTTGAATACCAGATAAACGCCACGCTTTACCTTTACCCTGGTCCCGA





AAGCGAACCCATCCGCGCTGCCGCTGTGAAAAAGCTGGAAGCGTATATCACGGCACAGC





ACCGGCTGGGGCGCGACATCCGTCTGTCTGCCATTTATGCCGCTTTGCATGTGGAAGGTG





TGCAGCGTGTCGAACTGGCTGCACCACTGGCCGACATCGTGCTCAACAGTACGCAGGCG





TCTTTCTGTACCGAATACCGCGTCGTGACCGGAGGCTCGGATGAGTGATTCGCGACTGCT





GCCGACCGGCTCATCACCGCTTGAGGTCGCCGCCGCAAAAGCCTGTGCGGAAATTGAAA





AAACGCCGGTCAGTATTCGTGAACTGTGGAACCCGGACACCTGTCCGGCAAATCTGCTGC





CGTGGCTGGCGTGGGCGTTTTCGGTCGACAGGTGGGATGAAAAGTGGCCGGAAGCGACA





AAACGCGCCGTTATCCGCGATGCCTATTTCATCCACTGTCATAAGGGCACGATAGGTGCA





ATCCGGCGTGTGGTGGAGCCGCTCGGCTATCTCATCAACGTGACGGAGTGGTGGGAAAA





CAGTGACCCGCCCGGCACCTTCCGGCTTGATATTGGTGTACTGGAAAGCGGTATCACAGA





GGCAATGTATCAGGAAATGGAACGGCTGATTGCTGATGCCAAACCTGCAAGCCGTCACC





TTATTGGCCTGAACATTACCCGGGACATTCCCGGCTATCTGTTCGCCGGTGGTGTGGCTT





ACGACGGCGATGTAATTACGGTTTACCCCGGATAAGTGAGGAATAATGAGCATAAAATT





CAGAACCGTTATCACCACTGCCGGTGCAGCAAAGCTGGCAGCGGCAACCGCGCCGGGAA





GGCGGAAGGTCGGCATTACCACGATGGCCGTCGGGGATGGCGGTGGTAAATTGCCTGTC





CCGGATGCCGGACAGACCGGGCTTATCCATGAAGTCTGGCGACATGCGCTGAACAAAAT





CAGCCAGGACAAACGAAACAGTAATTATATTATCGCCGAGCTGGTTATTCCGCCGGAGG





TGGGCGGTTTCTGGATGCGTGAGCTTGGCCTGTACGATGATGCGGGAACGTTAATTGCCG





TGGCGAACATGGCCGAAAGCTATAAGCCAGCCCTTGCCGAAGGCTCAGGACGTTGGCAG





ACCTGTCGCATGGTCATCATCGTCAGCAGTGTGGCCTCAGTGGAGCTGACCATTGACACC





ACAACGGTGATGGCGACGCAGGATTACGTTGATGACAAAATTGCAGAGCACGAACAGTC





ACGACGTCACCCGGACGCCTCGCTGACAGCAAAAGGTTTTACTCAGTTAAGCAGTGCGA





CCAACAGCACGTCTGAAACACTGGCCGCAACGCCGAAAGCGGTAAAGGCCGCGTATGAC





CTGGCTAACGGGAAATATACCGCACAGGACGCCACCACAGCGCGAAAAGGCCTTGTCCA





GCTTAGTAGCGCCACCAACAGCACGTCTGAAACGCTCGCCGCAACACCAAAAGCCGTTA





AGACGGTAATGGATGAAACGAACAAAAAAGCGCCATTAAACAGCCCTGCACTGACCGG





AACGCCAACGACGCCAACTGCGCGACAGGGAACGAATAATACTCAGATCGCAAACACG





GCTTTCGTTATGGCCGCGATTGCCGCCCTTGTAGACTCGTCGCCTGACGCACTGAATACG





CTGAACGAGCTGGCGGCGGCGCTGGGCAATGACCCGAATTTTGCTACCACCATGACTAA





TGCGCTTGCGGGTAAGCAACCGAAAGATGCTACCCTGACGGCGCTGGCGGGGCTTGCTA





CTGCGGCAGACAGGTTTCCGTATTTTACGGGGAATGATGTTGCCAGCCTGGCGACCCTGA





CAAAAGTCGGGCGGGATATTCTGGCTAAATCGACCGTTGCCGCCGTTATCGAATATCTCG





GTTTACAGGAAACGGTAAACCGAGCCGGGAACGCCGTGCAAAAAAATGGCGATACCTTG





TCCGGTGGACTTACTTTTGAAAACGACTCAATCCTTGCCTGGATTCGAAATACTGACTGG





GCGAAGATTGGATTTAAAAATGATGCCGATGGTGACACTGATTCATACATGTGGTTTGAA





ACGGGGGATAACGGCAATGAATATTTCAAATGGAGAAGCCGCCAGAGTACCACAACAA





AAGACCTGATGACGTTGAAATGGGATGCACTAAATATTCTTGTTAATGCCGTCATTAATG





GCTGTTTTGGAGTTGGTACGACGAATGCACTAGGTGGTAGCTCTATTGTTCTTGGTGATA





ATGATACCGGATTTAAACAGAATGGAGACGGTATTCTTGATGTTTATGCTAACAGTCAGC





GTGTATTCCGTTTTCAGAATGGAGTGGCTATTGCTTTTAAAAATATTCAGGCAGGTGATA





GTAAAAAGTTCTCGCTATCCAGCTCTAATACATCCACGAAGAATATTACCTTTAATTTAT





GGGGTGCTTCCACCCGTCCAGTGGTTGCAGAGTTAGGCGATGAGGCCGGATGGCATTTCT





ATAGCCAGCGAAATACAGATAACTCGGTAATATTTGCTGTTAACGGTCAGATGCAACCC





AGCAACTGGGGAAATTTTGATTCCCGCTATGTGAAAGATGTTCGCCTGGGTACGCGAGTT





GTTCAATTGATGGCGCGAGGTGGTCGTTATGAAAAAGCCGGACACACGATTACCGGATT





AAGAATCATTGGTGAAGTAGATGGCGATGATGAAGCCATCTTCAGGCCGATACAAAAAT





ACATCAATGGCACATGGTATAACGTTGCGCAGGTGTAAGTTATGCAGCATTTAAAGAAC





ATTAAGTCAGGTAATCCAAAAACAAAAGAGCAATATCAGCTAACAAAGAATTTTGATGT





TATCTGGTTATGGTCCGAAGACGGAAAAAACTGGTATGAGGAAGTGAAGAACTTTCAGC





CAGACACAATAAAGATTGTTTACGATGAAAATAATATTATTGTCGCTATCACCAGAGATG





CTTCAACGCTTAATCCTGAAGGTTTTAGCGTTGTTGAGGTTCCTGATATTACCTCCAACCG





ACGTGCTGACGACTCAGGTAAATGGATGTTTAAGGATGGTGCTGTGGTTAAACGGATTTA





TACGGCAGATGAACAGCAACAACAGGCAGAATCACAAAAGGCCGCGTTACTTTCCGAAG





CGGAAAACGTTATTCAGCCACTGGAACGCGCTGTCAGGCTGAATATGGCGACGGATGAG





GAACGTGCACGACTGGAGTCATGGGAACGTTACAGCGTTCTGGTCAGCCGTGTGGATCCT





GCAAATCCTGAATGGCCGGAAATGCCGCAATAA





″FI″ through ″ogr″


(SEQ ID NO: 10)



ATGAGTGACTATCATCACGGCGTGCAGGTGCTGGAGATTAACGAGGGCACCCGCGTCAT






TTCCACCGTATCCACGGCCATTGTCGGCATGGTCTGCACGGCCAGCGATGCAGATGCGGA





AACCTTCCCCCTCAATAAACCTGTGCTGATTACCAATGTGCAGAGCGCAATTTCAAAGGC





CGGTAAAAAAGGCACGCTGGCGGCATCGTTGCAGGCCATCGCTGACCAGTCAAAACCGG





TCACCGTTGTCATGCGCGTGGAAGACGGCACCGGTGATGACGAGGAAACGAAACTCGCG





CAGACCGTTTCCAATATCATCGGCACCACCGATGAAAACGGTCAGTACACCGGACTAAA





AGCCATGCTGGCGGCGGAGTCGGTAACCGGTGTTAAACCGCGTATTCTCGGCGTGCCGG





GACTGGATACCAAAGAGGTGGCTGTTGCACTGGCATCAGTCTGTCAGAAGCTGCGTGCTT





TCGGGTATATCAGCGCATGGGGCTGTAAAACCATTTCCGAGGTGAAAGCCTATCGTCAG





AATTTCAGCCAGCGTGAGCTGATGGTCATCTGGCCGGATTTCCTCGCATGGGATACGGTC





ACCAGTACCACCGCCACCGCGTATGCCACCGCCCGTGCGCTGGGGCTGCGCGCTAAAAT





CGACCAGGAGCAGGGCTGGCATAAAACGCTGTCCAATGTCGGGGTGAACGGTGTTACCG





GCATCAGCGCATCTGTATTCTGGGATTTGCAGGAGTCCGGCACCGATGCTGACCTGCTTA





ACGAGTCAGGCGTCACTACGCTGATTCGCCGCGACGGTTTCCGCTTCTGGGGTAACCGTA





CCTGCTCTGATGACCCGCTGTTCCTCTTTGAAAACTACACCCGCACCGCGCAGGTCGTGG





CCGACACGATGGCTGAGGCGCACATGTGGGCGGTGGACAAGCCCATCACTGCAACGCTG





ATTCGCGACATCGTTGACGGCATCAATGCCAAATTCCGTGAGCTGAAAACAAACGGCTA





TATCGTGGATGCGACCTGCTGGTTCAGCGAAGAATCCAACGATGCGGAAACCCTCAAGG





CCGGAAAACTGTATATCGACTACGACTATACACCGGTGCCTCCTCTCGAAAACCTGACCC





TGCGCCAGCGTATTACCGATAAATACCTGGCAAATCTGGTCACCTCGGTTAACAGCAATT





AAGGAGCCTGACCGATGGCAATGCCGCGCAAACTCAAGTTAATGAACGTCTTTCTGAAC





GGCTACAGCTATCAGGGCGTTGCAAAGTCCGTCACGCTGCCAAAACTGACCCGTAAGCT





CGAAAACTATCGCGGTGCGGGGATGAACGGCAGCGCACCGGTAGACCTCGGCCTTGATG





ACGATGCGCTGTCAATGGAGTGGTCGCTCGGTGGCTTCCCGGATTCGGTTATCTGGGAGC





TTTACGCCGCAACCGGTGTGGATGCCGTGCCGATTCGTTTTGCAGGCTCTTACCAGCGCG





ACGATACCGGCGAAACGGTGGCCGTCGAAGTGGTCATGCGTGGACGTCAGAAAGAAATC





GACACCGGCGAGGGTAAACAGGGAGAAGACACTGAGTCGAAAATCTCCGTGGTCTGCAC





CTATTTCCGGCTGACGATGGACGGTAAGGAGCTGGTCGAAATTGACACCATCAACATGA





TTGAGAAGGTGAACGGCGTCGATCGGCTGGAGCAACACCGCCGCAATATCGGCCTGTGA





TTTTCATCCGGTCAGCCTGGCTGGCCGGTTAACCCTGATTCAGAAGTGAGAAAACCATGA





ACAAAGAAAATGTCATTACCCTGGACAATCCGGTCAAACGTGGTGAGCAGGTTATCGAA





CAGGTCACGCTGATGAAACCCAGTGCCGGGACGCTACGCGGTGTCAGTCTGGCTGCGGT





TGCAAACTCCGAAGTCGATGCACTGATTAAGGTGCTGCCGCGCATGACGGCACCGATGC





TGACCGAGCAGGAAGTCGCCGCGCTGGAACTGCCTGACCTTGTGGCGCTGGCCGGTAAG





GTGGTCGGTTTTTTGTCGCCGAACTCGGTGCAGTGACGTTTCCGAAAAATCTCTCGGTCG





ATGACCTGATGGCGGATGTGGCAGTGATATTTCACTGGCCGCCATCAGAACTGTATCCCA





TGAGCCTGACCGAACTCATCACATGGCGCGAAAAGGCGCTCCGGCGAAGCGGAAACACG





AATGAGTAACAATGTAAAATTACAGGTATTGCTCAGGGCTGTTGACCAGGCATCCCGCCC





GTTTAAATCCATCCGCACAGCGAGCAAGTCGCTGTCGGGGGATATCCGGGAAACACAAA





AATCACTGCGCGAGCTGAACGGTCACGCATCCCGTATTGAGGGATTCCGCAAGACCAGT





GCACAGCTCGCCGTGACTGGTCATGCACTTGAAAAGGCACGGCAGGAGGCCGAAGCCCT





TGCCACACAGTTTAAAAACACCGAACGTCCGACCCGTGCTCAGGCGAAAGTCCTGGAAT





CCGCAAAGCGTGCGGCGGAGGACTTACAGGCGAAATATAACCGCCTGACAGATTCCGTT





AAACGCCAGCAGCGGGAACTGGCCGCTGTGGGAATTAATACCCGCAATCTTGCACATGA





TGAGCAGGGACTGAAAAACCGTATCAGTGAAACCACCGCACAGCTTAACCGTCAGCGTG





ATGCGCTGGTGCGTGTCAGTGCGCAACAGGCAAAACTTAACGCAGTAAAACAGCGTTAT





CAGGCCGGAAAGGAACTGGCCGGAAATATGGCCTCAGTGGGCGCTGCCGGTGTGGGGAT





TGCGGCGGCGGGAACGATGGCCGGTGTTAAGCTACTGATGCCCGGTTATGAGTTTGCGC





AGAAAAACTCAGAATTACAGGCTGTGATCGGAGTGGCAAAAGACTCCGCCGAAATGGCC





GCACTCCGCAAGCAGGCGCGCCAGCTCGGCGACAATACCGCCGCCTCGGCAGATGATGC





AGCCGGTGCGCAGATTATTATTGCGAAAGCCGGTGGGGATGTTGATGCCATTCAGGCGG





CAACGCCGGTCACGCTGAACATGGCGCTGGCGAACCGTCGCACAATGGAAGAAAACGCC





GCCCTGCTGATGGGGATGAAATCCGCCTTTCAGCTTTCAAACGATAAGGTCGCTCATATC





GGGGATGTTCTCTCCATGACGATGAACAAAACCGCCGCCGATTTTGACGGCATGAGCGA





TGCGCTGACCTATGCCGCACCTGTGGCAAAAAATGCCGGTGTCAGCATTGAAGAAACCG





CCGCAATGGTCGGGGCGCTGCATGATGCAAAAATCACAGGCTCAATGGCGGGGACGGGA





AGCCGTGCCGTGTTAAGCCGCCTGCAGGCACCGACGGGAAAAGCATGGGATGCACTCAA





AGAGCTTGGAGTGAAAACCTCAGACAGCAAAGGAAACACCCGGCCAATATTTACCATTC





TGAAAGAAATGCAGGCCAGTTTTGAGAAAAACCGGCTCGGTACTGCCCAGCAGGCTGAA





TACATGAAAACTATTTTCGGGGAGGAGGCCAGCTCAGCCGCTGCCGTGCTGATGACTGCC





GCCTCAACCGGAAAGCTGGACAAACTGACCGCTGCGTTTAAAGCCTCAGACGGGAAGAC





CGCCGAGCTGGTAAATATCATGCAGGACAACCTAGGCGGTGACTTTAAAGCGTTTCAGTC





CGCTTATGAGGCGGTGGGGACTGACCTGTTTGACCAGCAGGAAGGCGCGCTGCGTAAGC





TCACGCAGACGGCCACAAAGTATGTGTTAAAACTCGACGGCTGGATACAGAAAAACAAA





TCACTGGCGTCAACCATCGGCATCATTGCCGGCGGTGCACTGGCGCTTACTGGCATCATC





GGTGCCATTGGCCTCGTAGCCTGGCCGGTTATCACCGGCATCAATGCCATCATCGCGGCA





GCAGGCGCAATGGGGGCAGTCTTCACGACGGTTGGCAGTGCTGTTATGACCGCCATCGG





GGCTATTAGCTGGCCGGTTGTGGCCGTGGTGGCTGCCATTGTCGCCGGTGCGTTGCTTAT





CCGTAAATACTGGGAGCCTGTCAGCGCATTCTTTGGTGGTGTGGTTGAAGGGCTGAAAGC





GGCATTTGCGCCGGTGGGGGAACTGTTCACGCCACTTAAACCGGTTTTTGACTGGCTGGG





CGAAAAGTTACAGGCCGCGTGGCAGTGGTTTAAAAACCTGATTGCCCCGGTCAAAGCCA





CCCAGGACACCCTGAACCGTTGCCGTGACACGGGCGTCATGTTCGGGCAGGCACTGGCT





GACGCGTTGATGCTGCCGCTTAATGCGTTCAACAAACTGCGCAGTGGTATTGACTGGGTA





CTGGAAAAACTCGGTGTTATCAACAAAGAGTCAGACACACTTGACCAGACCGCCGCCAG





AACTCATACCGCCACGTATGGTACCGGTGACTATATTCCGGCGACCAGCTCTTATGCAGG





CTATCAGGCTTATCAGCCGGTCACGGCACCGGCTGGCCGCTCTTATGTAGACCAGAGTAA





AAACGAATATCACATCAGCCTGACGGGGGGGACTGCGCCGGGGACACAGCTTGACCGCC





AGTTACAGGATGCGCTCGAAAAATACGAGCGGGATAAACGTGCGCGCGCCCGTGCCAGC





ATGATGCATGACGGTTAAGGAGGTGACGAAAAATGATGCTCGCGTTAGGTATGTTTGTTT





TTATGCGCCAGACGCTGCCACACCAGACCATGCAGCGTGAATCAGATTATCGCTGGCCGT





CAAATTCCCGTATCGGTAAACGGGATGCCTTTCAGTTTCTCGGTGTGGGTGAGGAAAACA





TCACGCTGGCCGGTGTGCTTTATCCCGAACTGACCGGCGGCAAGCTGACGATGACCACGC





TCAGGCTGATGGCAGAGGAGGGGCGGGCGTGGCCGTTGCTGGATGGCACCGGCATGATT





TACGGCATGTATGTCATCAGCAGGGTGAGTGAAACAGGGAGTATTTTCTTTGCAGACGGC





ACACCCCGGAAAATTGATTTTACGCTGTCACTCACCCGCGTTGATGAATCACTGGCCGCG





CTTTATGGCGATATCGGTAAACAGGCGGAATCGCTCATCGGTAAGGCCGGCAGTATGGC





GACCAGATTCACAGGTATGACGGGGGCGGGATAATGCTGGATGCGCTGACATTTGATGC





AGGCAGTACGCTGACGCCGGATTACATGCTGATGCTCGACAGCAGGGATATTACCGGCA





ATATCAGCGACCGTCTGATGAGCATGACCCTGACGGATAACCGGGGCTTTGAGGCTGAC





CAGCTTGATATTGAACTGAACGATGCCGACGGGCAGGTCGGGCTGCCGGTTCGTGGCGC





TGTCCTGACGGTGTATATCGGCTGGAAAGGTTTTGCCCTGGTATGCAAAGGGAAATTTAC





CGTTGATGAGGTTGAACACCGGGGCGCACCGGATGTAGTCACCATCCGCGCCCGGAGTG





CAGATTTTCGCGGGACGCTCAATTCCCGCCGGGAAGGCTCCTGGCATGACACCACGCTCG





GTGCGATTGTTAAGGCGATAGCCACCCGTAACAGGCTGGAAGCCAGTGTCGCTCCGTCA





CTGGCCGGAATAAAAATTCCACACATCGACCAGTCGCAGGAGTCTGATGCGAAATTCCT





GACCCGTCTTGCAGAACGCAACGGCGGTGAGGTGTCGGTAAAAATGGGAAAACTGTTGT





TTCTCAAAGCGGGGCAGGGAGTGACGGCCAGCGGTAAAAAAATCCCGCAGGTCACCATA





ACCCGCAGCGACGGCGACCGCCATCATTTTGCGATTGCTGACCGTGGAGCCTACACCGGT





GTAACGGCAAAATGGCTACACACTAAAGACCCGAAGCCGCAAAAGCAGAAGGTAAAAC





TGAAACGCAAAAAGAAAGAGAAACACCTGCGCGCACTGGAGCACCCGAAAGCGAAACC





GGTCAGGCAGAAGAAAGCGCCTAAAGTACCGGAAGCGCGTGAAGGTGAATACATGGCC





GGTGAGGCTGACAACGTTTTTGCCCTGACCACGGTATATGCCACGAAAGCGCAGGCCAT





GCGCGCCGCTCAGGCGAAGTGGGATAAACTGCAACGGGGCGTTGCGGAGTTCTCTATCA





GCCTGGCTACCGGTCGGGCAGATATTTACACGGAAACACCGGTCAAAGTGTCTGGCTTTA





AGCGCGTCATAGACGAGCAGGACTGGACAATCACTAAGGTGACACATTTTCTGAATAAT





AGCGGCTTCACGACGTCCTTAGAGCTTGAGGTCAGGCTTTCTGATGTGGAGTACGAAACA





GAAGATGATGAGTGATGTTTTTGTTTTATCTGTTTGTTTTGTAAGGATAAATTAACTAAAA





TGGCACCATCAACAAAACCGGAAGAGGTGCTCGCGATGTTTCATTGTCCTTTATGCCAGC





ATGCCGCACATGCGCGTACAAGTCGCTATATCACTGACACGACAAAAGAGCGTTATCAT





CAGTGCCAGAACGTGAATTGCAGCGCCACGTTCATCACTTATGAGTCGGTACAGCGATAC





ATCGTGAAGCCGGGAGAAGTCCACGCCGTAAGGCCGCACCCGTTGCCATCAGGGCAGCA





AATTATGTGGATGTAA






Minimal genes to include from a SaPI on a vector or MGE. Several different SaPI systems exist. FIG. 2 is exemplified one of the well characterized SaPIs (SaPIbov1), which exploits phages phi11 or phi80alpha as helper phage. SaPIbov1 sequence (acc.number: AF217235.1)


Packaging Signal

If one uses a defective helper phage with deleted packaging signal one can use that signal from the helper phage. In this example from S. aureus phi11 (acc. number: AF424781), as follows:











(SEQ ID NO: 11)



ANGATTTANTCC






For small capsid size (packages 15.8 kb instead of 43.6 kb), one can include cpmA and/or cpmB in the MGE or vector.









cpmA


(SEQ ID NO: 12)


MKTESYFKEYNQFVLDQHKAIQELEQERNALESKIKLDKSTYKQLIMDGQ





DDKADNLYQATDADEKKLKALNKRLETKKSVSKEVKYQKTIELLKHQSEL





SSLYESEKQSAIEKLKKAVDAYNEIIDEIEDINDRYEDEHQQYASVYSQE





QLYDDKEARKALNGHFKENIFTSFINGNDLPYEHNNKLFLKC





cpmB (SEQ ID NO: 13):


MKTKYELNNTKKVANAFCLNEEDTNLLINAVDLDIKNNMQEISSELQQAE


QSKQKQYGTTLQNLAKQNRIIK






To activate helper phage phi11 one can include one, more or all of ptiA, B and M (provided separately in a host cell and not on the MGE or vector to be packaged)









ptiA


(SEQ ID NO: 14)


MDKQQIKDFVCDYHERTRSDVLIDDDINTDEFFSIADENSNEWMADDNID


DHIVKNHLEMIVDRVANDKEFYIFDSLIQGRSYQDISGVLDCSEQSVRFW


YETLLDKIVEVIE





ptiB


(SEQ ID NO: 15)


MESIAEKETYHLPTEHLQVFNVIKNTSNKYITKTKILNQLGYEYNSSNER


WLRRVINSLVYDYGYPIGCSYKPSERGYYIITTEQEKQQAMRSIKKLADG


SMKRYEALKRIEV





ptiM (SEQ ID NO: 16):


MIAYPIRVGSVYRGEQMKLLKTKNCLYYRNGDNKLSEYQLLTQFNPTFIN





KKIRMCEFQIESMYHMSASTTTCDEMMGVVSVSYPIEKLVIKIIETKARL





QNYKNRSISNMVLLKTVLNHYTEKEQKKVVKYMRSNGRYKPYNVIERLQV





DLYQASIKQRSERQKQRNIAIENSKIARVNAYHQSSYVKVV






Minimum genes to include in the host chromosome/episome from phi11.









Phi11 sequence (acc.number: AF424781)


gene #29 (terS) through gene #53 (lysin)


(SEQ ID NO: 17)


atgaacgaaaaacaaaagagattcgcagatgaatatataatgaatggatg





taatggtaaaaaagcagcaattacagcaggttatagtaagaaaacagcag





agtattagcaagtcgattgttaagaaatgttaatgtttcggaatatatta





aagaacgattagaacagatacaagaagagcgtttaatgagtattacagaa





gctttagcgttatctgcttctattgctagaggagaacctcaagaggctta





cagtaagaaatatgaccatttaaacgatgaagtggaaaaagaggttactt





acacaatcacaccaacttttgaagagcgtcagagatctattgaccacata





ctaaaagtacatggtgcgtatatcgataaaaaagaaattactcagaagaa





tattgagattaatattggtgagtacgatgacgaaagttaaattaaacttt





aacaaaccgtctaatgttttcaatagaaacatattcgaaatactaaccaa





ttacgataacttcactgaagtacattacggtggaggttcgagcggtaagt





ctcacggcgttatacaaaaagttgtactcaaagcattgcaagattggaaa





tatcctaggcgtatactgtggcttagaaaagtacaatcaacaattaaaga





tagtttgttcgaagatgttaaagattgtttgataaactttggtatttggg





acatgtgcctttggaataagactgataacaaagttgaattgccaaacggc





gcagatattgtttaaaggattagataacccagagaaaataaagtcgataa





aaggcatatcagacatagtcatggaagaagcgtctgaattcacactaaat





gattacacgcaattaacgttgcgtttgagggagcgtaaacacgtgaataa





gcaaatatttttgatgtttaacccagtatctaaactgaattgggtttata





agtatttctttgaacatggtgaaccaatggaaaatgtcatgattagacaa





tctagttatcgagataataagtttcttgatgaaatgacacgacaaaactt





agagttgttagcaaatcgtaatccagcatattacaaaatttatgcgttag





gtgaatttgctacactagacaaattggttttccctaagtatgaaaaacgt





ttaataaataaagatgagttaagacatttaccttcttattttggattgga





ctttggctacgttaatgatcctagtgcttttatacattctaaaatagatg





taaagaaaaagaagttatacatcattgaagagtatgttaaacaaggtatg





ctgaatgatgaaatagctaatgtcataaagcaacttggttatgctaaaga





agaaattacagcagatagtgcagaacaaaaaagtatagctgaattaagga





atctagggcttaaaaggattttaccaaccaaaaaagggaagggctcggtt





gtacaagggttacaattcttaatgcaatttgaaatcattgttgatgaacg





ttgtttcaagactattgaagagtttgacaactacacatggcaaaaggaca





aagatacaggtgaatataccaatgaaccagtagatacatacaatcattgt





atcgattcgttgcgttattcagtggaacgattctacagaccggttagaaa





acgcacaaatctcagttcgaaagttgacacaataaaatctctaggattat





aggagggaacaaatgttaaaagtaaacgaatttgaaacagatacagatct





acggggaaacataaattacttatttaatgatgaagccaatgttgtttaca





catatgacgggacggaatccgatttattacaaaacgttaatgaagtaagt





aaatacattgaacatcacatggattaccaacgacctagattgaaagtgtt





aagtgattattacgaaggtaaaactaagaacttagttgagttaacacgac





gcaaagaagagtacatggcagataaccgtgtagcgcatgattacgcatct





tatattagcgattttatcaacggctatttcttgggtaatccaattcaata





tcaagatgatgacaaagatgtattagaagttattgaggcgttcaatgatt





taaatgatgttgagtcacacaatagatctttaggattagatttgtcaatt





tatggcaaagcttatgagttaatgattagaaaccaagatgatgaaacgcg





tttatacaagagtgatgcaatgagtacttttgtcatatacgacaatacaa





ttgaacgtaatagtatcgcaggcgttagatatttaagaactaaaccaata





gacaagactgacgaagatgaagtgtttacagttgatttattcacttcaca





cggtgtttatagatatcttaccagtagaacaaatggattgaagctcacac





cacgtgaaaacggttttgaatcacactctttcgaacgtatgcctattaca





gaatttagcaacaacgaaagaagaaaaggggattatgagaaagtaatcac





tttaattgatttgtatgataatgctgaatcagatactgctaactatatga





gtgatttaaatgacgctatgttacttattaaaggtaatttaaatttagat





cctgtagaagttagaaaacaaaaggaagctaacgtgttgtattagaaccg





actgtttatgctgatagcgaaggtagagaaacagaaggctctgttgatgg





tggttatatttataagcaatacgatgtacaaggtaccgaagcttataaag





accgtttaaacagtgatatacacatgtttaccaacacgcctaacatgaaa





gatgataactttagcggcactcaatcgggcgaggcaatgaaatacaaatt





atttggattggaacaacgtactaaaactaaagaaggattgtttactaaag





ggttaagacgtcgtgctaagttgttagagacaatacttaaaaatacatgg





tcgattgacgctaacaaagatttcaatactgttagatacgtatacaacag





aaacttacctaaatcattgattgaagaattaaaagcttatattgattctg





gtgggaagattagccaaacaactttaatgtctctattctcgttcttccaa





gaccctgaattagaagttaagaaaatcgaagaagatgagaaagaatctat





taaaaaagctcaaaaaggtatttataaagaccctagagacatcaatgatg





acgaacaagatgatgatacaaaagatactgttgataaaaaggaatgattg





taattgcctaacaaaaacactcaagaatattgggaagaacgcggacgcaa





agcaatcgagaatgagttgaagcgtgataaaactaaagctgaagaaatag





aacgtatattgaatatgatgattaagcgcattgaaaaagagatcaatgcg





tttattgtcaagtacggagattttgcaggcgttacattacaagaagcaca





aaagattattgatgagttcgatgtaaaagcgtttcaagaagaagcaaaaa





gattggtcgaaaacaaggagtttagcgatagagcaaatgaagaattaaag





aagtataacacgaaaatgtatgtatctagagaacagatgttaaagattca





aatagaattcttaattgcttatgcaacagctcaaacagaattatcgatga





gggaatatttcgaatcaacagcttatcgtgtgttcagtgatcaagcgggt





attttaggtgaaggtgtacaagtagctaaagaagttatagatacaatcgt





tgatacacaatttcatggtgtcgtttggtcagagcgattatggactaata





ccgaagcaatgaaacaagaagtagaagaaataattgctaatgtagttatt





agaggtcgacatcctaatgaatatgttaaagatatgcgcaagcacttaaa





taaattcgaaggcacagcacgacaaaagaccgcagcaattaaatcattgc





tttatacggaatcggcacgtgttcacgcacaatcaagcattgacagcatg





aaagaaatttcaccggaaggatattatatgtatattgcaaaaatcgataa





tagaacaactaaagtatgcaaagggcttaatggagaaatattcaaagtta





aagacgctaaaattggtgttaatttctatcctatgcatatcaattgtcgt





tcagattgcgctttactacctaaatctatgtggccgaaaaaaccaagcaa





gaaacgaaaaacaaaatacttcggagggaaagtgaaaagcggtgattgat





ttaaaagtgaagatataaaggcaagttagttttgtatgacagtaaattaa





atgtttggaggatactaatatgagtaatactgacaaataccttagagaca





tagcaagagaattaaaaggtatacgtaaagagttacaaaagcgaaacgaa





acagttattattgatgcaaacttagacagtttaaggtcggcagtattagc





cgataaagaaaaatcgaaatataatgaacctctcattaatagctagcact





taattgtgttggctattattatgtccaaaacgtgctgatgacataaaaag





cacgcatggaaaaacagtcgacagactataaatggaggtatatctcatgg





aagaaaataaacttaagtttaatttgcaattattgcagaccaatcagatg





atccggacgaaccaggcggagatggtaaaaaaggaaatcctgataagaaa





gaaaatgacgaaggtactgaaataactttcacgccagagcaacaaaagaa





agttgatgaaatacttgaacgtcgtgtagcccacgaaaagaaaaaagctg





atgagtatgcaaaagaaaaagcagcagaagctgctaaagaagctgctaaa





ttagcgaaaatgaacaaggatcaaaaagatgaatatgaacgcgaacaaat





ggaaaaagaactggaacaattacgttcagaaaaacaattaaacgaaatgc





gttcagaagcacgaaaaatgttgagtgaagcggaagttgattcatcagat





gaggttgtcaatttagttgtaacagatactgctgaacaaactaaattgaa





tgttgaagctttttctaatgcagtaaaaaaagcggttaatgaagcggtta





aggttaacgctagacaatcgccattgactggtggagattcatttaatcac





tcgactaaaaataaaccgcaaaacttagctgaaatagctagacaaaaaag





aattattaaaaattaacggaggcatttaaatggaacaaacacaaaaatta





aaattaaatttgcaacattttgcaagtaacaatgttaaaccacaagtatt





taaccctgacaatgtaatgatgcatgaaaagaaagatggcacgttgttaa





acgactttacaacacctatcttacaagaggttatggaaaactctaaaatc





atgcaattaggtaagtacgaaccaatggaaggtactgagaagaagtttac





tttttgggctgataaaccaggtgcttactgggtaggtgaaggtcaaaaaa





tcgaaacgtctaaggctacttgggttaatgctacaatgagagcgtttaaa





ttaggggttatcttaccagtaacaaaagaattcttgaattacacttattc





acaattattgaagaaatgaaacctatgattgctgaagctttctataaaaa





gtttgacgaggcaggtattttgaatcaaggtaacaatccgttcggtaaat





caattgcacaatcaattgaaaaaactaataaggttattaaaggtgacttc





acacaagataacattattgatttagaggcattgcttgaagatgacgaatt





agaagcaaatgcatttatctcaaaaacacaaaacagaagcttgttacgta





aaattgtagatcctgaaacgaaagaacgtatttatgaccgtaacagtgat





tcgttagacggtctacctgtggttaaccttaaatcaagcaacttaaaacg





tggtgaattaatcactggtgacttcgacaaattgatttatggtatccctc





aattaatcgaatacaaaatcgatgaaactgcacaattatctacagttaaa





aacgaagatggcacacctgtaaacttgtttgaacaagacatggtggcatt





acgtgcaactatgcatgtagcattgcatattgctgatgataaagcgtttg





ctaagttagttcctgctgacaaaagaacagattcagttccaggagaagtt





taataaataattaggagtggtaacatgcccgaaatcattggaattgttaa





agtagattttacagatttagaagataacagacatgtctatatgaaagggc





atgtctaccctcgtaaaggttataatcctacagatgaacgtatcaaagct





ttagctagtgttgaaaataaacgcaacaaacaaatgatttacattgtaaa





tgacaaattaaccaaaaaagaacttgtcgaaatagcaagtgttgctggct





tacaagttgatgaaaaacaaacaaaagctgaaattatcaatgcttttgag





tcactagagtaggtggttatatgactacgctagctgatgtaaaaaaacgt





attggtcttaaagatgaaaagcaagatgaacaattagaagaaatcataaa





aagttgtgaaagccagttgttatcaatgttacctattgaagttgaacaaa





taccggaaaggtttagttacatgattaaagaagttgcagttaaacgctac





aacaggattggtgctgaaggtatgacatcagaagcggttgacggacgtag





caatgcgtatgaattgaacgatttcaaggagtatgaagctattattgata





attactttaatgctagaacgagaactaaaaaaggaagggctgtgttcttt





tgagatatgaagatagagttatttttcaattagaacaagtagcaacttac





aatcctaaaactagcaaaaaagaaaacacactaatcacttatgatgcgat





accatgcaatattaaccccatttctagagcaagaaagcaacttgaatttg





gtgatgtaaaaaacgatgtaagtgttctgaggataaaagaatcaatatct





taccctgttagccacgtgttggttaatggcattcgctacaagatagttga





tacaaggatatacagacacgaaacgtcatattatatcgaagaggtcaatt





gatgaatatagatggattagacgcactgttaaaccaatttcacgatatga





aaaccaacattgatgatgatgtagatgatattttacaggaaaacgccaaa





gaatatgtagtacgagctaaattgaaagctagagaagtaatgaataaggg





ttattggactggtaatttatcacgcaatatcagatataaaaaaactggcg





atttgcaatacactatcacatcgcacgcagcttatagtggtttcttagaa





tttggtactcgatacatggaggctgaaccttttatgtggccggtatacga





agtgattaggaaatcaactgtagaagaattgaaagcgttgtttgaatagg





agataaaagcatgacaccgaacttacaactttataataaagcgtatgaaa





cgctacaaggatatggattccctgttatttctcgtaaagagatgcaacaa





gagattccgtatcctattagtaataaaaatgccggagtcaaatagaagta





agtacacgtttgatagttattctggcgatacgaatttagttattgatatt





tggagtgtaagcgatgatttaggacatcatgacggacttgttaaaagatg





tattgatgatttaacacctagcgttaaaacaaacgattatgactttgaag





aagaagatactaacatcacacagttagttgatgatactaccaatcaagaa





ttgctacacacatcagtaacgatatcttacaaaacattttaaaaaacgga





ggaatattgaatggcaaatatgaaaaatagtaatgatcgtattattttat





ttagaaaagctggcgaaaaagtagatgctactaaaatgctttttttaact





gaatacggcttatcacatgaagctgatacagatacagaggatacaatgga





cggttcttataacactggtggttctgttgagtcaacaatgtctggtactg





ctaaaatgttttatggtgacgattttgcagatgaaattgaagatgcagtt





gtagatcgcgtattgtatgaagcttgggaagttgaaagtagaataccagg





caaaaatggggattccgctaaatttaaagcgaaatatttccaaggtttcc





acaataaatttgaattaaaagcagaagctaacggtattgatgaatatgaa





tatgaatatggagtgaatggtcgtttccaacgtggatttgcaacactacc





tgaggctgtaacaaagaaacttaaggcgactggatacagattccacgaca





ctacaaaagcagatgcattaactggcgaagatttaacagcaattccacaa





cctaaagtagattcaccaccggttgcaccaagagaggtataaaaataggg





cgttaagcccatttattagtttaaattaattatgaatggagattttaagt





tatgaatgtagaaattaacggaaagtcattagaattaagttttggtttta





aatttttaagagaaatcgataaccgattaggtttaaaagttgaacaagct





tctatcggtcaaggtgtatcaatgttgcctgtaggtttagaaagtggaaa





tccggttgtgattggcgaagttttaatcgcagctacatctcacttaaaaa





aacaagcaattactattaataacattgatgaagcattagatgaaatcgca





gaaaatatcggactagaagaattcggttcggatattttaacggagttggg





aaagcgacctatgacccgaaacctagtcgaagtagtggaaacggaagaaa





aaccagcggaagcctaataacttacgacagaatcgttataacttgtatgt





caacacttggtattacagatttgaacgttattgagcaaatgacattaaca





gaatataactatcgaatgtatgcgaaagagtatgaaatgctaacccaaga





attcgaacgttacaaacttgcgtttgctattcgtgatgctgcagctacta





aaaatgttgggacagaaaataaacctaaagaggaatatgtttttaacaat





gcaaacgacgtattgccttatgaagaaaatatccaacggcttaacgaagg





taaagatataagatttagtagcgaacgtgatgaatacgaaccacaaaata





atgaattattaaagttatagcagaatttaataagcaatagaaagagaggt





gttaatgtgacggaatataaaattaaagcgactattgaagctagtgtagc





caaattcaaaaggcaaattgatagtgcggttaagtctgtgcaaagattta





aacgagtagcagatcaaactaaagatgttgaattaaacgctaacgataaa





aatttacaaaaaactatcaaagttgctaaaaagtctttagatgcctttag





taacaaaaatgtaaaagctaaattagatgctagtatacaagatttacaac





aaaaggtactagaatcgaattttgaactagacaaactaaactctaaagaa





gttacaccagaagttaagttgcaaaaacaaaagttgattaaagatatcgc





tgaaacagaagctaaattatcagaattagaaaagaaacgtgtcaatattg





acgtcaatgcagataacagtaaattcaatcgagtgttaaaagtatctaaa





gctagtctcgaagcattaaataggtctaaagccaaagctattatagacgt





ggacaatggtgttgctaactctaaaatcaaacgtactaaagaagaactta





aaagtattccgaacaaaactagatctcgacttgatgtagatacagggctt





tctataccaactatttatgcgtttaaaaaatcattagacgcattgccgaa





caaaaaaacaacaaaggtagatgtcgatactaatggtttaaagaaagctt





atgcctacataataaaagcaaatgacaattttcaaagacagatggggaat





ttagctaatatgttccgtgtgttcggtactgtaggttctaatatggttgg





tggattacttacatcatcttttagtatcttaatacctgtaatagcgagcg





tagtacctgtagtatttgcgctattaaacgctatcaaagtgttaactggt





ggtgtacttgctttaggtggtgccgtagcaatagcgggagcaggatttgt





agcgtttggcgcaatggctatcagcgctataaagatgcttaatgatggca





ctttacaagctagctcagcaacaaacgaatacaaaaaagcgttagatggc





gtaaagtcagcatggactgatattataaagcaaaatcaatccgctatctt





cacaactcttgcaaatggtttaaatactgttaaaactgcaatgcagagct





tacaaccgatatagtggtatttcaagaggaatggaagaagcgtctcaaag





cgtgcttaaatgggctgaaaatagcagtgtagcttcaagattctttaata





tgatgaatacaacgggtgtttcggtatttaacaagctattaagtgctgca





ggtggttttggtgacggattagtcaatgtattcacgcaattagcaccact





gtttcaatggtcggctgattggttggatagattaggtcaatctttctcta





actgggctaatagtgcagctggagaaaattcgataactcgttttattgaa





tacacaaaaacaaacttacctatcattggtaatattttcaaaaatgtttt





cgttggaattaacaatttgatgaatgcattcagcggatcatcaactggca





tattccaatctcttgaacaaatgacagctaagtttagggaatggtctgaa





caagtaggacaatctcaagggtttaaagactttgtcagttatatacaaac





aaatggaccactaataatgcaattgattggaaacatcgcaagaggattag





ttgcattcgcaacagcaatggctcctatagctagtgcagtattacgcgtt





gcagttgcaataactggttggatagctaacttgtttgaggcgcatccagc





tacagcacaattagttggtgtcattataactttagttggtgcatttagat





ttttaataccgattattcttgctgtatctaactttatgggtggcggatta





ataggtagaatcattgcattagtaagtaagttcggtttattaagagcggg





attaacaattttaaaaggtgcgttcatgttattaaaaggaccattaaaaa





ttatatcagttatattccaattgttattcggtaagattggattaattaga





aatgctatcacaggactagtaactgtgtttggtattttaggcggtccaat





aacaatagtaattggtgtaattgctgcattaatagctatattcgttttat





tgtggaataaaaatgaaggattcagaaactttattataaatgcttggaat





gcgataaaaacgtttatggttaatgtttggaatgtattaaaagctgtagc





ttcggttgtatggaatgctattttaacagctatcactacagcagtatcga





atgtttacaattttataatgattgtttggaatcaaatagtcgcttattta





caagggctatggaatggaattatcgctattgcaacaacagtatggaacct





tttagttacaatcattacaactgttttcacgacgataatgacaatagtta





tgacgatatggacagctatttggacgttcttaagtacaatctggaatacg





ataattacaatcgctactacgatttggaatttgttagtcactgtaataac





tacagtgtttaccacaattatgactatcgcaataacaatttggaacgcta





tttggacgttcttacaaacgttgtggaacactatagttactgtggcaact





aaggtttggaacgctatcactacagctatatctactgcgttacaagcggc





atggagttttatttctaatatatggaatacgatttggagtttcttatctg





gtatattaacgacaatttggaataaagttgtaagcatattcacacaagtt





gtttcaactatatcagacaaaatgtctcaagcttggaacttcattgtcac





taaaggtatgcaatgggtatctactataacaagtacgctaattaactttg





ttaatagagttgttcaaggattcgttaatgttgtaaacaaagttagtcaa





ggtatgacaaatgcagtaaataaagttaaaagctttgtggatgactttgt





atcagcaggtgctgatatgatccgtggtttgatgagaggtattggtaata





tggctagagacttagctgaaaaagcagctagtgtagcaaaaggtgcttta





aatgcagccaaaagagcgctaggtattcactcaccttcacgtgaattcat





ggatgaggtatgtattcaatgttaggtacgttaaaggtatagataatcat





tcaagtaaagttatccgtaatgtttctaatgttgcagataaagtagttga





tgcatttcaacctacattaaacgcacctgacatttctagtattacaggaa





acttaagtaatttaggtggaaatataaatgcgcaagtacaacacacacat





tctattgaaacatcaccgaacatgaaaactgttaaagttgaattcgatgt





caataacgatgcgcttactagtattgttaacggcagaaatgctaaacgca





attctgagtattacttataaaggaggttacaaatggacatagaattaaca





aaaaaagatggtactgtaatcaaattaagtgaatacgggtttatcgttaa





cgatatagtaattgatagcatgcaaatcaacacaaagtatcaagacaaag





aaaatatgaacggtcgtatattaatggggagcaattatatcagtagagat





atagttgttccttgatagtaaagttaaaaatcgttcagacattgcttata





tgcgagatatgttgtattcgttaacgacagacatagaacctatgtatttg





cgagaaatcagaagaaaagaagagttgaattacaggtttactcaaccaac





ttctgatgattacgtgaaattagataaaaacaacttcccggattacgaat





attcaagacacgatcaacaaatttatgtaaatggtaaacagtataaagtt





atttttaacggagttataaaccctaaacaaaaaggtaataaagtttcttt





tgaactaaaattcgaaactacagaattaccatacggtgaaagtattggaa





caagcctagagttagaagaaaacaaaaaggttggattgtggtcgtttgat





tttaatattgattggcatgcaggcggagacaaaagaaagtatacatttga





aaatttgagcaaaggtacagtttactatcatggtagtgctcctaacgacc





aattcaacatgtataaaaagataacaattattttaggcgaagatacagaa





tcgtttgtatggaatttaacgcatgctgaaataatgaaaatcgaagggat





caaactaaaagctggagacagaattgtttatgatagcttccgagtttata





aaaacggtgttgaaataagtaccgaaacgaatatagcccaaccaaaattt





aaatacggagctaataaatttgagtttaatcaaacggtacaaaaagttca





gtttgatttgaaattttattataagtaggtgtcagaatgacaataactat





taaaccacctaaaggtaatggcgcacctgtaccagtagaaacaactttag





taaaaaaagttaatgctgacggtgtattaacttttgatattctagaaaat





aaatatacttatgaagttattaacgctatagggaaaagatggattgttag





tcatgtcgaaggtgaaaacgacaagaaagaatatgtaataactgtcattg





ataggaaatcagaaggcgacagacaactggttgaatgtactgctagagag





attcccatagacaagttaatgattgatagaatttatgttaatgtaacagg





atcttttacagtagaaagatattttaacattgtgtttcaaggtactggaa





tgctattgaagtcgagggcaaagttaaatcttcaaagtttgaaaatggtg





gtgaaggcgatacaaggttagaaatgtttaaaaagggattagaacatttc





ggtttagaatataaaataacgtatgacaaaaagaaagacagatataagtt





tgtattgacgccttttgcaaatcaaaaagcgtcttattttatttctgacg





aagtcaacgccaacgctataaaactcgaggaagatgcaagtgatttcgcc





accttcattagaggatatggtaattattcaggagaagaaacattcgaaca





cgctgggctcgtaatggaagctagaagtgcattagctgaaatatacggcg





acatccacgcagaaccatttaaagatggtaaagtgactgaccaagaaact





atggataaagaattacaatcgagattgaaaaagtcgttaaaacaatcttt





gtctttggactttttggtgttaagagaatcatatccagaagcagacccac





aacccggagacatagtacaaataaaatctaccaaactaggtttgaatgat





ttagtccgtatagtacaagttaaaacgattaggggtataaacaatgtaat





tgttaagcaagatgtaacgcttggtgagtttaatcgagaacaacgatata





tgaaaaaagttaatactgcagctaactatgtttctggattaaatgatgtt





aacctttctaatcctagtaaagcggcagaaaacttgaagtctaaagtagc





gtcaatagctaaatcaacactcgatttgatgagtagaactgatttgattg





aagataaacaacagaaggtaagctctaaaactgtgactacatctgacggc





actatcgttcatgattttatagataaatcaaacattaaagatgtaaaaac





gattggaacgattggcgattctgtagctagaggatcacatgcgaaaacta





atttcacagaaatgttaggcaagaagttaaaagctaaaacgaccaacctt





gcaagaggtggcgcaacaatggcaacagttccaataggtaaagaagcggt





agaaaacagcatttatagacaagcagagcaaataagaggagacctaatca





tattacaaggtacagatgatgactggttacatggttattgggcaggcgta





ccgataggcactgataaaaccgacactaaaacgttttacggcgccttttg





ttctgcaattgaagttatcaggaaaaataatccagcttcaaaaatacttg





taatgacagctactaggcaatgccctatgagtggtacaacgatacgccgt





aaagatacggacaaaaacaaactagggttaactttagaggattatgtcaa





tgctcagatattggcttgtagtgaattggatgtaccagtatatgatgctt





atcacacagattatttcaaaccatataatccagcatttagaaaatctagc





atgcctgatggattacatcctaatgaaagaggtcatgaagttattatgta





tgagcttattaaaaattattatcagttttatggatagtaaaggaggaaaa





catgagtaataaactaattacagatttaagtagagtctttgactacagat





atgtagatgaaaatgagtataactttaaacttatttcagacatgctgacg





gattttaatttctctcttgaataccacagaaataaagaggtattcgcaca





tgatggagaacaaataaagtatgaacatttaaatgttacaagtaacgtct





ctgactattaacatatttaaacggtcgatttagcaacatggtactaggtc





ataacggcgacggtatcaacgaagtaaaagacgcgcgcgttgataataca





ggttatggtcataagacattgcaagatcgtttgtatcatgattattcaac





actagatgttttcactaaaaaggttgagaaagctgtagatgaacactata





aagaatatcgagcgacagaataccgattcgaaccaaaagagcaagaaccg





gaatttatcactgatttatcgccatatacaaatgcagtaatgcaatcatt





ttgggtagaccctagaacgaaaattatttatatgacgcaagctcgtccag





gtaatcattacatgttatctagattgaagcccaacggacaatttattgat





agattgcttgttaaaaacggcggtcacggtacacacaatgcgtatagata





cattgatggagaattatggatttattcagctgtattggacagtaacaaaa





acaacaagtttgtacgtttccaatatagaactggagaaataacttatggt





aatgaaatgcaagatgtcatgccgaatatatttaacgacagatatacgtc





agcgatttataatccggtagaaaatttaatgatttttagacgtgaatata





aacccactgaaagacaacttaagaattcgttgaactttgttgaggttaga





agtgctgacgatattgataaaggtatagacaaagtattgtatcaaatgga





tatacctatggaatacacttcagatacacaacctatgcaaggtatcactt





atgatgcaggtatcttatattggtatacaggtgattcgaatacagccaac





cctaactacttacaaggcttcgatatcaaaacgaaagaattgttatttaa





acgtcgcatcgatataggcggtgtgaataacaactttaaaggagatttcc





aagaggctgagggtctagatatgtattacgatctagaaacaggacgtaaa





gcacttctaatcggggtaactattggacctggtaacaacagacatcattc





aatttattctatcggtcaaagaggtgtaaaccaattcttgaaaaacatcg





cacctcaagtatcaatgactgattcaggcggacgtgttaaaccgttacca





atacagaacccagcatatctaagtgatattacggaagttggtcattacta





tatctatacgcaagacacacaaaatgcattagatttcccgttaccgaaag





cgtttagagatgcagggtggttcttggatgtactgcctggacactataat





ggtgctctaagacaagtacttaccagaaacagcacaggtagaaatatgct





taaattcgaacgtgtcattgacattacaataagaaaaacaacggagcatg





gaatttctgcccgcaaaacgccggttattgggaacatatccctaagagta





ttacaaaattatcagatttaaaaatcgttggtttagatttctatatcact





actgaagaatcaaaccgatttactgattacctaaagactttaaaggtatt





gcaggttggatattagaagtaaaatcgaatacaccaggtaatacaacaca





agtattaagacgtaataacttcccgtctgcacatcaatttttagttagaa





actttggtactggtggcgttggtaaatggagtttattcgaaggaaaggtg





gttgaataatggtagtagataatttttcgaaagatgataacttaatcgag





ttacaaacaacatcacaatataatccggttattgacacaaacatcagttt





ctatgaatcagatagaggaactggtgttttaaattttgcagtaactaaga





ataacagacccttatctataagttctgaacatgttaaaacatctatcgtg





ttaaaaaccgatgattataacgtagatagaggcgcttatatttcagacga





attaacgatagtagacgcaattaatgggcgtttgcagtatgtgataccga





atgaatttttaaaacattcaggcaaggtgcatgctcaggcattctttaca





caaaacgggagtaataatgttgttgttgaacgtcaatttagcttcaatat





tgaaaatgatttagttagtgggtttgatggtataacaaagcttgtttata





tcaaatctattcaagatactatcgaagctgtcggtaaagattttaaccaa





ttaaagcaaaatatggctgatacacaaacgttaatagcaaaagtgaatga





tagtgcgacaaaaggcattcaacaaatcgaaatcaagcaaaacgaagcta





tacaagctattactgcgacgcaaactagtgcaacacaagctgttacagct





gaattcgataaaatagttgaaaaagagcaagcgatttttgaacgtgttaa





cgaagttgaacaacaaatcaatggcgctgaccttgttaaaggtaattcaa





caacgaattggcaaaagtctaaacttacagatgattacggtaaagcaatt





gaatcgtatgagcagtccatagatagcgttttaagcgcagttaacacatc





taggattattcatattactaatgcaacagatgcgccagaaaagacggata





taggcacgttagagaagcctggacaagatggtgttgatgacggttcttcg





ttcgatgaatcaacttatacatcaagcaaatctggtgtgttagttgttta





tgttgttgataataatactgctcgtgcaacatggtacccagacgattcaa





acgatgagtacacaaaatacaaaatctacggcacatggtacccgttttat





aaaaagaatgatggaaacttaactaagcaatttgttgaagaaacgtctaa





caacgctttaaatcaagctaagcagtatgtagatgataaattcggaacaa





cgagctggcaacaacataagatgacagaggcgaatggtcaatcaattcaa





gttaacttaaataatgcgcaaggcgatttgggatatttaactgctggtaa





ttactatgcaacaagagtgccggatttaccaggtagcgttgaaagttatg





agggttatttatcggtattcgttaaagatgatacaaacaagctatttaac





ttcacaccttataactctaaaaagatttacacacgatcaatcacaaacgg





cagacttgagcaacagtggacagttcctaatgaacataaatcaacggtat





tgttcgacggtggcgcaaatggtgtaggtacaacaatcaatctaactgaa





ccgtacacaaactattctattttgttggtaagtggaacttatccaggtgg





cgttattgagggattcggactaaccgcattacctaacgcgattcaattga





gtaaagcgaatgtagttgactcagacggcaacggtggcggtatttatgag





tgcttactatccaaaacaagtagcactactttaagaatagataacgatgt





gtactttgatttaggtaaaacatcaggttctggagcgaatgccaacaaag





ttactataactaaaattatggggtggaaataatgaaaatcacagtaaacg





ataaaaacgaagttatcggattcgttaatactggcggtttacgcaatagt





ttagatgtagatgataacaatgtgcctattaaatttaaagaagagttcga





acctagaaagtttgttttcactaacggcgaaattaaatacaatagcaatt





tcgaaaaagaagacgtaccgaatgcatcaaaccaacaaagtgcgtcagat





ttaagtgatgaggaacttcgcggaatggttgcgagtatgcaaatgcaggt





ggcacaagtaaacgtattaacaatggaattagctcaacaaaacgctatgt





taacacaacagttgactgaactgaaaactaacaaaacaagtactgagggg





gacgtttaaataatgaagatgatttatccaacttttaaagacattaaaac





tttttatgtttggggttactataaaaacgagcaaattaagtggtacgtag





acaagggtttaatcgataaagaagaatacgctttaatcactggagaaaaa





tatccagaaacaaaagatgaaaagtcacaggtgtaatgcttgtggctttt





taatttgaataaagtgggtggcataatgtttggatttaccaaacgacatg





aacaagattggcgtttaacgcgattagaagaaaatgataagactatgttt





gaaaaattcgacagaatagaagatagtcttagagcgcaagaaaagattta





tgacaaattagatagaaattttgaagaattaaagcgcgacaaggtagaag





atgaaaagaataaagaaaagaatgccaagaatattagagacataaaaatg





tggattctaggtttgatagggactatcttcagtacgattgtcatagcttt





actaagaactgtttttggtatttaaaggaggtgattaccatgcttaaagg





gattttaggatatagcttctgggcgtgcttctggtttggtaaatgtaaat





aacagttaagagtcagtgcttcggcactggctttttattttgattgaaat





gaggtgcatacatgggattacctaatccgaaaaatagaaagcccacagct





agtgaagtggttgaatgggcgttatatatcgctaaaaacaaaatagctat





tgatgtacctggttctggaatgggagcacaatgctgggatttacctaatt





atttactcgataaatattgggggtttagaacatggggaaatgctgatgct





atggctcaaaaatccaattatagaggtagagatttcaagataattagaaa





tacaaaagattttgtaccacaaccaggcgactggggtgtttggactggtg





gttgggcaggacatgtaaacattgtagtgggaccatgcacaaaagactat





tggtatggcgtagatcaaaactggtatacaaataacgcaacaggaagtcc





accttataaaattaaacactcttatcatgatggaccaggtggaggggtta





aatattttgttagaccaccatatcatccagacaaaactacaccggcacct





aaaccagaagatgatagtgatgataacgaaaaaaataataaaaaagttcc





aatttggaaagatgtaacaactataaagtacactatttctagccaagagg





ttaattatccagaatatatttatcactttatagtagaaggtaatcgacga





ctcgaaaaacctaaaggaataatgattagaaacgcacaaacgatgagctc





ggtagaaagtttatataacagtaggaagaaatacaaacaggatgtagaat





atccccacttttatgttgatagacataatatttgggcacctagaagagct





gtatttgaagttcctaatgaacctgattatatagttatagacgtatgtga





agattatagtgcgagtaaaaatgaatttatttttaatgagattcacgcaa





tggttgtagctgtagatatgatggccaaatatgagatacctctaagtatt





gaaaatttaaaagtagacgacagcatttggcgttcaatgttggaacatgt





taattggaatatgattgacaacggtgttcctcctaaagataaatacgaag





cattagaaaaggcattacttaatatatttaaaaacagagaaaaattatta





aattctataactaagccaacagtaacaaaatctagaataaaagttatggt





agataataaaaacgctgatatagctaatgtaagagactcgtcaccaacag





ccaacaatggttcggcatctaaacaaccgcagatcataacagaaacgagt





ccttatacattcaaacaagcactggataaacaaatggcaagaggtaaccc





gaaaaaatctaatgcttggggttgggctaacgctacacgagcacaaacga





gttcagcaatgaatgtaaagcgtatatgggaaagtaacacacaatgctac





caaatgcttaatttaggcaagtatcaaggtgtttcagttagcgcacttaa





taagatacttaaaggtaagggaacattgaataatcaaggtaaagcgttcg





cagaagcttgtaaaaagcacaacattaatgaaatttatttaatcgcgcat





gctttcttagaaagtggatatggaacaagtaacttcgctaacggaaaaga





tggagtatacaactacttcggcattggcgcttacgacaacaatcctaact





acgcaatgacgtagcaaggaataaaggttggacatctccagcaaaagcaa





tcatgggcggtgctagcttcgtaagaaaggattacatcaataaaggtcaa





aacacattgtaccgaattagatggaatcctaagaatccagctacccacca





atacgctactgctatagagtggtgccaacatcaagcaagtacaatcgcta





agttatataaacaaatcggcttaaaaggtatctacttcacaagggataaa





tataaataaagaggtgtgtaaatgtacaaaataaaagatgttgaaacgag





aataaaaaatgatggtgttgacttaggtgacattggctgtcgattttaca





ctgaagatgaaaatacagcatctataagaataggtatcaatgacaaacaa





ggtcgtatcgatctaaaagcacatggcttaacacctagattacatttgtt





tatggaagatggctctatattcaaaaatgagccccttattatcgacgatg





ttgtaaaaggtttccttacctacaagatacctaaaaaggttatcaaacac





gctggttatgttcgctgtaagctgtattagagaaagaagaagaaaaaata





catgtcgcaaacttttctttcaatatcgttgatagtggtattgaatctgc





tgtagcaaaagaaatcgatgttaaattggtagatgatgctattacgagaa





ttttaaaagataacgcgacagatttattgagcaaagactttaaagagaaa





atagataaagatgtcatttcttacatcgaaaagaatgaaagtagatttaa





aggtgcgaaaggtgataaaggtgaaccgggacaacctggagcaaaaggtg





aagcaggtaaaaaaggagaacaaggcgcacccggtaaaaacggtactgta





gtatcaatcaatcctgacactaaaatgtggcaaattgatggtaaagatac





agatatcaaagcagaacctgagttattggacaaaatcaatatcgcaaatg





ttgaagggttagaaaataaattgcaagaagttgaaaaaatcaaagataca





actctcaacgactctaaaacgtatacggatacaaaaattgctgaactagt





tgatagcgcgcctgaatctatgaacacattaagagaattagcagaagcaa





tacaaaacaactctatttcagaaagtgtattgcaacagattggctcaaaa





gttaatacagaagattttgaggaattcaaacaaacactaaatgatttata





tgctccaaaaaatcataatcatgacgagcggtatgattgtcatctcaagc





tatactaaacaacaagcggataatttatatcaactaaaaagcgcatctca





accgacggttaaaatttggacaggaacagaaaatgaatataactatatat





atcaaaaagacccgaatacgttatatttaattaaagggtgatttttatgg





aaggtaattttaaaaatgtaaagaagtttatttacgaaggtgaagaatat





acaaaagtatatgctggaaatatccaagtatggaaaaagccttcatcttt





tgtaataaaacccttacctaaaaataaatatccggatagcatagaagaat





caacagcaaaatggacaataaatggagttgaacccaataaaagttatcag





gtgacaatagaaaatgtacgtagcggtataatgaggatttcgcaaactaa





tttagggtcaagtgatttaggaatatcaggagtcaatagcggagttgcaa





gtaaaaatatcaactttagtaatccttcagggatgttgtacgtcactata





agtgatgtttattcaggatctccgacattgaccattgaataattttaaac





gactaatttttagtcgattatattaggataaaaggagcaaacaaatggat





attaactggaaattgagattcaaaaacaaagcagtactaactggtttagt





tggagcattgttgctatttatcaagcaagtcacggatttattcggattag





atttatctactcaattaaatcaagctagcgcaattataggcgctatcctc





acgttacttacaggtattggcgttattactgacccaacgtcaaaaggcgt





ctcagattcatctatagcacagacatatcaagcgcctagagatagcaaaa





aagaagaacaacaagttacgtggaaatcatcacaagacagtagtttaacg





ccggaattaagcgcgaaagcaccaaaagaatatgatacatcacaaccttt





cacagacgcctctaacgatgttggctttgatgtgaatgagtatcatcatg





gaggtggcgacaatgcaagcaaaattaactaaaaatgagtttatagagtg





gttgaaaacttctgagggaaaacaattcaatgtggacttatggtatggat





ttcaatgctttgattatgccaatgctggttggaaagttttgtttggatta





cttctaaaaggtttaggtgcaaaagatattccgttcgctaacaacttcga





cggattagctactgtataccaaaatacaccggacttcttagcacaacctg





gcgacatggtggtattcggtagcaactacggtgctggatatggtcacgtt





gcatgggtaattgaagcaactttagattacatcattgtatatgagcagaa





ttggctaggcggtggctggactgacggaatcgaacaacccggctggggtt





gggaaaaagttacaagacgacaacatgcttatgatttccctatgtggttt





atccgtccgaattttaaaagtgagacagcgccacgatcagttcaatctcc





tacacaagcacctaaaaaagaaacagctaagccacaacctaaagcagtag





aacttaaaatcatcaaagatgtggttaaaggttatgacctacctaagcgt





ggtagtaaccctaaaggtatagttatacacaacgacgcagggagcaaagg





ggcgactgctgaagcatatcgtaacggattagtaaatgcacctttatcaa





gattagaagcgggcattgcgcatagttacgtatcaggcaacacagtttgg





caagccttagatgaatcacaagtaggttggcataccgctaatcaaatagg





taataaatattattacggtattgaagtatgtcaatcaatgggcgcagata





acgcgacattcttaaaaaatgaacaggcaactttccaagaatgcgctaga





ttgttgaaaaaatggggattaccagcaaacagaaatacaatcagattgca





caatgaatttacttcaacatcatgccctcatagaagttcggttttacaca





ctggttttgacccagtaactcgcggtctattgccagaagacaagcggttg





caacttaaagactactttatcaagcagattagggcgtacatggatggtaa





aataccggttgccactgtctctaatgagtcaagcgcttcaagtaatacag





ttaaaccagttgcaagtgcatggaaacgtaataaatatggtacttactac





atggaagaaagtgctagattcacaaacggcaatcaaccaatcacagtaag





aaaagtggggccattcttatcttgtccagtgggttatcagttccaacctg





gtgggtattgtgattatacagaagtgatgttacaagatggtcatgtttgg





gtaggatatacatgggaggggcaacgttattacttgcctattagaacatg





gaatggttctgccccacctaatcagatattaggtgacttatggggagaaa





tcagttagaatgacatagtcatgtctatttaagcaggtgcgttacatacc





tgctttctatttacatttaaagataaaatgtgctattattttactagaac





tttttaacatttctctcaagatttaaatgtagataacaggcaggtactac





ggtacttgcctatttattatgcaaatataaaaaacactttactaataaac





atttgtttagtataattatatttgtaggttagttgatgacttacaaatta





tgtgtaaggaggtgaaaagcctcatgctagacataataaaaacacttcta





gaacatcaagtattggcagtactgataattccagaagtgttaaaacaact





tagagaatggcatctcggctacctagaccgaaagccaaacaacaaagatt





aacattatgcttggagcctgatggctcctccttacacttatataatataa





tattatttggaggttttcaattatgacagaacaaatgtatttaatattga





tttattaagcctaccattgttattatttatcgggagaaagacacattata





ttgtttagataaaaagaatggacgtagataatatgagtgattataaatta





aaaataattgaattgatcaaaagtgatataacaggttaccaaattcacaa





acaaactggcgtagcgcaatatgtaatttcacaattaaggcaaggaaagc





gcgaagtagataacttaactttaaatacaactgaaaaactatacagttac





gcacgacaagtgttataatataaatgtgaaatggtcattcttgaaatgac





tcggtcgctactggcacagaccgtttaaagtgtcaccacaacatgaactg





agaattcatatgacgttgctgacgagcgacaaagctctgtgttcctgaat





gggagtaggtttgtgtggtggtataatttagtaacagcatagactgtcta





tagcaaagttgccgaagagattctaaacgtatttataaatacgtggccct





tgctagataaccgcatcttaactgatgcggttatttttatccccacacaa





ccaacaaaaccacaccacctattaatttaggagtgtggttgttttaatat





gtgaagctaaaataactacaaatgataccatttttgataccattttgttg





taaaacagaaaaaataaggaaaataaaaaaggcaaaaaaacgcattaaat





caacgtttattgtctcatgaaatttaaatgtatataaatttca






A list of phage that work with SaPIs


Different SaPIs are linked to different helper phages (see FIG. 3 below)


One can mutates the helper phage to only contain structural genes to direct the phage to package in smaller capsids. If only looking at the genes responsible for small capsid packaging (cpmA and cpmB) these are highly conserved among staphylococci indicating that they will function to redirect packaging in a variety of p hages broader than the list below (FIG. 3).









TABLE 1





Example Bacteria








Abiotrophia




Abiotrophia
defectiva




Acaricomes




Acaricomes
phytoseiuli




Acetitomaculum




Acetitomaculum
ruminis




Acetivibrio




Acetivibrio
cellulolyticus




Acetivibrio
ethanolgignens




Acetivibrio
multivorans




Acetoanaerobium




Acetoanaerobium
noterae




Acetobacter




Acetobacter
aceti




Acetobacter
cerevisiae




Acetobacter
cibinongensis




Acetobacter
estunensis




Acetobacter
fabarum




Acetobacter
ghanensis




Acetobacter
indonesiensis




Acetobacter
lovaniensis




Acetobacter
malorum




Acetobacter
nitrogenifigens




Acetobacter
oeni




Acetobacter
orientalis




Acetobacter
orleanensis




Acetobacter
pasteurianus




Acetobacter
pornorurn




Acetobacter
senegalensis




Acetobacter
xylinus




Acetobactcrium




Acetobacterium
bakii




Acetobacterium
carbinolicum




Acetobacterium
dehalogenans




Acetobacteriam
fimetarium




Acetobacterium
malicum




Acetobacterium
paludosum




Acetobacterium
tundrae




Acetobaclerium
wieringae




Acetobacterium
woodii




Acetofilamentum




Acetofilamentum
rigidum




Acetohalobium




Acetohalobium
arabaticum




Acetomicrobium




Acetomicrobium
faecale




Acetomicrobium
flavidum




Acetonema




Acetonema
longum




Acetothermus




Acetothermus
paucivorans




Acholeplasma




Acholeplasma
axanthum




Acholeplasma
brassicae




Acholeplasma
cavigenitalium




Acholeplasma
equifetale




Acholeplasma
granularum




Acholeplasma
hippikon




Acholeplasma
laidlawii




Acholeplasma
modicum




Acholeplasma
morum




Acholeplasma
multilocale




Acholeplasma
oculi




Acholeplasma
palmae




Acholeplasma
parvum




Acholeplasma
pleciae




Acholeplasma
vituli




Achromobacter




Achromobacter
denitrificans




Achromobacter
insolitus




Achromobacter
piechaudii




Achromobacter
ruhlandii




Achromobacter
spanius




Acidaminobacter




Acidaminobacter
hydrogenoformans




Acidaminococcus




Acidaminococcus
fermentans




Acidaminococcus
intestini




Acidicaldus




Acidicaldus
organivorans




Acidimicrobium




Acidimicrobium
ferrooxidans




Acidiphilium




Acidiphilium
acidophilum




Acidiphilium
angustum




Acidiphilium
cryptum




Acidiphilium
multivorum




Acidiphilium
organovorum




Acidiphilium
rubrum




Acidisoma




Acidisoma
sibiricum




Acidisoma
tundrae




Acidisphaera




Acidisphaera
rubrifaciens




Acidithiobacillus




Acidithiobacillus
albertensis




Acidithiobacillus
caldus




Acidithiobacillus
ferrooxidans




Acidithiobacillus
thiooxidans




Acidobacterium




Acidobacterium
capsulatum




Acidocella




Acidocella
aminolytica




Acidocella
facilis




Acidomonas




Acidomoms
methanolica




Acidothermus




Acidothermus
cellulolyticus




Acidovorax




Acidovorax
anthurii




Acidovorax
caeni




Acidovorax
cattleyae




Acidovorax
citrulli




Acidovorax
defluvii




Acidovorax
delafieldii




Acidovorax
facilis




Acidovorax
konjaci




Acidovorax
temperans




Acidovorax
valerianellae




Acinetobacter




Acinetobacter
baumannii




Acinetobacter
baylyi




Acinetobacter
bouvetii




Acinetobacter
calcoaceticus




Acinetobacter
gerneri




Acinetobacter
haemolyticus




Acinetobacter
johnsonii




Acinetobacter
junii




Acinetobacter
lwoffi




Acinetobacter
parvus




Acinetobacter
radioresistens




Acinetobacter
schindleri




Acinetobacter
soli




Acinetobacter
tandoii




Acinetobacter
tjernbergiae




Acinetobacter
towneri




Acinetobacter
ursingii




Acinetobacter
venetianus




Acrocarpospora




Acrocarpospora
corrugata




Acrocarpospora
macrocephala




Acrocarpospora
pleiomorpha




Actibacter




Actibacter
sediminis




Actinoalloteichus




Actinoalloteichus
cyanogriseus




Actinoalloteichus
hymeniacidonis




Actinoalloteichus
spitiensis




Actinobaccillus




Actinobacillus
capsulatus




Actinobacillus
delphinicola




Actinobacillus
hominis




Actinobacillus
indolicus




Actinobacillus
lignieresii




Actinobacillus
minor




Actinobacillus
muris




Actinobacillus
pleuropneumoniae




Actinobacillus
porcinus




Aclinobacillus
rossii




Actinobacillus
scotiae




Actinobacillus
seminis




Actinobacillus
succinogenes




Actinobaccillus
suis




Actinobacillus
ureae




Actinobaculum




Actinobaculum
massiliense




Actinobaculum
schaalii




Actinobaculum
suis




Actinomyces
urinale




Actinocatenispora




Actinocatenispora
rupis




Actinocatenispora
thailandica




Actinocatenispora
sera




Actinocorallia




Actinocorallia
aurantiaca




Actinocorallia
aurea




Actinocorallia
cavernae




Actinocorallia
glomerata




Actinocorallia
herbida




Actinocorallia
libanotica




Actinocorallia
longicatena




Actinomadura




Actinomadura
alba




Actinomadura
atramentaria




Actinomadura
bangladeshensis




Actinomadura
catellatispora




Actinomadura
chibensis




Actinomadura
chokoriensis




Actinomadura
citrea




Actinomadura
coerulea




Actinomadura
echinospora




Actinomadura
fibrosa




Actinomadura
formosensis




Actinomadura
hibisca




Actinomadura
kijaniata




Actinomadura
latina




Actinomadura
livida




Actinomadura
luteofluorescens




Actinomadura
macra




Actinomadura
madurae




Actinomadura
oligospora




Actinomadura
pelletieri




Actinomadura
rubrobrunea




Actinomadura
rugatobispora




Actinomadura
umbrina




Actinomadura
verrucosospora




Actinomadura
vinacea




Actinomadura
viridilutea




Actinomadura
viridis




Actinomadura
yumaensis




Actinomyces




Actinomyces
bovis




Actinomyces
denticolens




Actinomyces
europaeus




Actinomyces
georgiae




Actinomyces
gerencseriae




Actinomyces
hordeovulneris




Actinomyces
howellii




Actinomyces
hyovaginalis




Actinomyces
israelii




Actinomyces
johnsonii




Actinomyces
meyeri




Actinomyces
naeslundii




Actinomyces
neuii




Actinomyces
odontolyticus




Actinomyces
oris




Actinomyces
radingae




Actinomyces
slackii




Actinomyces
turicensis




Actinomyces
viscosus




Actinoplanes




Actinoplanes
auranticolor




Actinoplanes
brasiliensis




Actinoplanes
consettensis




Actinoplanes
deccanensis




Actinoplanes
derwentensis




Actinoplanes
digitatis




Actinoplanes
durhamensis




Actinoplanes
ferrugineus




Actinoplanes
globisporus




Actinoplanes
humidus




Actinoplanes
italicus




Actinoplanes
liguriensis




Actinoplanes
lobatus




Actinoplanes
missouriensis




Actinoplanes
palleronii




Actinoplanes
philippinensis




Actinoplanes
rectilineatus




Actinoplanes
regularis




Actinoplanes
teichomyceticus




Actinoplanes
utahensis




Actinopolyspora




Actinopolyspora
halophila




Actinopolyspora
mortivallis




Actinosynnema




Actinosynnema
mirum




Actinotalea




Actinotalea
fermentans




Aerococcus




Aerococcus
sanguinicola




Aerococcus
urinae




Aerococcus
urinaeequi




Aerococcus
urinaehominis




Aerococcus
viridans




Aeromicrobium




Aeromicrobium
erythreum




Aeromonas




Aeromonas
allosaccharophila




Aeromonas
bestiarnm




Aeromonas
caviae




Aeromonas
encheleia




Aeromonas
enteropelogenes




Aeromonas
eucrenophila




Aeromonas
ichthiosmia




Aeromonas
jandaei




Aeromonas
media




Aeromonas
popoffii




Aeromonas
sobria




Aeromonas
veronii




Agrobacterium




Agrobacterium
gelatinovorum




Agrococcus




Agrococcus
citreus




Agrococcus
jenensis




Agromonas




Agromonas
oligotrophica




Agromyces




Agromyces
fucosus




Agromyces
hippuratus




Agromyces
luteolus




Agromyces
mediolanus




Agromyces
ramosus




Agromyces
rhizospherae




Akkermansia




Akkermansia
muciniphila




Albidiferax




Albidiferax
ferrireducens




Albidovulum




Albidovulum
inexpectatum




Alcaligenes




Alcaligenes
denitrificans




Alcaligenes
faecalis




Alcanivorax




Alcanivorax
borkumensis




Alcanivorax
jadensis




Algicola




Algicola
bacteriolytica




Alicyclobacillus




Alicyclobacillus
disulfidooxidans




Alicyclobacillus
sendaiensis




Alicyclobacillus
vulcanalis




Alishewanella




Alishewanella
fetalis




Alkalibacillus




Alkalibacillus
haloalkaliphilus




Alkalilimnicola




Alkalilimnicola
ehrlichii




Alkaliphilus




Alkaliphilus
oremlandii




Alkaliphilus
transvaalensis




Allochromatium




Allochromatium
vinosum




Alloiococcus




Alloiococcus
otitis




Allokutzneria




Allokutzneria
albata




Altererythrohacter




Altererythrobacter
ishigakiensis




Altermonas




Altermonas
haloplanktis




Altermonas
macleodii




Alysiella




Alysiella
crassa




Alysiella
filiformis




Aminobacter




Aminobacter
aganoensis




Aminobacter
aminovorans




Aminobacter
niigataensis




Aminobacterium




Aminobacterium
mobile




Aminomonas




Aminomonas
paucivorans




Ammoniphilus




Ammoniphilus
oxalaticus




Ammoniphilus
oxalivorans




Amphibacillus




Amphibacillus
xylanus




Amphritea




Amphrilea
balenae




Amphritea
japonica




Amycolatopsis




Amycolatopsis
alba




Amycolatopsis
albidoflavus




Amycolatopsis
azurea




Amycolatopsis
coloradensis




Amycolatopsis
lurida




Amycolatopsis
mediterranei




Amycolatopsis
rifamycinica




Amycolatopsis
rubida




Amycolatopsis
sulphurea




Amycolatopsis
tolypomycina




Anabaena




Anabaena
cylindrica




Anabaena
flos-aquae




Anabaena
variabilis




Anaeroarcus




Anaeroarcus
burkinensis




Anacrobaculum




Anaerobaculum
mobile




Anaerobiospirillum




Anaerobiospirillum
succiniciproducens




Anaerobiospirillum
thomasii




Anaerococcus




Anaerococcus
hydrogenalis




Anaerococcus
lactolyticus




Anaerococcus
prevotii




Anaerococcus
tetradius




Anaerococcus
vaginalis




Anaerofustis




Anaerofustis
stercorihominis




Anaeromusa




Anaeromusa
acidaminophila




Anaeromyxobacter




Anaeromyxobacter
dehalogenans




Anaerorhabdus




Anaerorhabdus
furcosa




Anaerosinus




Anaerosinus
glycerini




Anaerovirgula




Anaerovirgula
multivorans




Ancalomicrobium




Ancalomicrobium
adetum




Ancylobacter




Ancylobacter
aquaticus




Aneurinibacillus




Aneurinibacillus
aneurinilyticus




Aneurinibacillus
migulanus




Aneurinibacillus
thermoaerophilus




Angiococcus




Angiococcus
disciformis




Angulomicrobium




Angulomicrobium
tetraedrale




Anoxybacillus




Anoxybacillus
pushchinoensis




Aquabacterium




Aquabacterium
commune




Aquabacterium
parvum




Aquaspirillum




Aquaspirillum
polymorphum




Aquaspirillum
putridiconchylium




Aquaspirillum
serpens




Aquimarina




Aquimarina
latercula




Arcanobacterium




Arcanobacterium
haemolyticum




Arcanobacterium
pyogenes




Archangium




Archangium
gephyra




Arcobacter




Arcobacter
butzleri




Arcobacter
cryaerophilus




Arcobacter
halophilus




Arcobacter
nitrofigilis




Arcobacter
skirrowii




Arhodomonas




Arhodomonas
aquaeolei




Arsenophonus




Arsenophonus
nasoniae




Arthrobacter




Arthrobacter
agilis




Arthrobacter
albus




Arthrobacter
aurescens




Arthrobacter
chlorophenolicus




Arthrobacter
citreus




Arthrobacter
crystallopoietes




Arthrobacter
cumminsii




Arthrobacter
globiformis




Arthrobacter
histidinolovorans




Arthrobacter
ilicis




Arthrobacter
luteus




Arthrobacter
methylotrophus




Arthrobacter
mysorens




Arthrobacter
nicotianae




Arthrobacter
nicotinovorans




Arthrobacter
oxydans




Arthrobacter
pascens




Arthrobacter
phenanthrenivorans




Arthrobacter
polychromogenes




Atrhrobacter
protophormiae




Arthrobacter
psychrolactophilus




Arthrobacter
ramosus




Arthrobacter
sulfonivorans




Arthrobacter
sulfureus




Arthrobacter
uratoxydans




Arthrobacter
ureafaciens




Arthrobacter
viscosus




Arthrobacter
woluwensis




Asaia




Ascua
bogorensis




Asanoa




Asanoa
ferruginea




Asticcacaulis




Asticcacaulis
biprosthecium




Asticcacaulis
excentricus




Atopobacter




Atopobacter
phocae




Atopobium




Atopobium
fossor




Atopobium
minutum




Atopobium
parvulum




Atopobium
rimae




Atopobium
vaginae




Aureobacterium




Aureobacterium
barkeri




Aurobacterium




Aurobacterium
liquefaciens




Avibacterium




Avibacterium
avium




Avibacterium
gallinarum




Avibacterium
paragallinarum




Avibacterium
volantium




Azoarcus




Azoarcus
indigens




Azoarcus
tolulyticus




Azoarcus
toluvorans




Azohydromonas




Azohydromonas
australica




Azohvdromonas
lata




Azomonas




Azomonas
agilis




Azomonas
insignis




Azomonas
macrocytogenes




Azorhizobium




Azorhizobium
caulinodans




Azorhizophilus




Azorhizophilus
paspali




Azospirillum




Azospirillum
brasilense




Azospirillum
halopraeferens




Azospirillum
irakense




Azotobacter




Azolobacter
beijerinckii




Azotobacter
chroococcum




Azotobacter
nigricans




Azotobacter
salinestris




Azotobacter
vinelandii




Bacillus



[see below]



Bacteriovorax




Bacteriovorax
stolpii




Bacteroides




Bacteroides
caccae




Bacteroides
coagulans




Bacteroides
eggerthii




Bacteroides
fragilis




Bacteroides
galacturonicus




Bacteroides
helcogenes




Bacteroides
ovatus




Bacteroides
pectinophilus




Bacteroides
pyogenes




Bacteroides
salyersiae




Bacteroides
stercoris




Bacteroides
suis




Bacteroides
tectus




Bacteroides
thetaiotaomicron




Bacteroides
uniformis




Bacteroides
ureolyticus




Bacteroides
vulgatus




Balnearium




Balnearium
lithotrophicum




Balneatrix




Balneatrix
alpica




Balneola




Balneola
vulgaris




Barnesiella




Barnesiella
viscericola




Bartonella




Bartonella
alsatica




Bartonella
bacilliformis




Bartonella
clarridgeiae




Bartonella
doshiae




Bartonella
elizabethae




Bartonella
grahamii




Bartonella
henselae




Bartonella
rochalimae




Bartonella
vinsonii




Bavariicoccus




Bavariicoccus
seileri




Bdellovibrio




Bdellovibrio
bacteriovorus




Bdellovibrio
exovorus




Beggiatoa




Beggiatoa
alba




Beijerinckia




Beijerinckia
derxii




Beijerinckia
fluminensis




Beijerinckia
indica




Beijerinckia
mobilis




Belliella




Belliella
baltica




Bellilinea




Bellilinea
caldifistulae




Belnapia




Belnapia
moabensis




Bergeriella




Bergeriella
denitrificans




Beutenbergia




Beutenbergia
cavernae




Bibersteinia




Bibersteinia
trehalosi




Bifidobacterium




Bifidobacterium
adolescentis




Bifidobacterium
angulatum




Bifidobacterium
animalis




Bifidobacterium
asteroides




Bifidobacterium
bifidum




Bifidobacterium
boum




Bifidobacterium
breve




Bifidobacterium
catenulatum




Bifidobacterium
choerinum




Bifidobacterium
coryneforme




Bifidobacterium
cuniculi




Bifidobacterium
dentium




Bifidobacterium
gallicum




Bifidobacterium
gallinarum




Bifidobacterium
indicum




Bifidobacterium
longum




Bifidobacterium
magnum




Bifidobacterium
merycicum




Bifidobacterium
minimum




Bifidobacterium
pseudocatenulatum




Bifidobacterium
pseudolongum




Bifidobacterium
pullorum




Bifidobacterium
ruminantium




Bifidobacterium
saeculare




Bifidobacterium
subtile




Bifidobacterium
thermophilum




Bilophila




Bilophila
wadsworthia




Biostraticola




Biostraticola
tofi




Bizionia




Bizionia
argentinensis




Blastobacter




Blastobacter
capsulatus




Blastobacter
denitrificans




Blastococcus




Blastococcus
aggregatus




Blastococcus
saxobsidens




Blastochloris




Blastochloris
viridis




Blastomonas




Blastomonas
natatoria




Blastopirellula




Blastopirellula
marina




Blautia




Blautia
coccoides




Blautia
hansenii




Blautia
producta




Blautia
wexlerae




Bogoriella




Bogoriella
caseilytica




Bordetella




Bordetella
avium




Bordetella
bronchiseptica




Bordetella
hinzii




Bordetella
holmesii




Bordetella
parapertussis




Bordetella
pertussis




Bordetella
petrii




Bordetella
trematum




Borrelia




Borrelia
afzelii




Borrelia
americana




Borrelia
burgdorferi




Borrelia
carolinensis




Borrelia
coriaceae




Borrelia
garinii




Borrelia
japonica




Bosea




Bosea
minatitlanensis




Bosea
thiooxidans




Brachybacterium




Brachybacierium
alimentarium




Brachybacterium
faecium




Brachybacterium
paraconglomeratum




Brachybacterium
rhamnosum




Brachybacterium
tyrofermentans




Brachyspira




Brachyspira
alvinipulli




Brachyspira
hyodysenteriae




Brachyspira
innocens




Brachyspira
murdochii




Brachyspira
pilosicoli




Bradyrhizobium




Bradyrhizobium
canariense




Bradyrhizobium
elkanii




Bradyrhizobium
japonicum




Bradyrhizobium
liaoningense




Brenneria




Brenneria
alni




Brenneria
nigrifluens




Brenneria
quercina




Brenneria
quercina




Brenneria
salicis




Brevibacillus




Brevibacillus
agri




Brevibacillus
borstelensis




Brevibacillus
brevis




Brevibacillus
centrosporus




Brevibacillus
choshinensis




Brevibacillus
invocatus




Brevibacillus
laterosporus




Brevibacillus
parabrevis




Brevibacillus
reuszeri




Brevibacterium




Brevibacterium
abidum




Brevibacterium
album




Brevibacterium
aurantiacum




Brevibacterium
celere




Brevibacterium
epidermidis




Brevibacterium
frigoritolerans




Brevibacterium
halotolerans




Brevibacterium
iodinum




Brevibacterium
linens




Brevibacterium
lyticum




Brevibacterium
mcbrellneri




Brevibacterium
otitidis




Brevibacterium
oxydans




Brevibacterium
paucivorans




Brevibacterium
stationis




Brevinema




Brevinema
andersonii




Brevundimonas




Brevundimonas
alba




Brevundimonas
aurantiaca




Brevundimonas
diminuta




Brevundimonas
intermedia




Brevundimonas
subvibrioides




Brevundimonas
vancanneytii




Brevundimonas
variabilis




Brevundimonas
vesicularis




Brochothrix




Brochothrix
campestris




Brochothrix
thermosphacta




Brucella




Brucella
canis




Brucella
neotomae




Bryobacter




Bryobacter
aggregatus




Burkholderia




Burkholderia
ambifaria




Burkholderia
andropogonis




Burkholderia
anthina




Burkholderia
caledonica




Burkholderia
caryophylli




Burkholderia
cenocepacia




Burkholderia
cepacia




Burkholderia
cocovenenans




Burkholderia
dolosa




Burkholderia
fungorum




Burkholderia
glathei




Burkholderia
glumae




Burkholderia
graminis




Burkholderia
kururiensis




Burkholderia
multivorans




Burkholderia
phenazinium




Burkholderia
plantarii




Burkholderia
pyrrocinia




Burkholderia
silvatlanlica




Burkholderia
stabilis




Burkholderia
thailandensis




Burkholderia
tropica




Burkholderia
unamae




Burkholderia
vietnamiensis




Buttiauxella




Buttiauxella
agrestis




Buttiauxella
brennerae




Buttiauxella
ferragutiae




Buttiauxella
gaviniae




Buttiauxella
izardii




Buttiauxella
noackiae




Buttiauxella
warmboldiae




Butyrivibrio




Butyrivibrio
fibrisolvens




Butyrivibrio
hungatei




Butyrivibrio
proteoclasticus




Bacillus




B. acidiceler




B. acidicola




B. acidiproducens




B. acidocaldarius




B. acidoterrestris




B. aeolius




B. aerius




B. aerophilus




B. agaradhaerens




B. agri




B. aidingensis




B. akibai




B. alcalophilus




B. algicola




B. alginolyticus




B. alkalidiazotrophicus




B. alkalinitrilicus




B. alkalisediminis




B. alkalitelluris




B. altitudinis




B. alveayuensis




B. alvei




B. amyloliquefaciens




B. a. subsp. amyloliquefaciens




B. a. subsp. plantarum




B. dipsosauri




B. drentensis




B. edaphicus




B. ehimensis




B. eiseniae




B. enclensis




B. endophyticus




B. endoradicis




B. farraginis




B. fastidiosus




B. fengqiuensis




B. firmus




B. flexus




B. foraminis




B. fordii




B. formosus




B. fortis




B. fumarioli




B. funiculus




B. fusiformis




B. galactophilus




B. galactosidilyticus




B. galliciensis




B. gelatini




B. gibsonii




B. ginsengi




B. ginsengihumi




B. ginsengisoli




B. globisporus



(eg, B. g. subsp. Globisporus; or



B. g. subsp. Marinus)




B. aminovorans




B. amylolyticus




B. andreesenii




B. aneurinilyticus




B. anthracis




B. aquimaris




B. arenosi




B. arseniciselenatis




B. arsenicus




B. aurantiacus




B. arvi




B. aryabhattai




B. asahii




B. atrophaeus




B. axarquiensis




B. azotofixans




B. azotoformans




B. badius




B. barbaricus




B. bataviensis




B. beijingensis




B. benzoevorans




B. beringensis




B. berkeleyi




B. beveridgei




B. bogoriensis




B. boroniphilns




B. borstelensis




B. brevisMigula




B. butanolivorans




B. canaveralius




B. carboniphilus




B. cecembensis




B. cellulosilyticus




B. centrosporus




B. cereus




B. chagannorensis




B. chitinolyticus




B. chondroitinus




B. choshinensis




B. chungangensis




B. cibi




B. circulans




B. clarkii




B. clausii




B. coagulans




B. coahuilensis




B. cohnii




B. composti




B. curdlanolyticus




B. cycloheptanicus




B. cytotoxicus




B. daliensis




B. decisifrondis




B. decolorationis




B. deserti




B. glucanolyticus




B. gordonae




B. gottheilii




B. graminis




B. halmapalus




B. haloalkaliphilus




B. halochares




B. halodenitrificans




B. halodurans




B. halophilus




B. halosaccharovorans




B. hemicellulosilyticus




B. hemicentroti




B. herbersteinensis




B. horikoshii




B. horneckiae




B. horti




B. huizhouensis




B. humi




B. hwajinpoensis




B. idriensis




B. indicus




B. infantis




B. infernus




B. insolitus




B. invictae




B. iranensis




B. isabeliae




B. isronensis




B. jeotgali




B. kaustophilus




B. kobensis




B. kochii




B. kokeshiiformis




B. koreensis




B. korlensis




B. kribbensis




B. krulwichiae




B. laevolacticus




B. larvae




B. laterosporus




B. salexigens




B. saliphilus




B. schlegelii




B. sediminis




B. selenatarsenatis




B. selenitireducens




B. seohaeanensis




B. shacheensis




B. shackletonii




B. siamensis




B. silvestris




B. simplex




B. siralis




B. smithii




B. soli




B. solimangrovi




B. solisalsi




B. songklensis




B. sonorensis




B. sphaericus




B. sporothermodurans




B. stearothermophilus




B. stratosphericus




B. subterraneus




B. subtilis



(eg, B. s. subsp. Inaquosorum; or



B. s. subsp. Spizizeni; or




B. s. subsp. Subtilis)




B. taeanensis




B. tequilensis




B. thermantarcticus




B. thermoaerophilus




B. thermoamylovorans




B. thermocatenulatus




B. thermocloacae




B. thermocopriae




B. thermodenitrificans




B. thermoglucosidasius




B. thermolactis




B. thermoleovorans




B. thermophilus




B. thermoruber




B. thermosphaericus




B. thiaminolyticus




B. thioparans




B. thuringiensis




B. tianshenii




B. trypoxylicola




B. tusciae




B. validus




B. vallismortis




B. vedderi




B. velezensis




B. vietnamensis




B. vireti




B. vulcani




B. wakoensis




B. weihenstephanensis




B. xiamenensis




B. xiaoxiensis




B. zhanjiangensis




B. peoriae




B. persepolensis




B. persicus




B. pervagus




B. plakortidis




B. pocheonensis




B. polygoni




B. polymyxa




B. popilliae




B. pseudalcalophilus




B. pseudofirmus




B. pseudomycoides




B. psychrodurans




B. psychrophilns




B. psychrosaccharolyticus




B. psychrotolerans




B. pulvifaciens




B. pumilus




B. purgationiresistens




B. pycnus




B. qingdaonensis




B. qingshengii




B. reuszeri




B. rhizosphaerae




B. rigui




B. ruris




B. safensis




B. salarius




B. lautus




B. lehensis




B. lentimorbus




B. lentus




B. licheniformis




B. ligniniphilus




B. litoralis




B. locisalis




B. luciferensis




B. luteolus




B. luteus




B. macauensis




B. macerans




B. macquariensis




B. macyae




B. malacitensis




B. mannanilyticus




B. marisflavi




B. marismortui




B. marmarensis




B. massiliensis




B. megaterium




B. mesonae




B. methanolicus




B. methylotrophicus




B. migulanus




B. mojavensis




B. mucilaginosus




B. muralis




B. murimartini




B. mycoides




B. naganoensis




B. nanhaiensis




B. nanhaiisediminis




B. nealsonii




B. neidei




B. neizhouensis




B. niabensis




B. niacini




B. novalis




B. oceanisediminis




B. odysseyi




B. okhensis




B. okuhidensis




B. oleronius




B. oryzaecorticis




B. oshimensis




B. pabuli




B. pakistanensis




B. pallidus




B. pallidus




B. panacisoli




B. panaciterrae




B. pantothenticus




B. parabrevis




B. pciraflexus




B. pasteurii




B. patagoniensis




Caenimonas




Caertimonas
koreensis




Caldalkalibacillus




Caldalkalibacillus
uzonensis




Caldanaerobacter




Caldanaerobacter
subterraneus




Caldanaerobius




Caldanaerobius
fijiensis




Caldanaerobius
polysaccharolyticus




Caldanaerobius
zeae




Caldanaerovirga




Caldanaerovirga
acetigignens




Caldicellulosiruptor




Caldicellulosiruptor
bescii




Caldicellulosiruptor
kristjanssonii




Caldicellulosiruptor
owensensis




Campylobacter




Campylobacter
coli




Campylobacter
concisus




Campylobacter
curvus




Campylobacter
fetus




Campylobacter
gracilis




Campylobacter
helveticus




Campylobacter
hominis




Campylobacter
hyointestinalis




Campylobacter
jejuni




Campylobacter
lari




Campylobacter
mucosalis




Campylobacter
rectus




Campylobacter
showae




Campylobacter
sputorum




Campylobacter
upsaliensis




Capnocytophaga




Capnocytophaga
canimorsus




Capnocytophaga
cynodegmi




Capnocytophaga
gingivalis




Capnocytophaga
granulosa




Capnocytophaga
haemolytica




Capnocytophaga
ochracea




Capnocytophaga
sputigena




Cardiobacterium




Cardiobacterium
hominis




Carnimonas




Carnimoncis
nigrificans




Carnobacterium




Carnobacterium
alterfunditum




Carnobacterium
divergens




Carnobacterium
funditum




Carnobacterium
gallinarum




Carnobacterium
maltaromaticum




Carnobacterium
mobile




Carnobacterium
viridans




Caryophanon




Caryophanon
latum




Caryophanon
tenue




Catellatospora




Catellatospora
citrea




Catellatospora
methionotrophica




Catenococcus




Catenococcus
thiocycli




Catenuloplanes




Catenuloplanes
atrovinosus




Catenuloplanes
castaneus




Catenuloplanes
crispus




Catenuloplanes
indicus




Catenuloplanes
japonicus




Catenuloplanes
nepalensis




Catenuloplanes
niger




Chryseobacterium




Chryseobacterium
balustinum




Citrobacter




C. amalonaticus




C. braakii




C. diversus




C. farmeri




C. freundii




C. gillenii




C. koseri




C. murliniae




C. pasteurii[1]




C. rodentium




C. sedlakii




C. werkmanii




C. youngae




Clostridium



(see below)



Coccochloris




Coccochloris
elabens




Corynebacterium




Corynebacterium
flavescens




Corynebacterium
variabile




Curtobacterium




Curtobacterium
albidum




Curtobacterium
citreus




Clostridium




Clostridium
absonum,




Clostridium
aceticum,




Clostridium
acetireducens,




Clostridium
acetobutylicum,




Clostridium
acidisoli,




Clostridium
aciditolerans,




Clostridium
acidurici,




Clostridium
aerotolerans,




Clostridium
aestuarii,




Clostridium
akagii,




Clostridium
aldenense,




Clostridium
aldrichii,




Clostridium
algidicarni,




Clostridium
algidixylanolyticum,




Clostridium
algifaecis,




Clostridium
algoriphilum,




Clostridium
alkalicellulosi,




Clostridium
aminophilum,




Clostridium
aminovalericum,




Clostridium
amygdalinum,




Clostridium
amylolyticum,




Clostridium
arbusti,




Clostridium
arcticum,




Clostridium
argentinense,




Clostridium
asparagiforme,




Clostridium
aurantibutyricum,




Clostridium
autoethanogenum,




Clostridium
baratii,




Clostridium
barkeri,




Clostridium
bartlettii,




Clostridium
beijerinckii,




Clostridium
bifermentans,




Clostridium
bolteae,




Clostridium
bornimense,




Clostridium
botulinum,




Clostridium
bowmanii,




Clostridium
bryantii,




Clostridium
butyricum,




Clostridium
cadaveris,




Clostridium
caenicola,




Clostridium
caminithermale,




Clostridium
carboxidivorans,




Clostridium
carnis,




Clostridium
cavendishii,




Clostridium
celatum,




Clostridium
celerecrescens,




Clostridium
cellobioparum,




Clostridium
cellulofermentans,




Clostridium
cellulolyticum,




Clostridium
cellulosi,




Clostridium
cellulovorans,




Clostridium
chartatabidum,




Clostridium
chouvoei,




Clostridium
chromiireducens,




Clostridium
citroniae,




Clostridium
clariflavum,




Clostridium
clostridioforme,




Clostridium
coccoides,




Clostridium
cochlearium,




Clostridium
colletant,




Clostridium
colicanis,




Clostridium
colinum,




Clostridium
collagenovorans,




Clostridium
cylindrosporum,




Clostridium
difficile,




Clostridium
diolis,




Clostridium
disporicum,




Clostridium
drakei,




Clostridium
durum,




Clostridium
estertheticum,




Clostridium
estertheticum
estertheticum,




Clostridium
estertheticum
laramiense,




Clostridium
fallax,




Clostridium
felsineum,




Clostridium
fervidum,




Clostridium
fimetarium,




Clostridium
formicaceticum,




Clostridium
frigidicarnis,




Clostridium
frigoris,




Clostridium
ganghwense,




Clostridium
gasigenes,




Clostridium
ghonii,




Clostridium
glycolicum,




Clostridium
glycyrrhizinilyticum,




Clostridium
grantii,




Clostridium
haemolyticum,




Clostridium
halophilum,




Clostridium
hastiforme,




Clostridium
hathewayi,




Clostridium
herbivorans,




Clostridium
hiranonis,




Clostridium
histolyticum,




Clostridium
homopropionicum,




Clostridium
huakuii,




Clostridium
hungatei,




Clostridium
hydrogeniformans,




Clostridium
hydroxybenzoicum,




Clostridium
hylemonae,




Clostridium
jejuense,




Clostridium
indolis,




Clostridium
innocuum,




Clostridium
intestinale,




Clostridium
irregulare,




Clostridium
isatidis,




Clostridium
josui,




Clostridium
kluyveri,




Clostridium
lactatifermentans,




Clostridium
lacusfryxellense,




Clostridium
laramiense,




Clostridium
lavalense,




Clostridium
lentocellum,




Clostridium
lentoputrescens,




Clostridium
leptum,




Clostridium
limosum,




Clostridium
litorale,




Clostridium
lituseburense,




Clostridium
ljungdahlii,




Clostridium
lortetii,




Clostridium
lundense,




Clostridium
magnum,




Clostridium
malenominatum,




Clostridium
mangenotii,




Clostridium
mayombei,




Clostridium
methoxybenzovorans,




Clostridium
methylpentosum,




Clostridium
neopropionicum,




Clostridium
nexile,




Clostridium
nitrophenolicum,




Clostridium
novyi,




Clostridium
oceanicum,




Clostridium
orbiscindens,




Clostridium
oroticum,




Clostridium
oxalicum,




Clostridium
papyrosolvens,




Clostridium
paradoxum,




Clostridium
paraperfringens



(Alias: C. welchii),



Clostridium
paraputrificum,




Clostridium
pascui,




Clostridium
pasteurianum,




Clostridium
peptidivorans,




Clostridium
perenne,




Clostridium
perfringens,




Clostridium
pfennigii,




Clostridium
phytofermentans,




Clostridium
piliforme,




Clostridium
polysaccharolyticum,




Clostridium
populeti,




Clostridium
propionicum,




Clostridium
proteoclasticum,




Clostridium
proteolyticum,




Clostridium
psychrophilum,




Clostridium
puniceum,




Clostridium
purinilyticum,




Clostridium
putrefaciens,




Clostridium
putrificum,




Clostridium
quercicolum,




Clostridium
quinii,




Clostridium
ramosum,




Clostridium
rectum,




Clostridium
roseum,




Clostridium
saccharobutylicum,




Clostridium
saccharogumia,




Clostridium
saccharolyticum,




Clostridium
saccharoperbutylacetonicum,




Clostridium
sardiniense,




Clostridium
sartagoforme,




Clostridium
scatologenes,




Clostridium
schirmacherense,




Clostridium
scindens,




Clostridium
septicum,




Clostridium
sordellii,




Clostridium
sphenoides,




Clostridium
spiroforme,




Clostridium
sporogenes,




Clostridium
sporosphaeroides,




Clostridium
stercorarium,




Clostridium
stercorarium
leptospartum,




Clostridium
stercorarium
stercorarium,




Clostridium
stercorarium
thermolacticum,




Clostridium
sticklandii,




Clostridium
straminisolvens,




Clostridium
subterminale,




Clostridium
sufflavum,




Clostridium
sulfidigenes,




Clostridium
symbiosum,




Clostridium
tagluense,




Clostridium
tepidiprofundi,




Clostridium
termitidis,




Clostridium
tertium,




Clostridium
tetani,




Clostridium
tetanomorphum,




Clostridium
thermaceticum,




Clostridium
thermautotrophicum,




Clostridium
thermoalcaliphilum,




Clostridium
thermobutyricum,




Clostridium
thermocellum,




Clostridium
thermocopriae,




Clostridium
thermohydrosulfuricum,




Clostridium
thermolacticum,




Clostridium
thermopalmarium,




Clostridium
thermopapyrolyticum,




Clostridium
thermosaccharolyticum,




Clostridium
thermosuccinogenes,




Clostridium
thermosulfurigenes,




Clostridium
thiosulfatireducens,




Clostridium
tyrobutyricum,




Clostridium
uliginosum,




Clostridium
ultunense,




Clostridium
villosum,




Clostridium
vincentii,




Clostridium
viride,




Clostridium
xylanolyticum,




Clostridium
xylanovorans




Dactylosporangium




Dactylosporangium
aurantiacum




Dactylosporangium
fulvum




Dactylosporangium
matsuzakiense




Dactylosporangium
roseum




Dactylosporangium
thailandense




Dactylosporangium
vinaceum




Deinococcus




Deinococcus
aerius




Deinococcus
apachensis




Deinococcus
aquaticus




Deinococcus
aquatilis




Deinococcus
caeni




Deinococcus
radiodurans




Deinococcus
radiophilus




Delftia




Delflia
acidovorans




Desulfovibrio




Desulfovibrio
desulfuricans




Diplococcus




Diplococcus
pneumoniae




Echinicola




Echinicola
pacifica




Echinicola
vietnamensis




Enterobacter




E. aerogenes




E. amnigenus




E. agglomerans




E. arachidis




E. asburiae




E. cancerogenous




E. cloacae




E. cowanii




E. dissolvens




E. gergoviae




E. helveticus




E. hormaechei




E. intermedius




Enterobacter
kobei




E. ludwigii




E. mori




E. nimipressuralis




E. oryzae




E. pulveris




E. pyrinus




E. radicincitans




E. taylorae




E. turicensis




E. sakazakii




Enterobacter
soli




Enterococcus




Enterococcus
durans




Enterococcus
faecalis




Enterococcus
faecium




Erwinia




Erwinia
hapontici




Escherichia




Escherichia
coli




Faecalibacterium




Faecalibacterium
prausnitzii




Fangia




Fangia
hongkongensis




Fastidiosipila




Fastidiosipila
sanguinis




Fusobacterium




Fusobacterium
nucleatum




Flavobacterium




Flavobacterium
antarcticum




Flavobacterium
aquatile




Flavobacterium
aquidurense




Flavobacterium
balustinum




Flavobacterium
croceum




Flavobacterium
cucumis




Flavobacterium
daejeonense




Flavobacterium
defluvii




Flavobacterium
degerlachei




Flavobacterium
denitrificans




Flavobacterium
filum




Flavobacterium
flevense




Flavobacterium
frigidarium




Flavobacterium
mizutaii




Flavobacterium
okeanokoites




Gaetbulibacter




Gaetbulibacter
saemankumensis




Gallibacterium




Gallibacterium
anatis




Gallicola




Gallicola
barnesae




Garciella




Garciella
nitratireducens




Geobacillus




Geobacillus
thermoglucosidasius




Geobacillus
stearothermophilus




Geobacter




Geobacter
bemidjiensis




Geobacter
bremensis




Geobacter
chapellei




Geobacter
grbiciae




Geobacter
hydrogenophilus




Geobacter
lovleyi




Geobacter
metallireducens




Geobacter
pelophilus




Geobacter
pickeringii




Geobacter
sulfurreducens




Geodermatophilus




Geodermatophilus
obscurus




Gluconacetobacter




Gluconacetobacter
xylinus




Gordonia




Gordonia
rubripertincta




Haemophilus




Haemophilus
aegyptius




Haemophilus
aphrophilus




Haemophilus
felis




Haemophilus
gallinarum




Haemophilus
haemolyticus




Haemophilus
influenzae




Haemophilus
paracuniculus




Haemophilus
parahaemolyticus




Haemophilus
parainfluenzae




Haemophilus
paraphrohaemolyticus




Haemophilus
parasuis




Haemophilus
pittmaniae




Hafnia




Hafnia
alvei




Hahella




Hahella
ganghwensis




Halalkalibacillus




Halalkalibacillus
halophilus




Helicobacter




Helicobacter
pylori




Ideonella




Ideonella
azotifigens




Idiomarina




Idiomarina
abyssalis




Idiomarina
baltica




Idiomarina
fontislapidosi




Idiomarina
loihiensis




Idiomarina
ramblicola




Idiomarina
seosinensis




Idiomarina
zobellii




Ignatzschineria




Ignatzschineria
larvae




Ignavigranum




Ignavigranum
ruoffiae




Ilumatobacter




Ilumatobacter
fluminis




Ilyobacter




Ilyobacter
delafieldii




Ilyobacter
insuetus




Ilyobacter
polytropus




Ilyobacter
tartaricus




Janibacter




Janibacter
anophelis




Janibacter
corallicola




Janibacter
limosus




Janibacter
melonis




Janibacter
terrae




Jannaschia




Jannaschia
cystaugens




Jannaschia
helgolandensis




Jannaschia
pohangensis




Jannaschia
rubra




Janthinobacterium




Janthinobacterium
agaricidamnosum




Janthinobacterium
lividum




Jejuia




Jejuia
pallidilutea




Jeotgalibacillus




Jeotgalibacillus
alimentarius




Jeotgalicoccus




Jeotgalicoccus
halotolerans




Kaistia




Kaistia
adipata




Kaistia
soli




Kangiella




Kangiella
aquimarina




Kangiella
koreensis




Kerstersia




Kerstersia
gyiorum




Kiloniella




Kiloniella
laminariae




Klebsiella




K. granulomatis




K. oxytoca




K. pneumoniae




K. terrigena




K. variicola




Kluyvera




Kluyvera
ascorbata




Kocuria




Kocuria
roasea




Kocuria
varians




Kurthia




Kurthia
zopfii




Labedella




Labedella
gwakjiensis




Labrenzia




Labrenzia
aggregata




Labrenzia
alba




Labrenzia
alexandrii




Labrenzia
marina




Labrys




Labrys
methylaminiphilus




Labrys
miyagiensis




Labrys
monachus




Labrys
okinawensis




Labrys
portucalensis




Lactobacillus



[see below]



Laceyella




Laceyella
putida




Lechevalieria




Lechevalieria
aerocolonigenes




Legionella



[see below]



Listeria




L. aquatica




L. booriae




L. cornellensis




L. fleischmannii




L. floridensis




L. grandensis




L. grayi




L. innocua




Listeria ivanovii




L. marthii




L. monocytogenes




L. newyorkensis




L. riparia




L. rocourtiae




L. seeligeri




L. weihenstephanensis




L. welshimeri




Listonella




Listonella
anguillarum




Macrococcus




Macrococcus
bovicus




Marinobacter




Marinobacter
algicola




Marinobacter
bryozoorum




Marinobacter
flavimaris




Meiothermus




Meiothermus
ruber




Methylophilus




Methylophilus
methylotrophus




Microbacterium




Microbacterium
ammoniaphilum




Microbacterium
arborescens




Microbacterium
liquefaciens




Microbacterium
oxydans




Micrococcus




Micrococcus luteus




Micrococcus lylae




Moraxella




Moraxella
bovis




Moraxella
nonliquefaciens




Moraxella
osloensis




Nakamurella




Nakamurella
multipartita




Nannocystis




Nannocystis
pusilla




Natranaerobius




Natranaerobius
thermophilus




Natranaerobius
trueperi




Naxibacter




Naxibacter
alkalitolerans




Neisseria




Neisseria
cinerea




Neisseria
denitrificans




Neisseria
gonorrhoeae




Neisseria
lactamica




Neisseria
mucosa




Neisseria
sicca




Neisseria
subflava




Neptunomonas




Neptunomonas japonica




Nesterenkonia




Nesterenkonia
holobia




Nocardia




Nocardia
argentinensis




Nocardia
corallina




Nocardia
otitidiscaviarum




Lactobacillus




L. acetotolerans




L. acidifarinae




L. acidipiscis




L. acidophilus




Lactobacillus
agilis




L. algidus




L. alimentarius




L. amylolyticus




L. amylophilus




L. amylotrophicus




L. amylovorus




L. animalis




L. antri




L. apodemi




L. aviarius




L. bifermentans




L. brevis




L. buchneri




L. camelliae




L. casei




L. kitasatonis




L. kunkeei




L. leichmannii




L. lindneri




L. malefermentans




L. catenaformis




L. ceti




L. coleohominis




L. collinoides




L. composti




L. concavus




L. coryniformis




L. crispatus




L. crustorum




L. curvatus




L. delbrueckii subsp. bulgaricus




L. delbrueckii subsp. delbrueckii




L. delbrueckii subsp. lactis




L. dextrinicus




L. diolivorans




L. equi




L. equigenerosi




L. farraginis




L. farciminis




L. fermentum




L. fornicalis




L. fructivorans




L. frumenti




L. mali




L. manihotivorans




L. mindensis




L. mucosae




L. murinus




L. nagelii




L. namurensis




L. nantensis




L. oligofermentans




L. oris




L. panis




L. pantheris




L. parabrevis




L. parabuchneri




L. paracasei




L. paracollinoides




L. parafarraginis




L. homohiochii




L. iners




L. ingluviei




L. intestinalis




L. fuchuensis




L. gallinarum




L. gasseri




L. parakefiri




L. paralimentarius




L. paraplantarum




L. pentosus




L. perolens




L. plantarum




L. pontis




L. protectus




L. psittaci




L. rennini




L. reuteri




L. rhamnosus




L. rimae




L. rogosae




L. rossiae




L. ruminis




L. saerimneri




L. jensenii




L. johnsonii




L. kalixensis




L. kefiranofaciens




L. kefiri




L. kimchii




L. helveticus




L. hilgardii




L. sakei




L. salivarius




L. sanfranciscensis




L. satsumemis




L. secaliphilus




L. sharpeae




L. siliginis




L. spicheri




L. suebicus




L. thailandensis




L. ultunensis




L. vaccinostercus




L. vaginalis




L. versmoldensis




L. vini




L. vitulinus




L. zeae




L. zymae




L. gastricus




L. ghanensis




L. graminis




L. hammesii




L. hamsteri




L. harbinensis




L. hayakitensis




Legionella




Legionella
adelaidensis




Legionella
anisa




Legionella
beliardensis




Legionella
birminghamensis




Legionella
bozemanae




Legionella
brunensis




Legionella
busanensis




Legionella
cardiaca




Legionella
cherrii




Legionella
cincinnatiensis




Legionella
clemsonensis




Legionella
donaldsonii




Legionella
drancourtii




Legionella
dresdenensis




Legionella
drozanskii




Legionella
dumoffii




Legionella
erythra




Legionella
fairfieldensis




Legionella
fallonii




Legionella
feeleii




Legionella
geestiana




Legionella
genomospecies




Legionella
gormanii




Legionella
gratiana




Legionella
gresilensis




Legionella
hackeliae




Legionella
impletisoli




Legionella
israelensis




Legionella
jamestowniensis



Candidatus Legionella jeonii



Legionella
jordanis




Legionella
lansingensis




Legionella
londiniensis




Legionella
longbeachae




Legionella
lytica




Legionella
maceachernii




Legionella
massiliensis




Legionella
micdadei




Legionella
monrovica




Legionella
moravica




Legionella
nagasakiensis




Legionella
nautarum




Legionella
norrlandica




Legionella
oakridgensis




Legionella
parisiensis




Legionella
pittsburghensis




Legionella
pneumophila




Legionella
quateirensis




Legionella
quinlivanii




Legionella
rowbothamii




Legionella
rubrilucens




Legionella
sainthelensi




Legionella
santicrucis




Legionella
shakespearei




Legionella
spiritensis




Legionella
steelei




Legionella
steigerwaltii




Legionella
taurinensis




Legionella
tucsonensis




Legionella
tunisiensis




Legionella
wadsworthii




Legionella
waltersii




Legionella
worsleiensis




Legionella
yabuuchiae




Oceanibulbus




Oceanibulbus
indolifex




Oceanicaulis




Oceanicaulis
alexandrii




Oceanicola




Oceanicola
batsensis




Oceanicola
granulosus




Oceanicola
nanhaiensis




Oceanimonas




Oceanimonas
baumannii




Oceaniserpentilla




Oceaniserpentilla
haliotis




Oceanisphaera




Oceanisphaera
donghaensis




Oceanisphaera
litoralis




Oceanithermus




Oceanithermus
desulfurans




Oceanithermus
profundus




Oceanobacillus




Oceanobacillus
caeni




Oceanospirillum




Oceanospirillum
linum




Paenibacillus




Paenibacillus
thiaminolyticus




Pantoea




Pantoea
agglomerans




Paracoccus




Paracoccus
alcaliphilus




Paucimonas




Paucimonas
lemoignei




Pectobacterium




Pectobacterium
aroidearum




Pectobacterium
atrosepticum




Pectobacterium
betavasculorum




Pectobacterium
cacticida




Pectobacterium
carnegieana




Pectobacterium
carotovorum




Pectobacterium
chrysanthemi




Pectobacterium
cypripedii




Pectobacterium
rhapontici




Pectobacterium
wasabiae




Planococcus




Planococcus
citreus




Planomicrobium




Planomicrobium
okeanokoites




Plesiomonas




Plesiomonas
shigelloides




Proteus




Proteus
vulgaris




Prevotella




Prevotella
albensis




Prevotella
amnii




Prevotella
bergensis




Prevotella
bivia




Prevotella
brevis




Prevotella
bryantii




Prevotella
buccae




Prevotella
buccalis




Prevotella
copri




Prevotella
dentalis




Prevotella
denticola




Prevotella
disiens




Prevotella
histicola




Prevotella
intermedia




Prevotella
maculosa




Prevotella
marshii




Prevotella
melaninogenica




Prevotella
micans




Prevotella
multiformis




Prevotella
nigrescens




Prevotella
oralis




Prevotella
oris




Prevotella
oulorum




Prevotella
pallens




Prevotella
salivae




Prevotella
stercorea




Prevotella
tannerae




Prevotella
timonensis




Prevotella
veroralis




Providencia




Providencia
stuartii




Pseudomonas




Pseudomonas
aeruginosa




Pseudomonas
alcaligenes




Pseudomonas
anguillispetica




Pseudomonas
fluorescens




Pseudoalteromonas
haloplanktis




Pseudomonas
mendocina




Pseudomonas
pseudoalcaligenes




Pseudomonas
putida




Pseudomonas
tutzeri




Pseudomonas
syringae




Psychrobacter




Psychrobacter
faecalis




Psychrobacter
phenylpyruvicus




Quadrisphaera




Quadrisphaera
granulorum




Quatrionicoccus




Quatrionicoccus
australiensis




Quinella




Quinella
ovalis




Ralstonia




Ralstonia
eutropha




Ralstonia
insidiosa




Ralstonia
mannitolilytica




Ralstonia
pickettii




Ralstonia
pseudosolanacearum




Ralstonia
syzygii




Ralstonia
solanacearum




Ramlibacter




Ramlibacter
henchirensis




Ramlibacter
tataouinensis




Raoultella




Raoultella
ornithinolytica




Raoultella
planticola




Raoultella
terrigena




Rathayibacter




Rathayibacter
caricis




Rathayibacter
festucae




Rathayibacter
iranicus




Rathayibacter
rathayi




Rathayibacter
toxicus




Rathayibacter
tritici




Rhodobacter




Rhodobacter
sphaeroides




Ruegeria




Ruegeria
gelatinovorans




Saccharococcus




Saccharococcus
thermophilus




Saccharomonospora




Saccharomonospora
azurea




Saccharomonospora
cyanea




Saccharomonospora
viridis




Saccharophagus




Saccharophagus
degradans




Saccharopolyspora




Saccharopolyspora
erythraea




Saccharopolyspora
gregorii




Saccharopolyspora
hirsuta




Saccharopolyspora
hordei




Saccharopolyspora
rectivirgula




Saccharopolyspora
spinosa




Saccharopolyspora
taberi




Saccharothrix




Saccharothrix
australiensis




Saccharothrix
coeruleofusca




Saccharothrix
espanaensis




Saccharothrix
longispora




Saccharothrix
mutabilis




Saccharothrix
syringae




Saccharothrix
tangerinus




Saccharothrix
texasensis




Sagittula




Sagittula
stellata




Salegentibacter




Salegentibacter
salegens




Salimicrobium




Salimicrobium
album




Salinibacter




Salinibacter
ruber




Salinicoccus




Salinicoccus
alkaliphilus




Salinicoccus
hispanicus




Salinicoccus
roseus




Salinispora




Salinispora
arenicola




Salinispora
tropica




Salinivibrio




Salinivibrio
costicola




Salmonella




Salmonella
bongori




Salmonella
enterica




Salmonella
subterranea




Salmonella
typhi




Sanguibacter




Sanguibacter
keddieii




Sanguibacter
suarezii




Saprospira




Saprospira
grandis




Sarcina




Sarcina
maxima




Sarcina
ventriculi




Sebaldella




Sebaldella
termitidis




Serratia




Serratia
fonticola




Serratia
marcescens




Sphaerotilus




Sphaerotilus
natans




Sphingobacterium




Sphingobacterium
multivorum




Staphylococcus



[see below]



Stenotrophomonas




Stenotrophomonas
maltophilia




Streptococcus



[also see below]



Streptomyces




Streptomyces
achromogenes




Streptomyces
cesalbus




Streptomyces
cescaepitosus




Streptomyces
cesdiastaticus




Streptomyces
cesexfoliatus




Streptomyces
fimbriatus




Streptomyces
fradiae




Streptomyces
fulvissimus




Streptomyces
griseoruber




Streptomyces
griseus




Streptomyces
lavendulae




Streptomyces
phaeochromogenes




Streptomyces
thermodiastaticus




Streptomyces
tubercidicus




Tatlockia




Tatlockia
maceachernii




Tatlockia
micdadei




Tenacibaculum




Tenacibaculum
amylolyticum




Tenacibaculum
discolor




Tenacibaculum
gallaicum




Tenacibaculum
lutimaris




Tenacibaculum
mesophilum




Tenacibaculum
skagerrakense




Tepidanacrobaeter




Tepidanaerobacter
syntrophicus




Tepidibacter




Tepidibacter
formicigenes




Tepidibacter
thalassicus




Thermus




Thermus
aquaticus




Thermus
filiformis




Thermus
thermophilus




Staphylococcus




S. arlettae




S. agnetis




S. aureus




S. auricularis




S. capitis




S. caprae




S. carnosus




S. caseolyticus




S. chromogenes




S. cohnii




S. condimenti




S. delphini




S. devriesei




S. epidermidis




S. equorum




S. felis




S. fleurettii




S. gallinarum




S. haemolyticus




S. hominis




S. hyicus




S. intermedius




S. kloosii




S. leei




S. lentus




S. lugdunensis




S. lutrae




S. lyticans




S. massiliensis




S. microti




S. muscae




S. nepalensis




S. pasteuri




S. petrasii




S. pettenkoferi




S. piscifermentans




S. pseudintermedius




S. pseudolugdunensis




S. pulvereri




S. rostri




S. saccharolyticus




S. saprophyticus




S. schleiferi




S. sciuri




S. simiae




S. simulans




S. stepanovicii




S. succinus




S. vitulinus




S. warneri




S. xylosus




Streptococcus




Streptococcus
agalactiae




Streptococcus
anginosus




Streptococcus
bovis




Streptococcus
canis




Streptococcus
constellatus




Streptococcus
downei




Streptococcus
dysgalactiae




Streptococcus
equines




Streptococcus
faecalis




Streptococcus
ferus




Streptococcus
infantarius




Streptococcus
iniae




Streptococcus
intermedius




Streptococcus
lactarius




Streptococcus
milleri




Streptococcus
mitis




Streptococcus
mutans




Streptococcus
oralis




Streptococcus
tigurinus




Streptococcus
orisratti




Streptococcus
parasanguinis




Streptococcus
peroris




Streptococcus
pneumoniae




Streptococcus
pseudopneumoniae




Streptococcus
pyogenes




Streptococcus
ratti




Streptococcus
salivariu




Streptococcus
thermophilus




Streptococcus
sanguinis




Streptococcus
sobrinus




Streptococcus
suis




Streptococcus
uberis




Streptococcus
vestibularis




Streptococcus
viridans




Streptococcus
zooepidemicus




Uliginosibacterium




Uliginosibacterium
gangwonense




Ulvibacter




Ulvibacter
litoralis




Umezawaea




Umezawaea
tangerina




Undibacterium




Undibacterium
pigrum




Ureaplasma




Ureaplasma
urealyticum




Ureibacillus




Ureibacillus
composti




Ureibacillus
suwonensis




Ureibacillus
terrenus




Ureibacillus
thermophilus




Ureibacillus
thermosphaericus




Vagococcus




Vagococcus
carniphilus




Vagococcus
elongatus




Vagococcus
fessus




Vagococcus
fluvialis




Vagococcus
lutrae




Vagococcus
salmoninarum




Variovorax




Variovorax
boronicumulans




Variovorax
dokdonensis




Variovorax
paradoxus




Variovorax
soli




Veillonella




Veillonella
atypica




Veillonella
caviae




Veillonella
criceti




Veillonella
dispar




Veillonella
montpellierensis




Veillonella
parvula




Veillonella
ratti




Veillonella
rodentium




Venenivibrio




Venenivibrio
stagnispumantis




Verminephrobacter




Verminephrobacter
eiseniae




Verrucomicrobium




Verrucomicrobium
spinosum




Vibrio




Vibrio
aerogenes




Vibrio
aestuarianus




Vibrio
albensis




Vibrio
alginolyticus




Vibrio
compbellii




Vibrio
cholerae




Vibrio
cincinnatiensis




Vibrio
coralliilyticus




Vibrio
cyclitrophicus




Vibrio
diazotrophicus




Vibrio
fluvialis




Vibrio
furnissii




Vibrio
gazogenes




Vibrio
halioticoli




Vibrio
harveyi




Vibrio
ichthyoenteri




Vibrio
mediterranei




Vibrio
metschnikovii




Vibrio
mytili




Vibrio
natriegens




Vibrio
navarrensis




Vibrio
nereis




Vibrio
nigripulchritudo




Vibrio
ordalii




Vibrio
orientalis




Vibrio
parahaemolyticus




Vibrio
pectenicida




Vibrio
penaeicida




Vibrio
proteolyticus




Vibrio
shilonii




Vibrio
splendidus




Vibrio
tubiashii




Vibrio
vulnificus




Virgibacillus




Virgibacillus
halodenitrificans




Virgibacillus
pantothenticus




Weissella




Weissella
cibaria




Weissella
confusa




Weissella
halotolerans




Weissella
hellenica




Weissella
kandleri




Weissella
koreensis




Weissella
minor




Weissella
paramesenteroides




Weissella
soli




Weissella
thailandensis




Weissella
viridescens




Williamsia




Williamsia
marianensis




Williamsia
maris




Williamsia
serinedens




Winogradskyella




Winogradskyella
thalassocola




Wolbachia




Wolbachia
persica




Wolinella




Wolinella
succinogenes




Zobellia




Zobellia
galactanivorans




Zobellia
uliginosa




Zoogloea




Zoogloea
ramigera




Zoogloea
resiniphila




Xanthobacter




Xanthobacter
agilis




Xanthobactcr
aminoxidans




Xanthobacter
autotrophicus




Xanthobacter
flavus




Xanthobacter
tagetidis




Xanthobacter
viscosus




Xanthomonas




Xanthomonas
albilineans




Xanthomonas
alfalfae




Xanthomonas
arboricola




Xanthomonas
axonopodis




Xanthomonas
campestris




Xanthomonas
citri




Xanthomonas
codiaei




Xanthomonas
cucurbitae




Xanthomonas
euvesicatoria




Xanthomonas
fragariae




Xanthomonas
fuscans




Xanthomonas
gardneri




Xanthomonas
hortorum




Xanthomonas
hyacinthi




Xanthomonas
perforans




Xanthomonas
phaseoli




Xanthomonas
pisi




Xanthomonas
populi




Xanthomonas
theicola




Xanthomonas
translucens




Xanthomonas
vesicatoria




Xylella




Xylella
fastidiosa




Xylophilus




Xylophilus
ampelinus




Xenophilus




Xenophilus
azovorans




Xenorhabdus




Xenorhabdus
beddingii




Xenorhabdus
bovienii




Xenorhabdus
cabanillasii




Xenorhabdus
doucetiae




Xenorhabdus
griffiniae




Xenorhabdus
hominickii




Xenorhabdus
koppenhoeferi




Xenorhabdus
nematophila




Xenorhabdus
poinarii




Xylanibacter




Xylanibacter
oryzae




Yangia




Yangia
pacifica




Yaniella




Yaniella
flava




Yaniella
halotolerans




Yeosuana




Yeosuana
aromativorans




Yersinia




Yersinia
aldovae




Yersinia
bercovieri




Yersinia
enterocolitica




Yersinia
entomophaga




Yersinia
frederiksenii




Yersinia
intermedia




Yersinia
kristensenii




Yersinia
mollaretii




Yersinia
philomiragia




Yersinia
pestis




Yersinia
pseudotuberculosis




Yersinia
rohdei




Yersinia
ruckeri




Yokenella




Yokenella
regensburgei




Yonghaparkia




Yonghaparkia
alkaliphila




Zavarzinia




Zavarzinia
compransoris




Zooshikella




Zooshikella
ganghwensis




Zunongwangia




Zunongwangia
profunda




Zymobacter




Zymobacter
palmae




Zymomonas




Zymomonas
mobilis




Zymophilus




Zymophilus
paucivorans




Zymophilus
raffinosivorans




Zobellella




Zobellella
denitrificans




Zobellella
taiwanensis




Zeaxanthinibacter




Zeaxanthinibacter
enoshimensis




Zhihengliuella




Zhihengliuella
halotolerans




Xylanibacterium




Xylanibacterium
ulmi






Optionally, the host cells are selected from this Table and/or the target cells are selected from this Table (eg, wherein the host and target cells are of a different species; or of the same species but are a different strain or the host cells are engineered but the target cells are wild-type or vice versa). For example the host cells are Ecoli cells and the target cells are Cdificile, Ecoli, Akkermansia, Enterobacteriacea, Ruminococcus, Faecalibacterium, Firmicutes, Bacteroidetes, Salmonella, Klebsiella, Pseudomonas, Acintenobacter or Streptococcus cells.





Claims
  • 1-119. (canceled)
  • 120. An antibacterial composition comprising a plurality of non self-replicative transduction particles comprising a nucleic acid encoding an antibacterial agent or component thereof, wherein the antibacterial agent is toxic to target bacterial cells, wherein the particles are capable of transducing into the target bacterial cells the nucleic acid encoding the antibacterial agent or component thereof for expression of the antibacterial agent or component in the target bacterial cells; wherein a) the antibacterial agent comprises a guided nuclease system;b) the particles comprise one, more or all of the tail proteins, portal protein and tail fiber proteins of a first phage and capsid proteins of the first phage;c) the nucleic acid comprises an origin of replication (ori) operable in a bacterial host cell for replication of the nucleic acid encoding the antibacterial agent or component thereof, wherein the first phage is capable of infecting cells of the same species or strain as the bacterial host cell;d) the nucleic acid comprises a packaging signal comprising a pac, cos or a homologue thereof that is operable with the first phage to package the nucleic acid in non self-replicative transduction particles;e) the particles are devoid of all phage terminase genes; andf) the particles are devoid of all phage structural protein genes.
  • 121. The antibacterial composition of claim 120, wherein the particles are devoid of all phage genes.
  • 122. The antibacterial composition of claim 120, wherein the nucleic acid is comprised by a shuttle vector that can be replicated in first bacteria, wherein the shuttle vector can further be replicated and packaged into said particles in the bacterial host cell in the presence of the first phage, wherein the first bacteria are of a strain or species that is different from the strain or species of the bacterial host cell.
  • 123. The antibacterial composition of claim 122, wherein the first bacteria are E coli.
  • 124. The antibacterial composition of claim 120, wherein the nucleic acid comprises a constitutive promoter that is operably linked to a nucleotide sequence encoding the antibacterial agent or component thereof for constitutive expression of the antibacterial agent or component thereof in the target bacterial cells.
  • 125. The antibacterial composition of claim 124, wherein the antibacterial composition is a pharmaceutical composition comprising the particles and a pharmaceutically acceptable excipient, diluent or carrier.
  • 126. The antibacterial composition of claim 120, wherein the particles comprise some, but not all, capsid proteins of the first phage.
  • 127. The antibacterial composition of claim 120, wherein the antibacterial composition comprises an antibiotic, wherein the guided nuclease is operable to cut an antibiotic resistance gene in the target bacterial cells, wherein the antibiotic resistance gene renders the target bacterial cells resistant to the antibiotic comprised by the antibacterial composition.
  • 128. The antibacterial composition of claim 120, wherein the packaging signal is a packaging signal sequence endogenous to the first phage.
  • 129. The antibacterial composition of claim 120, wherein the particles comprise said nucleic acid packaged in temperate phage coat proteins.
  • 130. The antibacterial composition of claim 120, wherein the first phage is a temperate phage.
  • 131. The antibacterial composition of claim 120, wherein the first phage is a P2 phage.
  • 132. The antibacterial composition of claim 131, wherein the particles comprise a P4 packaging signal.
  • 133. The antibacterial composition of claim 120, wherein the packaging signal is P4 phage Sid and/or psu; or the packaging signal is SaPI cpmA and/or cpmB.
  • 134. The antibacterial composition of claim 120, wherein the particles comprise a morphogenesis (cpm) module.
  • 135. The antibacterial composition of claim 120, wherein the particles comprise cpmA and/or cpmB.
  • 136. The antibacterial composition of claim 120, wherein the nucleic acid is comprised by a plasmid.
  • 137. The antibacterial composition of claim 120, wherein the target bacterial cells are cells of a species selected from a species in Table 1.
  • 138. The antibacterial composition of claim 120, wherein the target bacterial cells are cells of a species selected from the group consisting of Shigella, E coli, Salmonella, Serratia, Klebsiella, Yersinia, Pseudomonas and Enterobacter.
  • 139. The antibacterial composition of claim 120, wherein the nucleic acid comprises a modified genomic island.
  • 140. The antibacterial composition of claim 120, wherein the nucleic acid comprises a modified pathogenicity island.
  • 141. The antibacterial composition of claim 120, wherein the nucleic acid comprises a modified SaPI, or a modified V cholerae or E. coli PLE.
  • 142. The antibacterial composition of claim 120, wherein the antibacterial composition does not comprise first phage particles.
  • 143. The antibacterial composition of claim 120, comprising at least 103,104105 or 106 non-self replicative particles, as indicated in a transduction assay using target bacterial cells.
  • 144. The antibacterial composition of claim 120, wherein the antibacterial composition is a herbicide, pesticide, food or beverage processing agent, food or beverage additive, petrochemical or fuel processing agent, water purifying agent, cosmetic additive, detergent additive, environmental additive or cleaning agent.
  • 145. The antibacterial composition of claim 120, wherein the guided nuclease system is selected from the group consisting of a CRISPR/Cas system, TALEN system, meganuclease system or zinc finger system.
  • 146. The antibacterial composition of claim 145, wherein the guided nuclease system is a CRISPR/Cas system and each particle encodes: (a) a CRISPR array encoding a crRNA, or (b) a nucleic acid encoding a guide RNA; wherein the crRNA or gRNA is operable with a Cas in a target bacterial cell, wherein the crRNA or gRNA guides the Cas to a target nucleic acid sequence in the target bacterial cell to modify the target nucleic acid sequence.
  • 147. The antibacterial composition of claim 145, wherein the guided nuclease system is a CRISPR/Cas system and each particle encodes a Cas that is operable in a target bacterial cell to modify a target nucleic acid sequence comprised by the target bacterial cell.
  • 148. The antibacterial composition of claim 145, wherein the guided nuclease system is a CRISPR/Cas system and each particle encodes one or more Cascade Cas.
  • 149. The antibacterial composition of claim 120, wherein each particle comprises a total of 30-150 kb of DNA, wherein the DNA comprises said nucleic acid.
Priority Claims (2)
Number Date Country Kind
GB1719896.1 Nov 2017 GB national
GB1808063.0 May 2018 GB national